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and aim of this thesis
Chapter 18 9General introduction and aim of this thesis
1. Migraine during gp Consultations
Headache is a problem for which patients occasionally attend a general practitioner 
(GP). remarkable is that although headache has a high prevalence, occurs often fre-
quently and has a high burden of illness, only a small proportion of people with 
headache visit the GP.
On a recent regular Monday in practice, my agenda shows 35 regular consultations (of 
which 5 are booked for double time), 12 consultations by telephone, 24 repeated pre-
scriptions, 1 surgical intervention, 1 therapeutic injection and 2 home visits. 
accidentally there are remarkably many headache patients this day. I would like to 
discuss these with you.
Consultations for headache:
I.  In the morning one consultation about the attack treatment of migraine. 
 Patient C.
II.  Just before the morning coffee break authorization of a repeated prescription 
 for the attack treatment of migraine for a patient using much attack treatment.  
 Patient D.
III. at the end of the morning a telephone consultation about preventive therapy.  
 Patient a.
IV. In the afternoon a patient makes a visit to start preventive therapy, 
 after previous consultations about possible benefits. Patient B.
These patients give a good impression of how GPs encounter migraine, though in real-
ity this is too many consultations on one day. One migraine patient each day would 












Migraine 99 58 126 74
Tension type headache 71 42 77 45
Undifferentiated 
headache
34 20 51 30
Cluster headache 2 1 4 2
* Prevalent headache patients consulting the GP for headache in one year
In my practice, migraine was the 16th
 
most prevalent disorder encountered in 2008. 
This corresponds with the average incidence/prevalence in general practice. according 
to the second Dutch national GP survey the migraine incidence in 2004 was 2.9 and 
the prevalence was 10.2 on an annual basis (male and female, /1000)1. Migraine is the 
most common disorder in the ICPC-chapter ̀ n’, the nervous system. some examples 
of migraine compared to other disorders encountered by the GP from the same chap-
ter (neurology) are as follows; GPs encounter migraine 3 times as frequently as epilepsy 
(prevalence 2.9/1000), 6 times as frequently as concussion (prevalence 1.8/1000), 1.4 
times as frequently as tension type headache (prevalence 7.3/1000) and 132 times as 
frequently as cluster headache (pr evalence 0.3/1000).1
2. preventive therapy for Migrane
Case A
Patient A is 44 year old male, suffering from migraine from the age of 7. He called the 
practice with some questions on preventive treatment for migraine. Every month he suffers 
from 3-4 attacks. Being a professional photographer, he frequently has to cancel appoint-
ments. He is reluctant against the daily use of tablets. He fears to go the same way as his 
old mother, who daily uses several prescription drugs. He also fears the side effects of 
prophylaxis.
The goal of preventive treatment of migraine is to reduce the attack frequency and 
thereby lowering the severity of the attacks. Limiting the burden of the disease and 
regaining of personally and socially functioning are the aims of preventive therapy. 
nevertheless this treatment is not popular: only 7-19% of the patients who qualify for 
this therapy are effectively prescribed this treatment.2-4 several considerations play a 
role at the choice for preventive treatment. a first condition is when the frequency, 
intensity and duration of the attacks, in spite of optimum attack treatment, influence 
the quality of life seriously negative. a factor which also counts is that a high attack 
frequency and migraine with aura are associated with signs of cerebral damage on 
MrI5, although it has not been shown yet that preventive treatment can prevent these 
white matter lesions effectively. Moreover preventive treatment has been designated 
when overuse of attack medication threatens and/or MOH develops. The relevance of 
this is once more underlined because chronic daily headache, mostly by over use of 
pain killers or triptans, comprehends in the netherlands approximately 4% of the 
adult population.6
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2.1 Qualitative studies on migraine prevention
Case B
Patient B is a 33 year old female, working in child nursery, suffering from migraine from 
the age of 10. The GP did offer her two years ago preventive therapy. At that point she told 
that she suffered frequently from migraine attacks. Attack medication helps rather well. 
She experiences more benefits from NSAID then from triptans. In general, she can continue 
her work after a couple of hours. She postponed the use of preventive medication each time 
and did not find her migraines worse enough. Nevertheless, now she has made an appoint-
ment to start with a preventive treatment.
Primary care is an important setting for the management of migraine and in many 
countries the majority of migraine consultations occur in this context. For example, 
in the netherlands 95% of triptans are prescribed in primary care. 
Despite the fact that that preventive therapy is a safe and effective intervention7-9, 
only few of the migraine patients who qualify for preventive therapy receive it10 and 
when they do adherence is modest.7 This under-use is in contrast with the opinion of 
many patients. some patients even express a desire for preventive therapy for infre-
quent headache. Both GPs and patients are reluctant to exploit the preventive 
possibilities. 
We could study these issues in qualitative studies. In qualitative research – with some 
overstatement – it is not the number of patients that counts, but is the views, opinions 
and emotions as such. Focus group research does not provide a statistical overview of 
patients’ opinions on migraine preventive therapy.Qualitative research on preventive 
therapy provides input for other studies on preventive therapy. For example, the 
items that have been identified can be further explored in questionnaires. It can sup-
port the preparation of intervention studies by providing input for the training for the 
participating physicians who have to offer the therapeutic interventions.11,12 The re-
sults of qualitative studies can also be very helpful in developing continuous medical 
education (CMe). 
Qualitative research should be as carefully worked out as other forms of research. 
Little is known about the opinions of GPs and patients on preventive migraine therapy 
or about the dimensions of the decision to introduce it. In order to reduce the unmet 
need of migraine patients, it is important to know why GPs are not prescribing pre-
ventive therapy and why patients are not asking for it. 
although migraine is embedded in a complex biopsychosocial context, there have 
only been few qualitative studies in the area. reports have included patients’ percep-
tions of migraine and chronic daily headache13,14, the needs of migraine patients15,16, 
migraine-related decision-making17-19, the burden of migraine and impact on quality 
of life20,21 patient experience and expectations of management.22-24 However, none of 
these studies explores views on prevention.
2.3 surveys on preventive therapy
Guidelines on migraine preventive therapy differ widely, with preventive treatment 
recommended for patients from two attacks per month up to twice a week. There is no 
objective threshold determining from which number of attacks or duration of the at-
tacks a preventive treatment for migraine is indicated. The time spent with headache 
is the frequency multiplied by the duration of the attack. It is unclear whether patients 
regard this as the basis of their decision to accept preventive therapy. Other factors are 
also frequently mentioned, such as the response on attack treatment, avoidance of 
medication-overuse headache (MOH), the impact, subjective experienced burden, 
social non-functioning, absence at work, coping behaviour, etc. 
at present, there are many thresholds used, generally established on basis of consen-
sus under physicians. In a survey under specialists it was found that the indication for 
prescribing preventive medications was 3–4 attacks per month in 85.8% of physicians 
and at least 8 days of acute medication use per month in 64.3%.25
2.4 opinion of the migraine patient
In the Us, 50% of patients with migraine meet the criteria for use of preventive treat-
ment, but only 5-12% actually uses it.26 In the netherlands, 12% of all patients with 
migraine use preventive treatment.10 It is unknown to what extend patients with mi-
graine consulting their GP are interested in using preventive therapy. That makes it 
interesting to investigate how many and which patients use preventive therapy in 
primary care, and how many patients would like to use this form of treatment in pri-
mary care or have interest in it (and should be actively informed by their GP). another 
question that can be answered by using a questionnaire is how frequency, duration, 
severity, and impact of migraine attacks are related to the wish to use preventive 
treatment.
It is also unknown if patients with fewer than two attacks per month (the threshold 
used in many guidelines) would like to consider preventive treatment. Do patients 
feel sufficiently confident to approach their GP themselves for preventive therapy? 
How many patients prefer an active approach by their physician? a Uk study reports 
that patients often do not consult their GP for their headache symptoms but still 
would like more help.15
2.5 prevalence of preventive treatment
How effective attack treatment of migraine may be, the negative influence of the 
headache attacks on the daily living of the patient is most decreased when migraine 
patients successfully experience a reduction of the attack frequency. a recent Us study 
showed that only 13% of the migraine patients who qualified for preventive treat-
ment actually get this.2,3 a study from 2002 on preventive migraine treatment in the 
netherlands shows that 12% of the triptan or ergotamine users also use prevention 
therapy. another study showed that 28% of the triptan and ergotamine users did ever 
start with preventive therapy.4,10 
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Guidelines on migraine treatment advice to start preventive therapy starting from 
two attacks each month up to 4 attacks each month27,28. 
The most often applied way to explore preventive therapy is to assess the numbers of 
patients using preventive treatments in drug databases.10 To see if preventive therapy 
is sufficiently prescribed is determined by how frequent preventive medication is 
prescribed, and that finding is subsequently compared with the prevalence of mi-
graine in the total population. shortcomings of this approach are that it is actually 
unknown for which disorder medication (like nsaIDs) is prescribed. Therefore, 
sometimes only more headache-specific medication like triptans and ergotamines are 
included in such studies. In addition, medication used in the preventive treatment of 
migraine is also used for other indications, like heart disorders and epilepsy. 
Consequently, estimates based on this approach are often incorrect. Often, this ap-
proach doesn’t reveal the number of patients who started with preventive therapy 
and later stopped using it, e.g. in which preventive therapy actually failed. It is also is 
unknown which part of the migraine patients visited their physician for migraine and 
the percentage of them receiving preventive therapy.
To gain more insight into preventive treatment of migraine we performed a popula-
tion-based cohort study to estimate the incidence of migraine in the netherlands and 
to assess preventive treatment approaches in Dutch general practice, covering the last 
10 years.
3. attaCK treatMent of Migraine
Case C
Patient C is a 44 year old female who suffers from migraine once or twice each month. 
Initially she always used ibuprofen. Five years ago she tried a triptan, but because of the 
side effects she never wanted to try it again. She has more than one severe migraine attack 
each month and wants information on the best way to treat attacks now. The use of ibu-
profen only results in a decrease of headache severity, and she still has to stop all her activi-
ties during a migraine attack. Is nausea the problem for the lack of efficacy? Should 
another NSAID been given, accompanied with anti-emetics, or should a triptan be tried 
again? 
attack treatments for migraine range from simple analgesics to migraine-specific 
treatments. Before the introduction of the triptans, selective 5-HT1 agonists, in the 
early 1990s, accepted attack treatments were paracetamol, acetylsalicylic acid, 
nsaIDs and ergots. still many patients use this kind of medication and in most 
guidelines it is still the first step in attack treatment (except for ergotamines, the use of 
which has vanished). Many patients and prescribers learned the benefits of the 
triptans, but still there is no direct evidence that triptans treat migraines better than 
analgesics or nsaIDs. To compare the benefits of triptans versus analgesics or nsaIDs 
there are a number of approaches possible. One of them is to assess the efficacy in tri-
als and to compare that. There are many trials of triptans and other classes of attack 
treatment compared to placebo. Triptans show only moderate efficacy (on average 
30% pain free at 2 hours), as shown in the largest available review.29 From the evidence 
based point of view it is most desirable to have results of head-to-head trials. There are 
some of these trials, also gathered in a review.30,31 These trials show no clear superior-
ity from one class of drugs above the other. 
The question still is whether there is better efficacy of triptans or that others factors 
also determine the extent of triptan use, for example the substantial marketing by 
drug companies. another attribute in the choice of attack treatment is the question 
whether the cost of triptans compared to nsaIDs justify the large use of triptans.31 
However, this attribute is getting less relevant, since the cost of triptans is lowering 
during the last years. The average price of a triptan tablet was in 2011 between 5 and 6 
euros and in 2013 a several generic triptans are in the netherlands for under 25 cents 
per tablet. 
a point of interest in this discussion is the disadvantage of trials in general, that trials 
compare large groups with each other, and don’t show the response of individual pa-
tients. Clinical trials comparing migraine treatments traditionally use a parallel-group 
design. The endpoints are defined as headache free after two hours post dose, im-
provement of pain on a 4-point headache scale, etcetera. These study designs reveal 
the efficacy of attack treatment on a predetermined aspect on a predetermined out-
come measure in a group and do not reveal individual or group preferences of the in-
cluded patients. 
3.1 preference studies 
To better answer this question is it necessary to assess the patients’ preference for ei-
ther one of the headache treatments, which can be done in so-called “patients prefer-
ence studies”. Per sonal preference seems more relevant, especially when the disorder 
presents itself as attacks. The main difference is that now the endpoint focuses on the 
patient and is determined by the patient (patient centred endpoint). an important 
Triptans*
Almotriptan  tablet 12,5 mg
Eleptriptan tablet 40 mg
Frovatriptan tablet 2,5 mg
Naratriptan tablet 2,5 mg
Rizatriptan tablet 10 mg, melt tablet 10 mg, tablet 5 mg, melt tablet 5mg
Sumatriptan  nasal spray 10 mg, nasal spray 20 mg, injection 12 mg/ml 0,5 ml,
  suppository 25 mg, tablet 100 mg, tablet 50 mg
Zolmitriptan tablet 2,5 mg, melt tablet 2,5 mg
*available in the Netherlands
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4. triptan overuse
Case D
Patient D is a 51 year old women, suffering from migraine from the age of 12. She did call 
the practice assistant for a repeated prescription of sumatriptan 100mg tablets. In the 
past she had migraine attack in average two times each month. The EPR (Electronic 
Patient Register) now shows that this would be the second prescription of 12 sumatriptan 
100 mg tablets this month. The EPR also shows that Mrs. D received prescriptions for in 
total 36 tablets during last 3 months. Is this amount a risk for overuse? Should the patient 
be invited for consultation or should the prescription just be authorized? 
Medication overuse headache (MOH) is the name for the problem that occurs, when 
headache patients start using more and more pain-killers or triptans for the treatment 
of headache attacks. If for a longer period the use exceeds a certain threshold, in some 
patients it is striking that more and more headaches appear and then eventually daily 
headache with variable intensity develops. The criteria for MOH have been established 
by the International Headache society (IHs) and are based on observational research 
and consensus.46 It is not the total number of used tablets per period, which is respon-
sible for the arising of the daily headache. The most important parameter is the number 
of days that the painkillers are used per period. For painkillers and nsaIDs the critical 
threshold of use lies on 15 days per month and for triptans on 10 days per month and 
this should endure at least three consecutive months.46 Little knowledge exists on how 
headache (as well tension type headache as migraine) transforms in MOH and on 
endpoint for one person does not have to be of equal importance for another person. 
some migraine patients, for example, may prioritize rapid onset of pain relief, while 
others may find it a more welcome experience that adverse events are absent. so in a 
preference study patients weight for themselves the benefits versus harms and are 
able to choose the individually optimal tailored attack treatment. Two or more treat-
ments are compared in a randomized crossover design: patients use treatment a in 
the first attacks and then treatment B secondly in later attacks, or vice versa. The pri-
mary outcome measure is the proportion of patients preferring the one treatment to 
the other (are more satisfied with the one treatment above the other). The optimal 
design for preference studies is currently a debate, such as on how one should interpret 
the results when patients have no preference.32,33
3.2.1. triptan versus nsaid  
The triptan rizatriptan is the second most prescribed triptan in the netherlands and 
has a good efficacy.29 In the netherlands it is a prescription only drug. Ibuprofen is 
widely used for migraine, probably still the most used treatment in migraine attacks 
the world nowadays, because it is everywhere available and shows good efficacy.34-36 It 
is available in the netherlands as OTC. 
as mentioned before, in studies of triptans versus nsaIDs there are no benefits from 
one above the other.30 There is one head-to-head study between rizatriptan and ibu-
profen and this study shows no difference on the endpoint of 2 hour pain free37.
3.2.2. triptan versus analgesics
The triptan naratriptan is the fourth most prescribed triptan in the netherlands. 
Paracetamol is an effective treatment for the attack treatment in children, adolescents 
and adults, with the remark, that most evidence for its efficacy is sometimes fairly 
old.38-40 Traditionally paracetamol is the often used over the counter (OTC) painkiller 
in the netherlands. There are no direct head to head studies of naratriptan with para-
cetamol.41 Yet there are rCTs comparing paracetamol with other triptans, showing 
equal efficacy42,43 or even more efficacy when used in combination with aspirin and 
caffeine.44 a review on the use of paracetamol for migraine has been published, and it 
is a moderately effective intervention.45 
Stop or cut back with pills/
ideas or promises to do so
Pressure of themselves, family
 or social environment to take










Problems in use and/
or with prescribers or
pharmacies
Figure 1. Aspects of addiction in medication overuse headache
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which mechanisms the process is based. It is known that the migraine frequency plays 
an important role, as well as a low socio-economic status, overweight and psychiatric 
comorbidity.6,47,48 More and more MOH is seen as a form of addiction or addictive be-
haviour, with corresponding characteristics of addiction.49-53 see figure 1.
Because the threshold for triptan overuse differs from other classes of headache attack 
treatment, triptan overuse headache (TOH) is a separate diagnostic entity46. From the 
experience in headache clinics can be learned, that triptan continued use of 18 single 
doses per month or more leads almost always results in daily headache.54
MOH is increasingly recognized as a problem worldwide, with an estimated preva-
lence in the general population of 1-4%.6,55 It is unknown whether the prevalence 
MOH is rising or that the problem gets more attention nowadays. 
according to Dutch guidelines the best intervention in MOH is totally stopping with 
the drug causing it.56,57 Other sources recommend several drugs to support the stop-
ping with overuse.58
In general practice there is a problem in recognition of MOH because OTCs remain 
outside the direct observation of the GP. In addition, there is a problem at discovering 
overuse of triptans, in spite of the fact that these drugs are prescription only drugs (at 
least in the netherlands). The main reasons for this are unfamiliarity with the risk of 
overuse of attack medication and problems with the arrangements for repeated pre-
scriptions in general practice.
There are many studies on MOH, mostly in tertiary headache centers.55,59-61 The preva-
lence of TOH is likely to increase with the expected increasing availability of OTC 
triptans (now Uk, Germany, romania) and the currently often advocated, but still 
unproven, instruction62 to treat attacks as early as possible while the headache is still 
mild. TOH can have a major impact on the quality of life of migraine patients48,63 and 
causes a considerable increase in cost.59
The assessment of the prevalence and associated cost of triptan-overuse and whether 
the risk of overuse differs among the seven available triptans has been not well 
mapped yet. In a small population-based study in Denmark 5% of sumatriptan-users 
used > 30 DDDs per month and were responsible for 38% of the total sumatriptan 
consumption and costs.64 In two French studies, 25-30% of triptan users were overus-
ers65 and 12% became overusers (defined as ≥180 DDDs/yr.) within one year from 
starting using triptans.66 In an Italian study a much lower rate of overuse was found 
(3.2%), but this is probably due to a low overall use of triptans in this country.67
a large scale observational study will provide insight in the prevalence of TOH and the 
individual role of the triptans.
5. aiMs and struCture of the thesis and Brief   
     desCription of the Chapters
The most important theme in this thesis is the “patient perspective”, illustrated by the 
fact that patients’ preference has been chosen as endpoint the two rCTs in this 
thesis.
This thesis is divided into three parts, described below.
5.1. preventive treatment of migraine
The first part of this thesis presents migraine treatment on the theme of “preventive 
treatment of migraine in general practice”, and contains five studies. 
The first chapter of part I is a narrative ‘umbrella’ review on effectiveness of preventive 
therapy for migraine (Chapter 2). For the readers who are interested in a further elabo-
ration on preventive therapy we refer to this chapter. 
The second chapter of part I is an observational study in a large primary care database 
in the netherlands (Chapter 3). To gain more insight to the potential impact and the 
preventive treatment of migraine, this chapter presents a population based cohort 
study, providing insight into the incidence of migraine and preventive treatment ap-
proaches in general practice during the last 11 years. Patients with migraine visit 
mostly the GP for migraine and preventive therapy is mostly initiated by them. even 
when a specialist (neurologist of paediatrician) initiates the preventive therapy, the 
GP will carry it out. For this reason general practice is the best place to investigate the 
use of preventive therapy. Furthermore, in this situation can be assessed which per-
centage of patients with migraine call upon the GP and again which of those get pre-
scriptions for preventive therapy.
Two qualitative studies, address how patients and GPs think and feel about preventive 
therapy (Chapter 4 and 5). Little is known about the opinions of GPs and patients on 
preventive treatment or on the inputs into the decision to introduce it. In order to re-
duce the unmet need of migraine patients, it is important to know why GPs are not 
prescribing preventive treatment and why patients are not asking for it. 
Chapter 4 is a qualitative study that seeks to explore the ideas, motives and expecta-
tions of GPs on preventive migraine therapy. 
The aim of chapter 5 is to explore the ideas, views, motives and expectations of mi-
graine patients with regard to preventive therapy: the “patients’ point of view”. 
Chapter 118 19General introduction and aim of this thesis
Chapter 4 and 5 have the same design and provide different perspectives on the same 
topic.
Chapter 6 presents a cross-sectional survey conducted in three general practices with 
five GPs and reveals what patients in general practice think about preventive therapy. 
The first study aim was to investigate how many and which patients use preventive 
therapy, and how many patients would like to use this form of treatment. The second 
aim was to investigate how frequency, duration, severity, and impact of migraine at-
tacks related to the patients’ need for preventive treatment.
5.2. attack treatment of migraine
This second part describes two rCTs with the patient preference as main endpoint 
(Chapter 7 and 8). 
Chapters 7 and 8 describe a double-blinded double dummy, cross-over trials, on riza-
triptan and ibuprofen (chapter 7) and on naratriptan and paracetamol (chapter 8). 
The aim of these studies was to evaluate; 1) the satisfaction of patients using a triptan 
in the attack treatment of migraine compared to the alternative medication, and 2) to 
evaluate whether a patient preference design is more sensitive to detect clinical rele-




Part III (Chapter 9) of this thesis is a study in which the overuse of triptans is assessed 
in the GIP-Database, a database of the Dutch Health Care Insurance Board which in-
cludes the drug prescriptions of 6.7 million people (46% of the total Dutch popula-
tion). For that purpose we defined two thresholds, a lower threshold from which up 
there is possible overuse, and a higher threshold, from which up there is almost cer-
tainly a diagnosis overuse. We assessed; 1) the prevalence and associated cost of 
triptan overuse in the Dutch general population; 2) the demographic characteristics 
of triptan overusers to identify possible risk factors; and 3) whether the risk of overuse 
differs among the seven available triptans.
6. final Chapters
Chapter 10 is general discussion and includes clinical implications, guiding and direc-
tions for further research. Chapter 11 is a summary of the main findings from this 
thesis in english. Chapter 11 is a summary in Dutch.  
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introduCtion 
Migraine is a complex, common and disabling disorder of the brain, and its mecha-
nisms are still not completed elucidated 1. The diagnosis of migraine is sometimes 
difficult to establish and should be based on the generally accepted criteria of the 
International Headache society (IHs 2004) 2.  
Preventive treatment of migraine may be considered when, despite optimal attack 
treatment, the frequency, intensity and duration of attacks severely affect the quality 
of life. Therefore, prior to initiating preventive treatment, the extent of disease burden 
should be established. This is difficult and it is not possible to base this on a single 
consultation. retrospectively reported symptoms are often not adequately expressed; 
generally, the last or most violent attack remains strongest in the memory. Furthermore, 
establishing the migraine burden may be difficult because many patients have a 
combination of headache types, or have headache as a result of overuse of pain killers, 
ergotamine or triptans. a headache diary often provides outcome information 3,4, and 
is essential for revealing clues to the diagnosis, for estimation of use of pain killers, and 
for determining the frequency of attacks. For a valid estimation of the often strongly 
fluctuating attack frequency, the diary must be maintained for a period of (minimally) 
two months 5. 
after starting preventive medication, it is recommended that the effectiveness of the 
treatment be assessed after at least two months use (with the exception of menstrual 
migraine) 6,7. In case of preventive treatments, attention should be paid to attack 
treatment, either via prescribed attack treatment or by self-medication.
These (and other) problems show that it is not an easy decision to start preventive 
treatment for migraine. similarly, it is can be difficult to choose between the options. 
Prior to the decision, it is necessary to establish: the benefits of preventive treatment 
(specified for all types of treatments), and the threshold from which patients will be 
eligible for preventive treatment. 
This narrative ‘umbrella’ review aims to provide an overview of the outcome of cur-
rent preventive treatments, and give an overview of the indications for preventive 
treatment from relevant guidelines.  
Methods
This review is based on an article previously published in Dutch 8. For an overview of 
preventive interventions for migraine, Medline and embase were searched using the 
terms migraine and preventive treatment (and synonyms thereof) . We searched for 
guidelines in the Guideline International network (GIn) database and the national 
Guideline Clearinghouse 9,10. For the present overview a selection was made based the 
relevance of the resources for the situation in the netherlands. Because of the diversity 
in methodology, study endpoints, and drug application schemes and administration, 
aBstraCt
Background
Migraine is a frequently occurring, disabling disorder. In addition to attack treatment, 
other useful interventions to reduce the burden of disease (such as preventive treat-
ment) should be applied.
Methods
This is a narrative ‘umbrella type’ review of preventive migraine treatment based on a 
search in Medline and embase. also presented is an overview of indications for pre-
ventive treatment mentioned in guidelines (identified with the same search method), 
complemented with guidelines from the Guidelines International network and the 
national Guideline Clearinghouse. 
Results
according to most sources, patients with an average of two or more attacks per month, 
when using attack treatment, are eligible for preventive treatment. This decision is 
also based on the (average) duration of attack, severity of attacks, and the response to 
attack treatment. In the present guidelines there is only limited involvement of pa-
tients, whereas this is an essential condition for treatment continuation and success. 
Before starting prevention, the average attack frequency should be determined, pref-
erably using a headache diary for 2-3 months, because of the highly variable frequency 
of migraine attacks. none of the currently available preventive medications (such as 
beta-blockers, sodium valproate, topiramate and candesartan) are specific for mi-
graine. To obtain good outcome, preventive treatment should be titrated up step-by-
step to the highest possible dose without side-effects. For about 50% of patients with 
preventive treatment, a 50% reduction in attack frequency can be achieved and the 
remaining attacks tend to become less severe.
Interpretation
Preventive treatment of migraine is a worthwhile intervention in primary care, for 
which beta-blockers and anti-epileptic drugs can be used. For many patients preven-
tive treatment will contribute to a greater reduction in disease burden than can be es-
tablished with attack treatment alone.
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Therefore, it is desirable that physicians/neurologists etc. other than GPs have a basic 
knowledge of the possibilities for preventive treatment of migraine. In addition, pa-
tients can also be educated to inform their other caretakers.
Preventive treatments for migraine
Beta-blockers
In the netherlands, beta-blockers are the most used preventive drugs for migraine and 
are the first-line choice in the nHG Guideline on headache. The anti-migraine activity 
is supposed to rely on noradrenergic and serotonergic impact on the central nervous 
system. In a Cochrane review, 58 trials with a total of 5072 patients were analyzed, in 
which propranolol was compared 26 times to a placebo and 47 times to another pre-
ventive medicine 7; the daily dosage in these studies ranged from 60-320 mg. 
Propranolol was more effective than placebo. However, no estimation was possibility 
of the relation between the effectiveness and dosages used each day 17-20.
The other beta-blockers (metoprolol, atenolol, bisoprolol and nebivolol) were also 
more effective than placebo, but these drugs do not seem to distinguish themselves 
from propranolol 21-33. Because these drugs have less ß2-properties in comparison with 
propranolol, they may have less side-effects. Beta-blockers with intrinsic sympatico-
mimetic activity (acebutolol, oxprenolol and pindolol) are not effective in migraine. 
side-effects of beta-blockers can be considerable and frequently lead to discontinua-
tion. The occurrence of side-effects shows wide diversity. From the Cochrane review 
the average percentage of persons dropping-out because of side-effects is 17% 7. In 
daily practice, this percentage is probably higher. In case of pregnancy there seem to 
be no teratogenic effects. Only propranolol and metoprolol are ‘labelled’ for migraine 
prevention in the netherlands. (figure 1, p 30)
Anti-epileptics
The mechanism of anti-epileptics in the preventive treatment of migraine is unclear. 
Because of the considerable pharmacological impact of these drugs, several assump-
tions are made. It is assumed that the GaBa neurotransmitter, nMDa receptors, cat-
echolamine induced and opioid neurotransmitter systems, and calcium and sodium 
canals are involved. In the netherlands two drugs of this group are frequently used: 
sodium valproate and topiramate. In the Cochrane review, 8 randomized controlled 
studies with sodium valproate and 7 with topiramate were summarized 6. sodium 
valproate showed to be consistently more effective than placebo 34. The side-effects of 
sodium valproate should be taken seriously. In older patients cognitive impairments 
and Parkinsonism have been reported. The drug is not allowed during pregnancy.
(figure 2, p 31)
a systematic analysis of migraine preventive therapy as a whole could not be performed. 
Therefore, the findings are presented in the format of a so-called ̀ umbrella’ review, 
covering various treatment options. 
summary tables for the various medications were made using review Manager, ver-
sion 5.0.24.
Threshold for preventive therapy
The Dutch College of General Practitioners (nHG) guideline on headache, recom-
mends a prevention threshold of two attacks and more 11, whereas the guideline of the 
Dutch society of neurologists states three attacks or more per month as threshold 12. 
Other international guidelines provide a divergent range of recommendations (Table 
1). selection of the guidelines in Table 1 was mainly based on the relevance of the 
guideline (e.g. the number of patients to which it applies). In addition, we present 
guidelines that are mainly relevant for the netherlands. We conclude that there is a 
large diversity in the content of the guidelines, as well as in the factors leading to a 
decision. The most frequently mentioned factors are:
- attack frequency;
- failure, poor response or side-effects of attack treatment;
- frequency or extent of use of attack treatment;
- reduced quality of life, or inability to perform activities of daily living;
- patient’s preference.
Patient preference is mentioned in only a few guidelines. This is in contrast to current 
opinion that patient preference is a major factor in decision-making related to preven-
tive treatment 1,13-16. Less mentioned aspects of decision-making on prophylaxis are 
absenteeism, status after withdrawal of chronic pain treatment, costs of attack treat-
ment, uncommon migraine forms, and frequent or long-lasting aura.
Effectiveness of preventive treatment 
The available preventive medicines have not been specifically developed and regis-
tered for migraine, and all have other another intended indication. The anti-migraine 
effects are reported to be ‘nicely tolerated’. The effectiveness for roughly all treatments 
is that in just over 50% of the patients the frequency decreases by 50% 6,7. In addition, 
the remaining attacks often become less severe. 
General practitioners (GPs) should address a number of potential pitfalls when initiat-
ing preventive treatment of migraine. Patients often have motivation problems, 
partly due to a lack of trust in the efficacy, and frustration when nevertheless attacks 
occur. also, many patients resent the daily use of medication 14-16. Other important 
pitfalls are a too rapid increase in dose, an insufficiently long or a too low dose, and the 
use of wrong or obsolete treatments. 
a problem often encountered with beta-blockers prescribed for migraine is that they 
are sometimes changed by drugs belonging to another class (from a cardiovascular 
perspective), by e.g. cardiologists or internists, thereby losing the benefit for migraine. 
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Figure 1. Number of responders in migraine preventive therapy with beta-blockers. Based on 
Linde K, Cochrane database of reviews 20097. 
Figure 2. Number of responders in migraine preventive therapy with anti-convulsants. Based 




Figure 2. Number of responders in migraine preventive therapy with anti-convulsants. 
Based on Chronicle E, Cochrane database of reviews 20096 .   
Topiramate has also b en shown to improve headache better ha  placebo 35-38. The 
optimum amount is 100 mg d ily (in two doses), but many undesirable side-effects have 
been reported. At a daily dosage of 100 mg side-effects led to discontinuation in 23% of 
the patients 6. The drug is not allowed during pregnancy. Two gabapentin trials showed 
a lowering of migraine attack frequency; however, these studies had methodological 
shortcomings 39. After accusations of withholding scientific proof concerning the 
effectiveness of the drug, doubts related to gabapentin have increased 40. For the 
remaining anti-epileptics (carbamazepine, lamotrigine, clonazepam) there is insufficient 
or no evidence 35,41-43. In the Cochrane analysis it is concluded that anti-epileptics are an 
effective preventive treatment of migraine. However, only for sodium valproate and 
topiramate is there sufficient evidence to justify their use for the prevention of migraine 
attacks (topiramate is ‘labelled’ for this indication). 
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that acetylsalicylic acid is not indicated as preventive migraine therapy 23,58,59. 
Three placebo-controlled trials investigated verapamil, but because the results are in-
conclusive 60-62 there is no place for its use in migraine. 
Two placebo-controlled and three open studies in patients with episodic migraine 
show that the effects of botulinum toxin injections in frontal and occipital muscles do 
not differ from placebo 63-65. Trials in patients with chronic migraine (migraine head-
ache on ≥ 15 days/month), have shown that injections with onabotulinumtoxina 
lead to a reduction of the impact of migraine 66. However, whereas the therapeutic 
gain over placebo was statistically significant, the clinical significance was modest 67.
riboflavin and coenzyme Q10 each have each been examined in a placebo-controlled 
study, both being positive. Based on these very limited data, these remedies are not yet 
recommended 68. Four out of five controlled studies with tanacetum parthenium (fe-
verfew) were positive 69; the effectiveness is strongly dependent on the resorption of 
the obligatory preparation, which limits its practical usability.
 
Combination therapy in preventive treatment
a few studies explored the combination of different preventive treatments in patients 
who did not benefit from one single preventive. These studies sometimes include ex-
pert opinions or overviews 70-72, case reports or small series 73,74 and a few comparative 
trials 75-78. Two studies show a benefit of combination therapy (topiramate plus nor-
triptyline; beta blocker plus topiramate) 75,76. In two studies there was no added benefit 
of the combination (propranolol plus nortriptyline; flunarizine plus topiramate) 77-79. 
at present, the use of a combination of different preventives remains uncertain.
Prevention in menstrually-related migraine
The acute treatment of menstrually-related migraine is identical to that of other mi-
graine attacks. some authors express a preference for naproxen, as this has a reasonable 
effect on the migraine as well as being effective for menstrual complaints 80.
Pure menstrual migraine attacks occur exclusively on days -2 to +3 of the menstrua-
tion period in at least two out of three menstrual cycles. and at on no other moments 
of the cycle 2. 
In menstrually-related migraine all preventive therapies for migraine are applied 81-84. 
Because only small studies are available on the efficacy of preventive treatment for 
menstrually-related migraines, current treatment is actually based on consensus 82-86. 
short-term prevention focuses only on days -2 before to +4 days after start of the 
menstruation) 83,84,86. There is also a variation of this strategy, with duration up to 11 
days (a somewhat older strategy, day -2 up to +9).
 nsaIDs are an option for short-term prophylaxis in general practice, because there is 
a more or less reliable effect on migraine as well as on menstrual complaints 80,87,88. as 
in attack treatment, naproxen is the most often used option 80.
Triptans are also an option in the short-term prophylaxis of migraine 89-96. several 
small studies have shown a consistent positive effect. as the duration of triptan use 
Topiramate has also been shown to improve headache better than placebo 35-38. The 
optimum amount is 100 mg daily (in two doses), but many undesirable side-effects 
have been reported. at a daily dosage of 100 mg side-effects led to discontinuation in 
23% of the patients 6. The drug is not allowed during pregnancy. Two gabapentin trials 
showed a lowering of migraine attack frequency; however, these studies had methodo-
logical shortcomings 39. after accusations of withholding scientific proof concerning 
the effectiveness of the drug, doubts related to gabapentin have increased 40. For the 
remaining anti-epileptics (carbamazepine, lamotrigine, clonazepam) there is insuffi-
cient or no evidence 35,41-43. In the Cochrane analysis it is concluded that anti-epileptics 
are an effective preventive treatment of migraine. However, only for sodium valproate 
and topiramate is there sufficient evidence to justify their use for the prevention of 
migraine attacks (topiramate is ‘labelled’ for this indication).
Other treatments in migraine prevention
Of the remaining treatments, flunarizine has been well studied. nine placebo-con-
trolled studies include a relatively small number of patients 44-52. In 2 of 9 studies, no 
advantage of flunarizine was shown compared to placebo 48,49. The remaining 7 studies 
showed an advantage. Flunarizine is effective in the prevention of migraine; however, 
the treatment is no longer popular because of the risk of serious side-effects, such as 
extrapyramidal dysfunction and drowsiness. 
Pizotifen was evaluated in 11 placebo-controlled studies and showed improvement 
compared with placebo, except in children 53. However, most of the studies were 
small, with often no more than 50 patients. Pizotifen is frequently not well tolerated 
and the most important side-effects are weight increase, fatigue and drowsiness. This 
means that when weighing the advantages and disadvantages, the result is often nega-
tive for pizotifen. 
Methysergide has been registered for many years; however, because of the rare side-
effects of retroperitoneal, pulmonary and/or endocardial fibrosis, the drug is only to 
be prescribed by experienced physicians and after very careful assessment. 
antidepressants are frequently prescribed for the treatment of migraine, especially in 
the Usa. Because the evidence for ssrIs is moderate, they are not included in the 
Dutch guidelines. amitriptyline can be considered in case of additional tension-type 
headache, and can be useful in some migraine patients. There is no evidence for the 
use of ssrIs in migraine 54.
There are studies with lisinopril (aCe inhibitor), candesartan and telmisartan (aII 
antagonist). The studies with lisinopril and candesartan show benefit, for telmisartan 
the primary endpoint was not significantly better (probably because of the too small 
numbers). In spite of the few side-effects of these drugs, the ‘level of evidence’ is still 
too low to recommend their large-scale use 55-57. 
acetylsalicylic acid has been used for migraine prevention and some researchers claim 
success. However, positive preventive effects do not occur in more than 20-26% of the 
patients and this does not exceed the placebo effect. Therefore, most researchers find 
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neurological societies (eFns) for the treatment of MOH mentions prednisolone for 
the treatment of withdrawal symptoms, based on three open-label studies and two 
placebo-controlled trials 129. The three open-label trials claimed a beneficial effect of 
prednisolone on the severity and duration of withdrawal symptoms 130-132. However, 
due to the low quality, these studies are not a proper basis for a guideline 133. Of the two 
placebo-controlled trials, in the largest trial (n=102) prednisolone showed no benefit 
compared to placebo, and the other smaller trial (n=18) suggests some benefit of 
prednisolone 128,134. according to the eFns, prednisolone may have an advantage, be-
cause all other medications even cause MOH. However, it is doubtful whether this is 
the right argument when claims of efficacy are unsupported. The eFns guideline also 
mentioned amitriptyline as a possible treatment for withdrawal symptoms; however, 
this is also not based on evidence, but on consensus 129.
There are no randomised direct comparisons between withdrawal with and without 
using supportive medication 111. Drug intervention studies for MOH only show small 
improvements. On the other hand, the studies with withdrawal of the causing agent 
show a consistent effect 135-137. 
In conclusion, withdrawal seems to be the best intervention and best matches the 
Dutch attitude regarding drug use in general. In addition, there is some evidence for 
the effectiveness of other strategies, such as behavioural therapies 138-147.
Many GPs have noted that MOH has some characteristics of addiction, comparable to 
alcohol or smoking addiction. Characteristic of MOH is that patients at the acute stage 
of withdrawal experience a strong increase in headache (rebound phenomenon). 
MOH patients often experience some results from attack medication; it can temporar-
ily relieve the complaints. In general, patients do not recognize that the daily use of 
medication is the actual cause of the headache. 
Comparative studies on preventive therapy
Many comparative studies between preventive treatments have been performed, with 
differing combinations, mainly with beta-blockers, sodium valproate, topiramate, flu-
narizine, pizotifen, methysergide, verapamil, nimodipine and amitriptyline 6,7,79,148-169. 
In these studies, the most frequently used comparator is flunarizine 44,47,79,149-164. as the 
use of flunarizine often leads to side-effects such as drowsiness, lethargy, weight gain, 
increased appetite, depression and extrapyramidal symptoms, these comparisons 
with flunarizine are of limited value for daily practice. 
a point of interest is the comparison within the group of anti-epileptic drugs. Only 
one study has compared sodium valproate with topiramate, and showed a small ad-
vantage of topiramate; however, the daily dosages of both drugs were lower than usual 
169. For the remaining drugs no significant differences were shown.
does not exceed 6 days each month, medication overuse headache (MOH) is not likely 
to emerge. When there are also migraine attacks in between menstruations, and those 
attacks are also treated with triptans, there is a danger of developing MOH . This also 
applies when using nsaIDs, but for this medication class there is a greater margin. In 
addition, preventive treatment of menstrual migraines with triptans is relatively 
costly.
estrogens are mainly used as short-term prophylaxis. studies on preventive use of es-
trogens, especially percutaneous estradiol gel, still show considerable disagreement 
on effectiveness. Most trials with estrogens show robust effects 83, but some trials have 
disappointing results 84. 
another option is the continuous use of combined oral contraceptives 83,84,97. The re-
sults are sometimes disappointing; only a proportion of patients respond well to this 
therapy. Often, when there is a good response to this intervention, there are break-
through bleedings, resulting in termination of this therapy. a contemporary approach 
to breakthrough bleedings under continuous oral contraceptive use is that, at the start 
of a bleeding, a 7-day pause is started. However, it is unclear what the impact of this 
strategy is on the frequency of migraines.
Because migraine with aura is a risk factor for cerebrovascular accidents and this risk is 
increased when using oral contraceptives 98, recent guidelines advise not to prescribe 
oral contraceptives for patients with migraines, especially not for migraine with aura. 
Young women who have migraine with aura should be strongly advised to stop smok-
ing, and to consider a form of birth control other than oral contraceptives 98. 
Preventive treatment in case of medication overuse
The recommended action in case of MOH is withdrawal of the drug that is causing the 
headache 5,99-102.  In earlier definitions of the IHs classification 2 the disappearance or 
decrease of the headache after withdrawal was an obligatory criterion for MOH. In the 
present version, that requirement is replaced by the requirement that the headache 
should have developed or has markedly worsened during medication overuse. Many 
studies show a return of daily headache back to a less frequent episodic headache after 
withdrawal 99,103-120. In the netherlands, this knowledge has resulted in the consensus 
that withdrawal is the preferred approach 11,12. It is unclear if this approach is suffi-
ciently `evidence based’, or just suits Dutch ‘culture’ (when you use too much of 
something, this cannot be good and you must stop). and, above all, in the netherlands, 
for MOH it is recommended not to add extra drugs.
some studies on interventions with specific medication have been done on MOH, 
with varying results. Four studies with topiramate showed a small but significant re-
duction in headache 121-124. studies with sodium valproate also showed relief 125,126. 
sometimes also naproxen is used because of the incorrect assumption that nsaIDs do 
not increase the risk of MOH 127. Prednisolone has also been used to reduce withdrawal 
headache, but this is not supported by controlled clinical trials. although the evidence 
is not conclusive 128, the recent european guideline of the european Federation of 
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‘First choice’ in preventive treatment are beta-blockers (propranolol and metoprolol) 
and anti-epileptic drugs (sodium valproate and topiramate). ‘second choice’ preven-
tives are those which have demonstrated some preventive effect, but with limited evi-
dence. These treatments come into play when ‘first choice’ treatments are ineffective 
or not tolerated, and the patient is motivated for further attempts. ‘Third choice’ 
treatments have demonstrated preventive effect, but sometimes at the cost of severe 
side-effects, or only with important and specific terms and conditions. Botulinum 
toxin does not show convincing benefits in episodic migraine whereas in chronic mi-
graine there can be some benefit; however, the therapeutic gain seems very modest 67.
Table 3. Available medications for the preventive treatment of migraine
Drug Dosage  
(step by step titration)




1000 - 1500 mg (mostly 50% 
compared to epilepsy, phasing 
out schedule necessary)
Topiramate 50 bd (25-100 mg)








(for physicians with 
special interest)    
Pizotifeen More dis- than advantages, 
weight gain
Flunarizine rare side effects  
(extrapyramidal symptoms)
Methysergide Interval treatment,  
serious adverse events
amitriptyline Conflicting evidence
Insufficient evidence, no 
proven efficacy, too many / 
serious side-effects
Gabapentin, lamotrigin, ssrIs,  
acetylsalicylic acid, verapamil, riboflavin, 
botulinum toxin, tenacetum partenium 
 
disCussion 
In general, preventive treatment of migraine is a well accessible and at times useful 
intervention, but only when carried out correctly and carefully. as about half the dis-
ease burden can be decreased, there is a large gain for patients with a high disease 
burden. Preventive treatment for migraine is a tailor-made task, adapted to the indi-
vidual patient. Table 2 presents a summary of the principles of preventive migraine 
treatment, and table 3 lists the treatments used.
Table 2. Principles of preventive treatment of migraine; recommendations based on the out-
come of the present review
Basic principles of preventive migraine treatment 
Indication −   at least two or more attacks per month
−   Patient preference
Factors to take into 
account for indication
attack intensity, duration, response to attack treat-
ment, extent of attack medication, quality of life, 
and interference with patient activities
Important points −   Based on average attack frequency in three 
      preceding months
−   start with low dosage and titrate up step-by-step,    
      until maximal accepted dose without 
      side-effects
−   always in combination with provision of attack 
      treatment
−   Individualized approach to treatment type and 
      dosage (avoid side-effects or interference with 
      lifestyle)
−   Beta-blockers and anticonvulsants both well 
      applicable in general practice
Duration −   at least 2-3 months before effect assessment
−   When effective, continuation for 9-12 months
−   In case of recurrence start preventive treatment 
      again
 















Dutch  College of General 
Practitioners 11
2 or more - - - -
Domus Medica, Society of 
General Practitioners, 
Belgium 176
2 or more - - Yes Yes#
Migraine in Primary Care 
Advisers (MIPCA), 177 
England
4 or more - - Yes -
American Academy of 
Family Physicians 178
2 or more Yes Yes# Yes > 2 days / 
week
Dutch Society for 
Neurologists 12
3 or more Yes - Yes > 8 days / 
month
EFNS (European Federation 
National Neurological 
Societies) 179
2 or more - - Yes -
AAN (American 
Neurological Society) 180
Yes# - - Yes Yes#
Canadian Medical 
Association 181




3 or more Yes Yes - -
BASH guideline (British 
Association for the Study of 
Headache) 183
Yes# - - Yes Yes#
Scottish Intercollegiate 
Guidelines Network (SIGN) 
184
Yes# - - Yes -
National Agency of 
Accreditation and 
Evaluation in Health, 
France (ANAES) 185
Yes# Yes - - > 6-8 dose 
/ month
German Society for 
Neurology (DGN) 186
3 or more Yes > 72 
hours
Yes Yes
German Migraine and 
Headache Society 
(DMKG) 187
3 or more - > 72 
hours
Yes > 10 days 
/ month








Additional Level of care 
covered*
- - - Yes, in 
agreement
not in case of MOH Primary
- Yes - Yes, willing-
ness daily 
medication 




- - - - Primary
- Yes Yes# Uncommon migraine 
conditions
Primary
- - - - - Primary and 
secondary





- Yes Yes Yes,
opinion on 
severity






Yes -  - Yes# - Primary and 
secondary
- - Yes - Primary, second-
ary and tertiary
- Yes - Yes# not in case of MOH, Primary, second-
ary and tertiary




Yes - - - Primary, second-
ary and tertiary








   
Table 1. Indications for preventive treatment of migraine addressed in guidelines
# Unspecified. MOH = medication overuse headache  
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introduCtion
Migraine is a common, chronic, incapacitating neurovascular disorder, characterized 
by attacks of severe headache, autonomic nervous system dysfunction, and in some 
patients, an aura involving neurological symptoms1. The mean one-year prevalence in 
adults aged 18 – 65 years of migraine is over 10% (10.9% in the americas and 14.8% in 
europe)2.
an important treatment goal is reducing the attack frequency. Preventive treatment 
includes beta-blockers and anti-epileptics and is recommended in guidelines3-6. In the 
netherlands preventive treatment with propranolol or metoprolol is recommended 
for patients with an attack rate of two or more attacks per month3,4. 
several studies into preventive treatment for migraine suggest large under-treatment. 
a telephone survey in the Us showed that only 13% of the migraine patients who quali-
fied for preventive treatment actually received treatment7,8. an earlier questionnaire 
study showed similar low numbers (5% and 12.4%) for preventive treatment use9,10, 
although an additional 17.2% of patients used medication with potential antimigraine 
effects for other indications10. In France use of preventive treatment was estimated at 
6%11. In a small Dutch study in general practice 8% of the migraine patients used pre-
ventive medication12. recently, we described a Dutch pharmacy record study compris-
ing 6.2 million people, showing that 19% of the triptan users at some moment also take 
preventive medication13. Most studies on preventive migraine treatment use suffer 
from methodological shortcomings and differ amongst each other. In pharmacy 
records, the indication for drug prescribing is usually lacking, as a result of which the 
medication may be prescribed for other reasons (like hypertension). Questionnaire 
studies in the general population also may have included inappropriate migraine diag-
noses and misclassify frequent attack treatment as preventive treatment11.
For patients, the frequency of the migraine attacks is the most important consideration 
in the decision for preventive treatment12. Preventive treatment is also indicated when 
exuberant use of attack medication is imminent and when there is a risk of medication 
overuse headache (MOH), which has a population prevalence of 4% in adults14,15. Data 
on triptan use in the netherlands suggest that triptans possibly cause more headache 
than that they cure13. For policy making and optimizing routine care a valid estimate of 
the proportion of migraine patients receiving preventive treatment is necessary. We 
performed a population based cohort study in a general practitioners’ research database 




Preventive treatment of migraine contributes to reducing the impact of migraine but 
its extent of use in routine care is unknown. 
Objective 
To assess current use, previous use, duration and course of preventive treatment of 
migraine in Dutch general practice.
Methods
retrospective cohort study, for period between 1997 and 2007, in the Interdisciplinary 
Processing of Clinical Information (IPCI) database, a GP research database in The 
netherlands (source population over half million subjects). all prevalent and incident 
migraine patients (n = 7367) were included. 
Results 
about 13% of all migraine patients currently use preventive therapy and almost half 
of the migraine patients have prior use. Of those starting with preventive treatment 
56% (95%CI: 54.3-64.7) still used it after 9 months. There was a long delay between 
migraine diagnosis and preventive treatment start. 44% (95%CI 43.0-45.7) started 
preventive therapy in the study period. 
Conclusion 
This large primary care database study shows that a limited number of patients are 
current users of preventive treatment, but many patients have prior use. after diagno-
sis there is often an extended time before preventive treatment is applied. also there is 
often only one attempt. The continuation in time seems appropriate. Preventive 
therapy in migraine still deserves focus.
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ing, burning pain. We accepted GP diagnoses if they recurred in the patient record and 
if typical migraine symptoms were present. 
The index date was defined as the date of diagnosis of migraine. If the index date was 
on or after the start of follow-up the migraine was classified as incident. In other cases 
the migraine was considered as prevalent.
We distinguished two categories of migraine as abstracted from the database, namely 
‘uncertain migraine’ and ‘certain migraine’. Uncertain migraine comprised patients 
who expressed symptoms of migraine or had sporadic attacks, or were labelled by the 
physician as having migraine, but only visited the GP once for that reason. These pa-
tients had incomplete symptoms or were one time only indistinct associated with 
migraine in the whole research period (no preventive therapy). Uncertain migraine 
was not included in our analysis. This category has to be distinguished from ‘probable 
migraine’ from the IHs-classification.20 Migraine was classified as ‘certain migraine’ if 
the headaches features corresponded to the IHs criteria for migraine.20 We further de-
tailed certain migraine according to presence of aura and considered menstrually-re-
lated migraine (MrM) as a subgroup of certain migraine. Patients with typical aura 
without headache and patients with medication-overuse headache were considered 
separate from certain migraine.
Migraine treatment
Treatment details extracted from the database comprised the date of prescribing, full 
aTC-code, drug name, strength, dose instructions and primary indication for the 
prescription. as attack treatment we considered drugs mentioned in Dutch guidelines 
(paracetamol, acetylsalicylic acid, nsaIDs, triptans, ergots) and as preventive treat-
ment we considered agents which are mentioned in Dutch Guidelines or are officially 
approved preventive treatment (beta blockers without intrinsic sympathomimetic 
activity, valproic acid, topiramate, pizotifen, amitriptyline and flunarizine)3,4. 
Analysis
We calculated age and gender specific incidence rates of different types of migraine by 
dividing the number of incident cases by the total accumulated follow-up time. ninety-
five percent confidence intervals (95%CI) were calculated assuming a Poisson distribu-
tion. We used kaplan-Meier analysis to calculate the time to preventive treatment start 
following migraine diagnosis in patients who had not used any of the preventive 
treatment agents before. kaplan-Meier analysis was also used to estimate the11-year 
cumulative incidence of treatment initiation following migraine diagnosis. 
To assess duration of treatment we assessed the proportion of patients still using the 
initial medication in periods of 3, 6, 9 and 12 months following treatment start. 
Proportions were calculated by dividing the number of patients remaining on initial 
treatment divided by the number of patients still in follow-up at the end of the con-
cerned period. all the analyses were conducted using sPss for windows version 15.0 
(sPss Inc., Chigaco, Usa).  
Methods
Setting
The study was conducted in the Integrated Primary Care Information (IPCI) database, 
a longitudinal general practice research database in the netherlands. The IPCI data-
base is maintained by the Department of Medical Informatics of the erasmus MC, 
University Medical Centre rotterdam in the netherlands. The database contains 
longitudinal data from computer-based patient records of more than 150 GPs 
throughout the netherlands. Presently, the database comprises data on more than 
800,000 subjects, of whom the age and gender distribution is similar to the Dutch 
population. The registration uses the International Classification of Primary Care 
(ICPC)16,17 to register patient symptoms and diagnoses, although these can also be 
entered as free text. Prescription data include product name, quantity dispensed, 
dosage regimens, strength and indication. as of 1996, drugs are coded according to 
the anatomical Therapeutic Chemical (aTC) classification scheme recommended by 
the World Health Organisation (WHO)18. GPs who participate in the IPCI project are 
not allowed to use paper-based records.
The IPCI database system complies with european Union guidelines on the use of 
medical data for medical research and has been proven valid for pharmaco-epidemio-
logical research19. The scientific and ethical advisory Group of the IPCI project ap-
proved the study (number 05/92).
Study period and study population
We used data of all individuals with at least one year of follow-up data available in the 
database between January 1996 and December 2007 (n = 478,584). One year of data 
was needed to validly assess medical history and treatment history. study entry was 
defined as the date at which one year of follow-up was accumulated or 1st January 
1996 whichever was latest. Follow-up lasted until the end of the study period, end of 
patient registration with GP practice, death or last IPCI data delivery, whichever came 
first. Within the study population we identified a sub-cohort of patients with newly 
detected migraine (incident diagnosis).
Ascertainment of migraine
GPs have a diagnostic code for migraine (ICPC-code n89). additional potential cases 
were identified in the database through an inclusive string search on free text (‘mi-
grain*’). The presence and date of diagnosis of migraine were evaluated by a manual 
review of the electronic patient record of all the potential cases by the principal inves-
tigator (FD). Our case definition relied on the IHs-classification20. as typical migraine 
symptoms we considered attack frequency, duration of the headache, (unilateral) lo-
cation, pulsating quality, moderate or severe pain intensity, aggravation by or causing 
avoidance of routine physical activity (e.g. walking or climbing stairs), nausea or 
vomiting, photophobia and phonophobia, the existence of precipitating aura, shoot-
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migraine treatment at a high average age: 38.1 for males and 42.3 years for females.
among patients starting preventive treatment many had discontinued that treatment 
within three months, after which the percentage of users stabilized. The average pro-
portion of patients still using preventive treatment after 9 months of first start was 
55.6% (95%CI: 54.9-60.1) but strongly varied by treatment. Patients using beta-
blockers were most likely to continue treatment (59.6% after nine months, 95%CI 
54.3-64.7) whereas patients using pizotifen were least likely to continue (37.0% after 
nine months, 95%CI 26.2-49.1). among patients using beta-blockers prolonged use 
after nine months was 77.8% (95CI 62.5-88.3) for atenolol, 62.6% (95CI 53.4-71.0) for 
metoprolol and 50.3% (95CI 42.6-58.0) for propranolol. For patients using amitriptyl-
ine or valproic acid the numbers were too small to make reliable estimates.
We also studied the extent to which patients continued to use initial, prescribed attack 
treatment. The drop in attack treatment use was much larger than the drop in preven-
tive treatment. after 9 months the proportion still receiving prescriptions for a triptan 
was 26.7% (95%CI: 20.4-34.3) (not available as OTC in the netherlands) and for 
nsaIDs 26.8% (95%CI: 24.5-29.3) (available as OTC).
 
disCussion 
In a large Dutch longitudinal general practice research database we found that the 
percentage of all migraine patients receiving preventive treatment in the netherlands 
was 13.3% (95%CI: 12.4-14.3). approximately 56% of those starting preventive 
treatment, continued on it for a prolonged period of time (i.e. 9 months), suggesting 
good treatment effect and acceptable side-effects. The duration of first preventive 
treatment use was much longer than that for first attack treatment. In the vast major-
ity of patients only one type of preventive treatment was tried, which may be due to 
the fact that the current guideline recommends only beta blockers as preventive 
treatment.3 
The large time lapse between starting attack- and preventive treatment of 4.3 years 
and the high average age on start (male 38.1 and female 42.3 years) points out the at 
the start of  preventive therapy the burden of migraine often is already past its highest 
peak throughout life1. This underlines the reluctance to accept the daily use of preven-
tive medication21.
The number of new patients receiving preventive treatment remained stable over the 
study years. and as the incidence of new cases of migraine decreased over the years, 
there was a relative increase in the use of preventive treatment (data not shown).
We found no significant differences in migraine treatment prescribing between differ-
ent types of migraine, or between presence and absence of aura. We neither found a 
relation between prescribing of preventive treatment and that of attack treatment (see 
figure 1); only a small proportion of patients receiving preventive treatment also re-
ceived prescriptions for attack treatment. 
results
The total amount of follow-up time for the 472,033 subjects in the study population 
without migraine at baseline was 1,855,904 person years with an average of 3.9 person 
years per subject (sD: 2.99). We identified 7,525 first-time diagnoses of migraine or 
related headache disorders, of which 5,134 were certain migraine, 2081 uncertain 
migraine, and 152 typical aura without headache (aWoH) and 158 medication over-
use headache (MOH) (Figure 1). Menstrually-related migraine (MrM) was found in 
712 patients (table 1). Migraine patients were predominantly female (75%) and 
mostly between 30 and 40 years of age (table 1). The overall incidence rate of migraine 
over the entire study period, including uncertain cases, was 4.05 per 1000 person 
years (95%CI: 3.96-4.15). Considering certain migraine only the incidence rate was 
2.8 per 1000 person years (95%CI: 2.7-2.8).
Treatment of migraine
Out of 5,134 migraine patients, 684 (13.3%, 95%CI: 12.4-14.3) received preventive 
treatment prescription at any time during the study period, most of them without 
ever receiving attack treatment in the study period (no attack treatment out of 684: n 
= 501, 73.2%, 95%CI: 69.7-76.5) and consisting of a single type (n = 552, 80.7%, 
95%CI: 77.5-83.6). Of all patients receiving preventive therapy 21 patients (3.1%, 
95%CI: 2.0-4.7) had two or more preventive therapies (figure 1).
among patients diagnosed as having migraine with aura 11.2% (95%CI: 9.40-13.30) 
were prescribed preventive treatment. Migraine patients without aura received pre-
ventive treatment in 13.2 % (95%CI: 8.3-20.1) and in patients for whom the presence 
of aura was not mentioned the percentage of receiving preventive treatment was 13.1 
% (95%CI: 12.1-14.2). The odds ratio (Or) for having received preventive treatment 
in patients with aura versus patients not having aura or aura not specified was 0.87 
(95%CI: 0.70-1.08)). Typical aura without headache was recorded for 152 cases of 
whom 24 (15.8 %, 95%CI: 10.6-222.8) received preventive treatment (table 2).
Of the 1936 migraine patients using triptan, 92 (4.8%, CI: 3.87-5.52) also used preven-
tive medication. Of the 1,080 nsaID users 45 (4.2%, 95%CI: 3.09-5.58) also had pre-
ventive medication. 
The average age for prescribing attack treatment was 38.1 (sD 14.6) years and for pre-
ventive treatment 42.3 (sD 15.4) years. 
The kaplan-Meier analysis showed that first time preventive treatment prescriptions 
were issued mostly within the first two years following diagnosis but continued to be 
issued at a lower steady rate thereafter (figure 3). The cumulative incidence of ever 
having used preventive treatment within a study period of 11 years (average 3.9 person 
years (sD: 2.99)) was 44.3% (95% CI 43.0-45.7). For women this was 47.0% (95% CI 
43.4-48.6) and for male 36.1% (95% CI 33.4-38.9).
The average time lapse between starting attack treatment and starting preventive 
treatment was 4.3 years during this 11 year study period. Patients started preventive 
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between medication overuse and diagnosis of migraine (usually migraine, rarely ten-
sion type headache, as recorded in the ePr). Including patients with MOH in the 
analysis may have caused some contamination by tension-type headache but given 
the numbers it will not have a major impact on the estimates.
This study shows a long-lasting and continued use for 9-12 months of preventive 
medication in 56% of patients starting on preventive medication for migraine. 
although this real life study can not be compared with studies in an experimental 
setting, in our study the frequency of treatment withdrawal is much higher, especially 
for beta blockers31. In usual care treatment withdrawal can be interpreted, at least for 
a part, as non-response. The response rate in experimental trials is around 50%, which 
is in line with the withdrawal rate in our study31. The guideline compliance in our 
study was much better than in an older study (1995-1998)25.
The absence of differences in treatment patterns between types of migraine and be-
tween population subgroups suggest that this study gives no indication for extra at-
tention in the area of preventive treatment for any specific group of patients. 
Despite many efforts to improve the treatment of migraine and an otherwise well used 
headache guideline in the netherlands which promotes preventive treatment, there 
is much room for improvement. The compliance with treatment guidelines has im-
proved, but the actual number of patients with preventive treatment remains low. 
Qualitative research could give more insight into the reasons behind the little use of 
preventive medication in younger migraine patients, the extended duration between 
diagnosis and start of preventive treatment, and why and how prescribed attack 
treatment interferes with preventive treatment (e.g. whether patient and physicians 
only accept one treatment for one illness at the same time). 
This may point the way for better explanation and defending of preventive treatment 
to expand the use of it, also by encouraging more than one attempt using alternative 
medication. 
although compliance of preventive treatment has improved and many patients have 
experience with it, preventive treatment still needs attention in primary care. Further 
research into underlying reasons and motives of patients and physicians is desirable. 
Firstly most gain would be made when more patients would consult their GPs when 
they have migraine attacks an so more often migraine would be diagnosed. and sec-
ondly if this was more often and/or repeated followed by active inviting migraine pa-
tients for a personal consultation to discuss preventive treatment there even was more 
improvement. 
The attack frequency at which patients are recommended to start preventive therapy 
varies widely in guidelines22,23. The Dutch guidelines recommend preventive therapy 
in case of two or more attacks per month in primary care3 or advises preventive treat-
ment in case of three of more attacks per month in secondary care4.
Our rate of 13% preventive treatment is in line with studies in other countries7,9-12,24-27.
some studies, however, reported a lower frequency of use25,28. Others have estimated 
that 5-83% of the migraine patient qualifies for preventive treatment8,10,29. One study 
in the same population as ours claims much higher numbers for prevention30. 
However this study is performed in a high selective population of patients referred to 
a neurologist and as the presented data do not correspond with previous studies12,24,25, 
this study is of questionable importance to compare preventive treatment with. 
Our study period covers 11 years with in average for 3.9 person years availability, 
whereas most previous studies reported the actual number of patients per year. It 
shows that when cumulated over a longer period many more patients, 44.3% of all 
patients, have tried preventive treatment, which is well above previous 
estimates7,9-12,24-27.
In the recent study by Berger et al, based on a Us health insurance claims database, 
continued use was lower. For example, for beta-blocker use after 6 months continued 
use was 43.1%, compared to 59.6% in ours. However, there were various differences 
with our study. We used the volume of prescriptions, not only on the simple amount 
of prescriptions. Our inclusion is based on a validated method for diagnosis and their 
inclusion was also based on medication use as such (leading to higher numbers of pa-
tients). Finally their research period was shorter (2 years)28.
Preventive treatment is prescribed to only 4.8% of triptan users and to 4.2% of the 
nsaID users (applies only to prescribed medication, not to OTCs). This finding differs 
from other studies in which triptan users have more preventive medication.13,25 
However, other studies are usually not based on clinical diagnosis. 
In this study, using observational primary care information, misclassification of mi-
graine may have occurred. False negative misclassification could have occurred if pa-
tients did not seek GP attention or if they were treated solely by a specialist. as 
neurologists in the netherlands are treating 3% of migraine patients, the possible 
under presenting of severe migraine patients will likewise only be small13. 
Of the 478,585 eligible people in the database we identified 7525 certain and possible 
new migraine patients at an incidence rate of 4.05 per 1000 person years. These find-
ings may not apply to the overall migraine population. In the electronic patient 
record many characteristics of migraine, such as the presence of aura and relation to 
the menstrual period is often insufficiently described. This most likely explains the 
low proportion of patients with aura (20.5%) and the probable under-reporting of 
MrM migraine (9.1%) and typical aura without headache (3.0%). 
as preventive treatment for aWoH is not applicable or controversial, we did not in-
clude this diagnosis in our study. However, we included the MOH, since we had suffi-
cient observation time for each subject to reliably assess the temporal relationship 
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CliniCal iMpliCations
a limited number of patients are current users of preventive treatment (13%), but •	
many patients have prior use (44%). 
after diagnosis there is often an extended time before preventive treatment is ap-•	
plied, in average over 4 years. 
Often there is only one attempt in preventive therapy. •	
The continuation in time of preventive treatment equals study-level.•	
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          Male 1162830 (49.7) 1859 (25.2) 566 (26.7)
          Female 1178150 (50.3) 5508 (74.8) 1515 (72.3)
Age
          0-10 247506 (10.6) 258 (3.5) 90 (4.3)
          10-19 274523 (11.7) 880 (11.9) 256 (12.3)
          21-29 321827 (13.7) 1388 (18.8) 396 (19.0)
          31-39 391838 (16.7) 1826 (24.8) 497 (23.9)
          41-49 361684 (15.5) 1665 (22.6) 450 (21.6)
          51-59 303424 (13.0) 872 (11.8) 249 (12.0)
          61-70 270737 (11.6) 294 (4.0) 83 (4.0)
          71+ 169441 (7.2) 184 (2.5) 61 (2.9)
      










1213 (24.4) 55 (36.2) 25 (15.8)
3762 (75.5) 712 97 (63.8) 133 (84.2)
167 (3.4) - 1 (0.7) - -
607 (12.2) 36 (5.1) 5 (3.3) 12 (7.6)
947 (19.0) 135 (19.0) 12 (7.9) 33 (20.9)
1238 (24.9) 288 (40.4) 34 (22.4) 57 (36.1)
1162 (23.4) 220 (30.9) 30 (19.7) 23 (14.6)
557 (11.2) 33 (4.6) 39 (25.7) 27 (17.1)
191 (3.8) - - 16 (10.5) 4 (2.5)
106 (2.1) - - 15 (9.9) 2 (1.3)
          Table 1. Characteristics of the incident migraine, medication overuse and typical  aura with-
out headache in general practice
* MRM (= Menstrually-related migraine is a subgroup of certain migraine. † AWoH (Typical aura without 
headache) and # MOH (Medication-overuse headache) are not part of the total migraine (= all certain 
migraine). 
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Migraine (certain) AWoH MOH




























(36.7) 38 (32.2) 6 (31.6) 1
2





(25.4) 31 (26.3) 3 (15.8) 7 (25.9) 1 (41.7) 2 (13.3)
Other beta 
blockers
87 (12.7) 59 (11.3) 21 (18.8) 1 (5.3) 4 (14.8) 6 (25.0) -
AII-
antagonists
7 (1.1) 6 (1.1) 1 (0.8) - - - - -
Verapamil 6 (0.9) 5 (1.0) 1 (0.8) - - - - -
Valproic acid 16 (2.3) 8 (1.5) 4 (3.4) 3 (15.8) - - 1 (4.2) 2 (13.3)
Topiramate 2 (0.3) 2 (0.4) - - - - - - - - - -
Pizotifen 80 (11.7) 63 (12.0) 16 (13.6) 1 (5.3) - - - - 2 (13.3)
Clonidine 29 (4.4) 23 (4.4) 2 (1.7) 4 (21.1) 1 (3.7) 1 (4.2) - -
Flunarizine 9 (1.3) 7 (1.3) - - - - 1 (3.7) 2 (38) - -
Methysergide 3 (0.4) 2 (0.4) 1 (0.8) - - - - - - - -
Amitriptyline 36 (5.3) 31 (5.9) 4 (3.4) 1 (5.3) 2 (7.4) - - 2 (13.3)
       
Table 2. Use of preventive treatment in migraine
Figure 1. Process of identification of preventive migraine cases in the Integrated Primary Care 
Information (IPCI) database
Numbers of patients (percentage). MA+= migraine with aura. MA-= migraine without aura, MRM= menstrually-
related migraine (as mentioned in EPR, both regular and pure). AWoH = Typical aura without headache (mi-
graine sans migraine). MOH= medication overuse headache. * Without AWoH, including MOH.
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Figure 2. Kaplan-Meier graph of start with preventive treatment related to time after first diag-
nosis of migraine
Figure 3. Course of preventive treatment
One minus cumulative survival curve of the time span between initial migraine diagnosis and the start of 
preventive treatment, and the difference between males and females. 01= male 02 = female. Time is shown in 
days after initial diagnosis of migraine.
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introduCtion
Migraine is a common and disabling brain disorder, and many patients with migraine 
have severe and disabling attacks.1 Primary care is an important setting for the man-
agement of migraine; for example, in the netherlands, 95% of triptans are prescribed 
in primary care.2
Prophylactic therapy is an option for patients with frequent or long-lasting migraine, 
where treatment can reduce attack frequency by 50% and also reduce attack severity.3-5 
suggested thresholds for starting prophylactic therapy range from attacks twice a 
month to twice a week.3,4,6 Dutch headache guidelines for general practitioners (GPs) 
recommend discussing prophylactic therapy in case of (on average) at least 2 attacks 
each month.7 In Dutch general practice beta-blockers are the most frequently pre-
scribed preventive migraine medication, together with anti-epileptics and other 
anti-hypertensive drugs.8
Preventive therapy is probably indicated in about a third of patients with migraine, 
and a broad range of pharmaceutical and non-pharmaceutical options are available1. 
However, despite that prophylaxis is a safe and effective intervention9-11 only 5-13% 
of migraine patients who qualify for prophylaxis actually receive it.8,12 In many 
countries a substantial proportion of those who might benefit from prevention do not 
receive it.12,13 Moreover, the adherence to prophylaxis is modest.9 In addition, al-
though many patients express a wish for prophylaxis14 (even for infrequent headache) 
GPs and patients are often reluctant to exploit its possibilities.14 Little is known about 
the opinions of GPs and patients regarding prophylaxis or about the considerations 
involved in making a decision about prophylaxis.
To reduce the unmet needs of migraine patients, it is important to elucidate why GPs 
do not prescribe preventive medication and why many patients do not ask for it.14 




Because little is known about how GPs deal with preventive treatment of migraine 
and their underlying motivations, we chose for qualitative research. It was expected 
that, in a focus group, the GPs would stimulate one another to a more profound dis-
cussion on preventive treatment than might occur during an individual interview.
The aim was to recruit a sample of GPs that reflects a mix of urban/rural practitioners 
with a range of age, experience, gender, and type and size of practice. We used ‘theo-
retical sampling’ and expected to reach data saturation with 3-4 focus groups.15 GPs 
who appeared to have a special interest in headache were excluded. Four groups of 
GPs (2 urban and 2 rural) were recruited. The GPs were targeted as existing regional 
aBstraCt
Background
Despite the considerable impact of migraine the use of preventive medication in pri-
mary care is limited. Only about 5% of migraine patients who qualify for prophylaxis 
actually receive it and adherence is far from optimal.  
Aim
To explore the opinions of general practitioners (GPs) regarding preventive medica-
tion for migraine. 
Design




a total of 24 GPs.
Method
Four focus groups (6 GPs each) were formed. GPs were purposively sampled to acquire 
a range of participants, reflecting the more general GP population.
Results
GPs perceived patients’ concerns about the impact of migraine and the potential 
benefits of prophylaxis. However, some were hesitant to start prescribing prophylaxis 
due to doubts about effectiveness, potential side-effects, and the risk of developing 
drug dependency. GPs’ decisions were often based on considerations other than those 
presented in national guidelines, e.g. the patient’s need to control their own problem. 
Many GPs placed responsibility for initiating prophylaxis with the patient. 
Conclusion
Various considerations hamper GPs from managing migraine with preventive medi-
cation, and various patient-related concerns cause GPs to deviate from national 
headache guidelines.  
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results
analysis of the data revealed six main themes.
1) GPs’ general views on migraine
In the present study many GPs believed that even when acute treatment was optimal, 
migraine patients with frequent attacks still had a ‘serious’ health problem. Of the 24 
GPs, 17 stated that migraine patients need as much attention as patients with, e.g. 
COPD or diabetes, but migraine patients did not receive any form of chronic disease 
monitoring. 
‘Why is so little attention paid to migraine? We’re expected to go along with the hype that 
diabetes is a really nasty disease, asthma is a really nasty disease, but with migraine we 
just have to accept the lack of attention for it.’  (Group 3, GP 2)
However, a minority of GPs believed that the patient is to blame for the high attack 
frequency, or that the decision to consult the GP should be left to the patient without 
actively offering follow-up appointments.
GPs felt positive about migraine patients and their search for help, valued migraine 
consultations because they challenged their knowledge, believed that migraine is a 
treatable disease, and regarded their own treatment as sufficiently patient-centred. 
Those GPs with migraine themselves (at least one in each focus group) claimed a 
greater understanding of the significance of the impact of migraine. almost all GPs 
were able to describe the patients’ (or recall exceptional) stories about the severity of 
migraine attacks.
2) Reluctance to start prescribing prophylaxis
GPs frequently mentioned that patients were reluctant to take medication for preven-
tive purposes, even when they understood its benefit. Many GPs found that the disad-
vantages often outweigh the benefits of preventive therapy. For example, four GPs 
were concerned about the ‘medicalising’ effects of preventing migraine or thought 
that the patient’s concerns about this hampered the initiation of prevention. 
‘With migraine there’s a price to pay every single day for effective prevention, it’s the same 
with epilepsy.’ (Group 2, GP 4)
‘In my estimation, about half of the patients who qualify for prophylaxis don’t really 
want it.’ (Group 1, GP 6)
GPs believed that patients did take any downside of preventive treatment into ac-
count, such as adverse reactions and drug dependency. GPs told that they often heard 
from patients about their fear of drug dependency. These downsides of medication 
groups and all the GPs of the four groups received (via e-mail) an invitation and an 
answer form. 
Of the 32 invited GPs, 24 attended the focus group meetings, with (on average) 6 GPs 
per group. Their mean age was 48 (range 31-59) years and there were 10 females and 14 
males. This distribution broadly reflects the Dutch situation.8,14 Of the 24 GPs, 11 
worked in a group practice, 3 in a two-handed practice, and 10 in a single-handed 
practice. Of the 24 participating GPs, 18 had ≥ 10 years experience and 22 worked 
full-time in general practice. Of all GPs, 3 suffered from infrequent migraine them-
selves, and 2 suffered from frequent migraine attacks. 
Data generation
each focus group meeting was chaired by an independent health scientist experienced 
in moderating headache focus groups (Muller JaG, see acknowledgements). The 
moderator conducted the group meetings using an interview guide (compiled by akn 
and FD). To facilitate discussion we used the themes ‘general attitudes towards mi-
graine’ (such as feeling comfortable in consultations with migraine patients),16 and 
‘scenarios for treatment goals and prophylactic treatment’, supported by a range of 
questions and statements. each session lasted about 2 hours and was digitally re-
corded. The audio-recordings were transcribed. 
Analysis
The recordings were analysed independently by three researchers (FD, akn and Ba). 
Because the DVD recordings provided the most detailed information on both verbal 
and non-verbal communication, these served as the primary data source.17-19 The re-
searchers used regular DVD-reading software with good on-screen forward/backward 
and other search possibilities. The DVDs allowed both verbal and non-verbal indica-
tions to support an opinion given by others in the group. 
The three investigators independently identified ‘themes’ on preventive treatment, 
emerging from the data. These themes were written in text form and then organised 
into categories and (sub-) themes according to the rules of thematic analysis (by 
FD).19-21 The subsequent draft analytical framework was discussed and decided upon 
with the other members of the team. In case of disagreement between the researchers, 
the theme was analysed again by those involved; in case of a persisting discrepancy 
consensus was sought and reached between the researchers. Using this framework, an 
interpretative analysis of the data enabled to identify several related, but separate, 
topics of experience and reasoning regarding prophylactic treatment for migraine, 
and a tentative model to elucidate GPs’ considerations regarding preventive migraine 
treatment.
Chapter 476 77Prophylactic treatment of migraine by general practitioners; a qualitative study
GPs found that the threshold to instigate preventive medication in migraine was less 
clear than in other diseases, such as asthma. However, in migraine two factors were 
important. First, the patient’s feelings of being in control of the headache played an 
important role in determining whether they were satisfied with their therapy, a goal 
that was not always achieved with acute treatment only. second, the functional im-
pact on regular activities (work, school, etc) was also important. about 50% of the GPs 
reported that if they personally experienced two or more attacks each month, they 
would accept preventive treatment.
4) Taking the initiative for prophylaxis - patient or physician?
GPs felt reluctant to initiate or explore prophylactic treatment for some patients, even 
when they noticed a high frequency of migraine attacks. Generally, they responded to 
questions or cues coming from the patient. an important cue was when the patient 
expressed that they were unable to cope with their migraine. some GPs (especially 
those who monitored attack medication) noticed the need for prophylaxis at an earlier 
stage, e.g., in case of an excessive use of triptans. 
The approachability of the physician was considered to be an important factor in ex-
ploring or initiating preventive medication.
‘If a general practitioner is open and approachable, then it’s also the patient’s responsibil-
ity whether or not to start taking prophylactic treatment. Patients don’t need to be assertive 
when the doctor is approachable.’ (Group 3, GP 2)
GPs acknowledged the impact of medication overuse and its importance as a marker 
for possible preventive therapy. However, it was felt that this was an area that was not 
well recognised.
‘When practice assistants identify triptan overuse, this is a clear warning that the patient 
needs preventive treatment.’ (Group 1, GP 4)
When patients asked about preventive treatments, the GPs were of the opinion that 
they had already explored other therapies, including dietary approaches and comple-
mentary therapies. GPs considered it important to offer prophylaxis at the most ap-
propriate moment. This was not necessarily the moment of diagnosis, and was 
influenced by realising the impact of the problem by patients.  
‘When considering prophylaxis, you have to choose the right moment to present this op-
tion to the patient.’ (Group 2, GP 1)
5) Start prescribing and managing prophylaxis
GPs felt that their role differed from that of specialists, e.g. they differed in their mo-
tives for starting prophylaxis and its management. GPs were of the opinion that spe-
could make patients less positive toward preventive therapy. GPs understood and ac-
cepted this reluctance; this sometimes made them unwilling to initiate treatment 
and/or convince the patient about the benefits of prophylaxis.  
‘Whenever I offer prophylaxis for migraine I feel as though I’m adding another problem to 
the patient’s already existing health problems.’ (Group 4, GP 1)
‘Patients see prophylaxis as a heavy form of therapy – that’s the way they experience it. 
And that’s an important reason to decline prophylactic treatment.’ (Group 4, GP 4)
‘In the case of prophylaxis, patients receive a huge leaflet full of instructions and warnings 
- this means that the medication prescribed by GPs is a serious matter.’ (Group 4, GP 4)
secondly, GPs felt that when patients used a lot of medication to treat acute attacks, 
the patients would sometimes be more reluctant to consider further/more medica-
tion, even when it was for prevention purposes. Thirdly, GPs thought that patients 
had many concerns about the side-effects of prophylaxis; on this topic GPs thought 
they shared the concerns with their patients.  
‘In the case of migraine, the side-effects of beta-blockers weigh much more heavily (com-
pared with hypertension).’ (Group 2, GP 5)
although some GPs were pessimistic about changing the health behaviour of migraine 
patients, the majority believed that when the goals and benefits of preventive therapy 
were adequately explained, it should be possible to reduce the burden of migraine.
‘The unpredictability of the attacks makes migraine a serious problem; you can’t ignore 
that … and as a doctor you have to do something about it.’ (Group 2, GP 4)
3) Initiating prophylactic medication
a recurring theme was that the trigger to initiate prophylaxis was not a simple sum of 
migraine frequency plus duration. If acute attacks were treated successfully, patients 
are less likely to ask for other types of migraine treatment. However, in the GPs opin-
ion, many patients experienced insufficient relief from acute medication, whether or 
not prescribed by a specialist. GPs believed that patients often did not realise that their 
care was less than optimal.
‘You often hear: I’m satisfied, I don’t need daily treatment myself.’ (Group 2, GP 3)
‘Migraine patients come to the GP’s office only for that ‘stronger’ cure that they really hope 
is available.’ (Group 2, GP 2) 
Chapter 478 79Prophylactic treatment of migraine by general practitioners; a qualitative study
‘The ultimate aim of prophylactic therapy (‘to be free of migraine attacks’) can never really 
be reached.’ (Group 1, GP 6)
‘Sometimes it’s very difficult to give prophylaxis, especially when the patients keep coming 
back without good results.’ (Group 4, GP 3)
‘If a patient has suffered from migraine for the past 30 years, then he’ll also suffer for the 
next 30 years.’ (Group 3, GP 2)
  
‘Even after preventive treatment you don’t leave the surgery whistling, you know that 
you’re still in deep water ’ (Group 1, GP 4)
GPs felt that patients also differed in their appreciation of the benefits of prophylaxis. 
In the perception of GPs some patients were satisfied with only small benefits, whilst 
others expected total resolution of their headache. If patients had a long history of 
migraine, small benefits were often welcome. GPs emphasised that there is no gold 
standard or endpoint for measuring the effects of prophylaxis in the individual 
patient. 
disCussion
Summary of main findings
When considering preventive treatment for migraine, GPs related several facilitating 
and inhibiting factors influencing their actions (Figure 1). GPs perceived the patient’s 
concerns about the impact of migraine. although the benefits of prophylaxis were 
appreciated, they were hesitant about advising their patients, not because of lack of 
knowledge or lack of interest, but because of doubts about its effectiveness and fear of 
side-effects. 
It is not a simple matter to decide whether GPs sufficiently comply with the current 
guideline on headache. In the netherlands, most GPs generally tend to comply with 
their guidelines.22 However, in the present study the respondents deviate from the 
guidelines on the above-mentioned points, indicating that for GPs prophylaxis is not 
simply induced by multiplying duration by frequency. Other guidelines also tend to 
neglect the above-mentioned factors when discussing the decision whether or not to 
start preventive treatment.12,23-29 some guidelines refer to the patient’s wishes or pref-
erences;12,23,27 however, even when this is mentioned, this is not further specified.
another difference between the actions of our GPs and the Dutch GP guideline7 in-
volves taking the initiative for prophylaxis. On this issue some GPs were much more 
reluctant than advised in the guideline, because they felt that the responsibility for ini-
tiating prophylaxis should lie with the patient. Therefore, prophylaxis was not always 
promoted in an active way; this finding warrants further exploration.
cialists simply carried out their protocols (often personal protocols) whereas GPs also 
took co-morbidity and other health-related circumstances into account, and GPs 
thought they gave more notice to the complexity of the context in which prescribing 
took place. 
‘If migraine is combined with some other diseases, then you’re much more likely to give a 
beta-blocker (when indicated).’ (Group 3, GP 4)
‘When you think about the individual tailoring of prophylaxis, GPs handle a lot more 
co-morbidity than specialists.’ (Group 3, GP 5)
‘Migraine therapy actually involves quite a lot of creativity.’ (Group 4, GP 3)
‘Migraine management is more a medical art than just medicine itself.’ (Group 2, GP 1)
There was no consensus among GPs as to how to manage prophylaxis. some scheduled 
regular appointments whereas others had contact only at the start of prophylaxis and 
considered the patients to be responsible for their own subsequent treatment.
‘If the aim of the prophylaxis is achieved, your patients don’t come back again. If you 
compare migraine to diseases like asthma, the control policy is much more structured in 
those other diseases.’ (Group 2, GP 2)
‘Because starting preventive treatment is generally at the patient’s wish, then the moment 
to stop should also be the patient’s decision - I can accept that.’ (Group 4, GP 4)
For participating GPs, the first choice in preventive treatment were beta-blockers as 
prophylactic therapy and about 50% of the GPs thought that the use of beta-blockers 
would result in an additional cardiovascular health benefit. Less than 25% prescribed 
anti-epileptic medication. GPs reported that they were honest and open-minded with 
their patients about the claims made for prophylaxis in relation to the frequency and 
reduction in severity of attacks. non-compliance was seen as a common problem, but 
the GPs were not particularly worried about this. 
6) Expectations of the benefit of prophylaxis
GPs differed in their expectations regarding benefit. some suggested that prophylaxis 
should make migraine disappear, some accepted the evidence-based expectation of a 
50% reduction in attack frequency and attack severity, and others had a low expecta-
tion because of lack of efficacy or because of patients’ reluctance to accept regular 
medication. This low expectation was reflected in a reluctance to instigate prophylac-
tic treatment.
acceptation / rejection of preventive migraine treatment
Figure 1. Interactions of elements playing a role in the considerations of GPs, preventive treatment 
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chronic daily headache,32,33 the needs of migraine patients 34,35, migraine-related deci-
sion-making,36-38 the burden of migraine and impact on quality-of-life,39,40 patient’s 
experience and the expectations of management 16,41,42. One of these latter studies ad-
dressed prophylaxis,42 but the setting was a specialised care clinic and the study aim 
was different from ours. The latter study focuses on whether the physician involves 
the patient in choosing a preventive agent when the decision to start this was already 
made, not on the decision making in starting preventive therapy as in our study. a 
questionnaire study provided information on the extent to which patients accept the 
side-effects of preventive treatment, which is consistent with the findings in the 
present study.43 another study addressed how GPs treated themselves and close rela-
tives,44 one study explored physicians’ understanding of patients with migraine,45 and 
another study reports clinical determinants of preventive therapy in primary care.46
Implications for practice and future research
appropriate prophylaxis is an important factor in the aim to improve the quality of 
care of migraine patients by reducing attack frequency and duration, improving 
functioning and productivity, reducing use of acute medication, and preventing 
medication over-use. The present study has elucidated some factors that prevent GPs 
from adequately managing migraine from this perspective, and might inform the de-
velopment of educational strategies to improve migraine prophylaxis in general 
practice. The results also highlight the difficulties GPs experience in translating 
guidelines into practice and the need to develop guidelines that realistically reflect the 
context in which they are applied.
These factors should be addressed in guideline-setting and post-graduate education. 
Finally, some aspects of our findings need further exploration, and some deserve 
quantification.
a parallel study on migraine patients shows that some elements in the decision-making 
process are similar between GPs and patients, whereas differences also occur.30 For 
example, GPs more often mention the inability to cope with migraine attacks as a 
reason to start taking preventive treatment. It would be worthwhile to further quan-
tify these differences between GPs and patients. 
GPs indicated that they are more respectful to other patient-related conditions and 
co-morbidity than specialists. Contextual factors have a large influence on medical 
care as delivered by GPs. Further exploration of differences between GPs and special-
ists in the consideration of contextual factors needs further research.31  
Most GPs show realistic expectations, although in each focus group one or two were 
pessimistic. This might be due to the discrepancy between the ‘ideal’ of a total relief of 
migraine in contrast to a sometimes moderate or absent effect in actual practice. 
Because GPs and/or patients often have a too positive vision on prevention in advance, 
it is important discuss this issue in postgraduate training and patient education. 
In the present study the GPs expressed a fear regarding drug dependency, but it is un-
clear whether they refer to fear for actual addiction, such as with benzodiazepines. 
also, the GPs seemed to refer to a broader negative association with the daily use of 
medication, such as when patients use (too) many drugs.
GPs occasionally felt that patients were suggesting that they did not take migraine seri-
ously. The GPs did not agree with this and sincerely believed that they always paid ad-
equate attention to migraine headaches. The patients were told to be aware that, even 
with optimal attack treatment, migraine patients with frequent attacks had a ‘serious’ 
health problem. GPs’ approach to migraine as a health problem was not different from 
other diseases and some GPs regarded headache as an interesting problem because it 
challenges their own knowledge and skills. The lack of regular follow-up was seen as 
being unlike other chronic conditions in which preventive medication is used.
Study strengths and limitations
although the composition of the focus groups broadly reflects the characteristics of 
GPs in the netherlands, our GP group may have reflected those with a particular inter-
est in headache. In the fourth focus group no new themes or additional information 
on those themes were raised, so it is unlikely that we missed any important themes. 
a weakness of the study was that all meetings were conducted in the Dutch language 
and are reported here in english. Qualitative studies aim to capture meaning from the 
narrative of the respondents and some distortion may have occurred in the transla-
tion process. The text was corrected by two native english speakers, with the Dutch 
text at hand, and verified by a physician-headache expert.  
Comparison with other studies
although migraine has a complex biopsychosocial context, few qualitative studies on 
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Medicalising effect
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Large funtional impact on activities
No or moderate effect attack treatment




Chapter 482 83Prophylactic treatment of migraine by general practitioners; a qualitative study
 17.  Heath C, Hindmarsh J, Luff P. Video in Qualitative research. saGe. 2010.
18.  Pope C, Mays n. reaching the parts other methods cannot reach: an introduction 
to qualitative methods in health and health services research. BMJ 1995;311 
(6996):42-45.
19.  Pope C, Ziebland s, Mays n. Qualitative research in health care. analysing qualita-
tive data. BMJ 2000;320(7227):114-116.
20.  Joffe H, Yardley L. Content and thematic analysis. In: Marks DF, Yardley L, editors. 
research methods for clinical and health psychology. London, sage publications. 
2003. 56-68.
21.  Chamberlain k, Camic P, Yardley L. Qualitative analysis of experience: grounded 
theory and case studies. In: Marks DF, Yardley L, editors. research methods for 
clinical and health psychology. London, sage publications. 2003. 69-89.
22.  Lugtenberg M, Burgers Js, Westert GP. effects of evidence-based clinical practice 
guidelines on quality of care: a systematic review. Qual Saf Health Care 2009;18 
(5):385-392.
23.  D’amico D, Tepper sJ. Prophylaxis of migraine: general principles and patient ac-
ceptance. Neuropsychiatr Dis Treat 2008;4(6):1155-1167.
24.  Dowson aJ, Lipscombe s, sender J, rees T, Watson D. new guidelines for the 
management of migraine in primary care. Curr Med Res Opin 2002;18(7):414-439.
25.  evers s, afra J, Frese a, Goadsby PJ, Linde M, May a, sandor Ps. eFns guideline on 
the drug treatment of migraine - report of an eFns task force. Eur J Neurol 2006;13 
(6):560-572.
26.  Lewis D, ashwal s, Hershey a, Hirtz D, Yonker M, silberstein s. Practice parameter: 
pharmacological treatment of migraine headache in children and adolescents: 
report of the american academy of neurology Quality standards subcommittee 
and the Practice Committee of the Child neurology society. Neurology 2004;63 
(12):2215-2224.
27.  Modi s, Lowder DM. Medications for migraine prophylaxis. Am Fam Physician 
2006;73(1):72-78.
28.  Pryse-Phillips We, Dodick DW, edmeads JG, Gawel MJ, nelson rF, Purdy ra, 
robinson G, stirling D, Worthington I. Guidelines for the diagnosis and manage-
ment of migraine in clinical practice. Canadian Headache society. CMAJ 1997;156 
(9):1273-1287.
29.  Tepper sJ, D’amico D, Baos V, Blakeborough P, Dowson a. Guidelines for Prescribing 
Prophylactic Medications for Migraine: a survey among Headache specialist 
Physicians in Different Countries. Headache Care 2004;1(4):267-272.
30.  Dekker, F., knuistingh neven, a., andriesse, B., kernick, D., Ferrari, M. D., and 
assendelft, W. J. J. Prophylactic treatment of migraine; the patient’s view, a quali-
tative study. BMC Fam Pract 2012;13(1):13.
31.  Weiner sJ, schwartz a, Weaver F, Goldberg J, Yudkowsky r, sharma G, Binns-
Calvey a, Preyss B, schapira MM, Persell sD, Jacobs e, abrams rI. Contextual errors 
and failures in individualizing patient care: a multicenter study. Ann Intern Med 
2010;153(2):69-75.
references
1.  Goadsby PJ, sprenger T. Current practice and future directions in the prevention 
and acute management of migraine. Lancet Neurol 2010;9(3):285-298.
2.  Dekker F, Wiendels n, de Valk V, van der Vliet C, knuistingh neven a, assendelft 
WJJ, Ferrari MD. Triptan overuse in the Dutch general population: a nationwide 
pharmaco-epidemiology database analysis in 6.7 million people. Cephalalgia 
2011;31(8):943-952.
3.  D’amico D, solari a, Usai s, santoro P, Bernardoni P, Frediani F, De Marco r, 
Massetto n, Bussone G. Improvement in quality of life and activity limitations in 
migraine patients after prophylaxis. a prospective longitudinal multicentre 
study. Cephalalgia 2006;26(6):691-696.
4.  ramadan nM, schultz LL, Gilkey sJ. Migraine prophylactic drugs: proof of efficacy, 
utilization and cost. Cephalalgia 1997;17(2):73-80.
5.  silberstein sD, Winner Pk, Chmiel JJ. Migraine preventive medication reduces 
resource utilization. Headache 2003;43(3):171-178.
6.  silberstein sD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002;22 
(7):491-512.
7.  Grol MH, neven ak, Pijnenborg L, Goudswaard an. [summary of the practice 
guideline ‘Headache’ from the Dutch College of General Practitioners]. Ned 
Tijdschr Geneeskd 2006;150(6):305-309.
8.  rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, egberts aC. Incidence and 
determinants of migraine prophylactic medication in the netherlands. Eur J Clin 
Pharmacol 2002;58(2):149-155.
9.  Linde M, Jonsson P, Hedenrud T. Influence of disease features on adherence to 
prophylactic migraine medication. Acta Neurol Scand 2008;118(6):367-372.
10.  Mulleners WM, Chronicle eP. anticonvulsants in migraine prophylaxis: a 
Cochrane review. Cephalalgia 2008;28(6):585-597.
11.  Victor s, ryan sW. Drugs for preventing migraine headaches in children. Cochrane 
Database Syst Rev 2003;(4):CD002761.
12.  Lipton rB, Bigal Me, Diamond M, Freitag F, reed ML, stewart WF. Migraine preva-
lence, disease burden, and the need for preventive therapy. Neurology 2007;68 
(5):343-349.
13.  Cevoli s, D’amico D, Martelletti P, Valguarnera F, Del Be, De sr, sarchielli P, 
narbone M, Testa L, Genco s, Bussone G, Cortelli P. Underdiagnosis and under-
treatment of migraine in Italy: a survey of patients attending for the first time 10 
headache centres. Cephalalgia 2009;29(12):1285-1293.
14.  kol CM, Dekker F, neven ak, assendelft WJ, Blom JW. acceptance or rejection of 
prophylactic medicine in patients with migraine: a cross-sectional study. Br J Gen 
Pract 2008;58(547):98-101.
15.  kuper a, Lingard L, Levinson W. Critically appraising qualitative research. BMJ 
2008;337a1035.
16.  Morgan M, Jenkins L, ridsdale L. Patient pressure for referral for headache: a quali-
tative study of GPs’ referral behaviour. Br J Gen Pract 2007;57(534):29-35.
Chapter 484
32.  Peters M, abu-saad HH, Vydelingum V, Dowson a, Murphy M. Migraine and 
chronic daily headache management: a qualitative study of patients’ perceptions. 
Scand J Caring Sci 2004;18(3):294-303.
33.  Peters M, Huijer abu-saad H, Vydelingum V, Dowson a, Murphy M. The patients’ 
perceptions of migraine and chronic daily  headache: a qualitative study. 
J Headache Pain 2005;6(1):40-47.
34.  Belam J, Harris G, kernick D, kline F, Lindley k, McWatt J, Mitchell a, reinhold D. 
a qualitative study of migraine involving patient researchers. Br J Gen Pract 2005; 
55(511):87-93.
35.  Cottrell Ck, Drew JB, Waller se, Holroyd ka, Brose Ja, O’Donnell FJ. Perceptions 
and needs of patients with migraine: a focus group study. J Fam Pract 2002; 51(2): 
142-147.
36.  Peters M, abu-saad HH, Vydelingum V, Dowson a, Murphy M. Patients’ decision-
making for migraine and chronic daily headache management. a qualitative 
study. Cephalalgia 2003;23(8):833-841.
37.  Ivers H, McGrath PJ, Purdy ra, Hennigar aW, Campbell Ma. Decision making in 
migraine patients taking sumatriptan: an exploratory study. Headache 2000; 
40(2):129-136.
38.  Meyer Ga. The art of watching out: vigilance in women who have migraine 
headaches. Qual Health Res 2002;12(9):1220-1234.
39.  Tenhunen k, elander J. a qualitative analysis of psychological processes mediat-
ing quality of life impairments in chronic daily headache. J Health Psychol 2005; 
10(3):397-407.
40.  ruiz dV, I, Gonzalez n, etxeberria Y, Garcia-Monco JC. Quality of life in migraine 
patients: a qualitative study. Cephalalgia 2003;23(9):892-900.
41.  Moloney MF, strickland OL, Derossett se, Melby Mk, Dietrich as. The experi-
ences of midlife women with migraines. J Nurs Scholarsh 2006;38(3):278-285.
42.  rozen TD. Migraine prevention: what patients want from medication and their 
physicians (a headache specialty clinic perspective). Headache 2006;46(5):750-
753.
43.  kowacs Pa, Piovesan eJ, Tepper sJ. rejection and acceptance of possible side ef-
fects of migraine prophylactic drugs. Headache 2009;49(7):1022-1027.
44.  Ducros a, romatet s, saint MT, allaf B. Use of antimigraine treatments by general 
practitioners. Headache 2011;51(7):1122-1131.
45.  Lipton rB, stewart WF. acute migraine therapy: do doctors understand what pa-
tients with migraine want from therapy? Headache 1999;39(suppl 2):s20-s26.
46.  Valade D, Lanteri-Minet M, radat F, Mekies C, Lucas C, Vives e, Joubert JM, Geraud 
G. Clinical determinants of migraine preventive treatment: contribution of 




Prophylactic treatment of migraine;  







and Willem JJ assendelft
BMC Family Practice 2012; 13(1):13.
Chapter 586 87Prophylactic treatment of migraine; the patient’s view, a qualitative study
BaCKground
Primary care is an important setting for the management of migraine and in many 
countries most migraine consultations occur in this context1. In the netherlands, 
migraine is mainly managed in primary care and 95% of prescriptions for triptans are 
issued in this setting 2. 
Prophylactic therapy is an option for patients with frequent or long-lasting migraine 
headaches3-8. The results of 6-12 months of preventive treatment are that in about 
50% of patients the attack frequency decreases by 50%. also, the attacks are often less 
severe 9. Drop-out by adverse events is around 5%10, drop-out due to ineffectiveness is 
unknown in usual care.
Dutch GP guidelines on headache recommend discussing prophylactic therapy with 
patients who suffer (on average) 2 or more attacks each month11. Despite it being a safe 
and more or less effective treatment option, only 7-13 % of the migraine patients re-
ceive it7,12 and the benefits are not widely accepted. Little is known about the opinions 
of GPs and patients regarding prophylaxis, or the determinants behind decisions 
whether or not to start prophylaxis. 
This qualitative study explores the opinions, motives and expectations of migraine 
patients about prophylactic migraine therapy. a similar study focusing on GPs’ opin-




Three focus groups of migraine patients were formed, 2 from urban areas and 1 from a 
rural area. Patient selection was based on pre-specified criteria, aiming to reflect a 
broad range of experience (from young to old), gender (separate groups for males and 
females), attack frequency (≥ 2attacks/month) and pain level (≥ 6 on a scale of 10 
matching migraine, 1 being almost no headache and 10 being the worst headache 
ever). Our goal was to achieve a diversity of migraine patients, corresponding to gen-
eral practice and with a sufficiently high frequency to be eligible for preventive ther-
apy12,13. The study was approved by the ethics Committee of the Leiden University 
Medical Centre.
One group of 7 females and a second group of 6 males were recruited from 5 urban 
primary care health centres or group practices. see patient characteristics in Table 2. 
We selected patients based on the diagnosis migraine and all these patients used pre-
scribed medication for acute treatment. Thirteen patients had consulted their GP or a 
neurologist for their migraine (2 groups). a third group, comprising 7 females from a 
rural area, was recruited by a researcher investigating consumer behaviour. In this 
group each participant was approached by telephone and selected if they had migraine 




Prophylactic treatment is an important but under-utilised option for the manage-
ment of migraine. Patients and physicians appear to have reservations about initiating 
this treatment option. This paper explores the opinions, motives and expectations of 
patients regarding prophylactic migraine therapy. 
Methods
a qualitative focus group study in general practice in the netherlands with twenty 
patients recruited from urban and rural general practices. Three focus group meetings 
were held with 6-7 migraine patients per group (2 female and 1 male group). all partici-
pants were migraine patients according to the IHs (International Headache society); 
9 had experience with prophylactic medication. The focus group meetings were ana-
lysed using a general thematic analysis. 
Results
For patients several distinguished factors count when making a decision on prophy-
lactic treatment. The decision of a patient on prophylactic medication is depending 
on experience and perspectives, grouped into five categories, namely the context of 
being active or passive in taking the initiative to start prophylaxis; assessing the ad-
vantages and disadvantages of prophylaxis; satisfaction with current migraine treat-
ment; the relationship with the physician and the feeling to be heard; and previous 
steps taken to prevent migraine.
Conclusion
In addition to the functional impact of migraine, the decision to start prophylaxis is 
based on a complex of considerations from the patient’s perspective (e.g. perceived 
burden of migraine, expected benefits or disadvantages, interaction with relatives, 
colleagues and physician). Therefore, when advising migraine patients about prophy-
laxis, their opinions should be taken into account. Patients need to be open to advice 
and information and intervention have to be offered at an appropriate moment in the 
course of migraine.
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migraine over time, treatment for attacks, and treatment goals, etc.). Prophylaxis was 
discussed, including the advantages and disadvantages, and the patients’ experiences 
and attitudes towards preventive medication. In all focus groups sessions a topic list 
was used, which included some provocative statements to stimulate discussion and 
the exchange of ideas. The quantitative data listed in the results section are based on 
this topic list. all sessions were digitally recorded on DVD.  
Data analysis
The recordings were analysed independently by three researchers (FD, akn and Ba). 
Because the DVD recordings provided the most detailed information on both verbal 
and non-verbal communication, these served as the primary data source14-16. The re-
searchers used regular DVD-reading software with good on-screen forward/backward 
and other search possibilities. The DVDs allowed both hearing and seeing of non-
verbal indications as to whether or not an opinion was supported by others in the 
group. The three investigators individually identified ‘themes’, that is remarks con-
taining information on prophylactic therapy, or relevant or closely related to it. a 
transcript was made  of all the comments by the participants on preventive treatment. 
subsequently these comments were grouped independently by three researchers. The 
identified themes were written out and then organised into categories and (sub-) 
themes by the principal investigator, according to the rules of ‘thematic analysis16-18, 
into a draft analytical framework. This framework was consecutively discussed and 
decided upon with the other members of the team. 
When there was disagreement between researchers in the analysis, the theme was ana-
lysed again by the disagreeing researchers and in case of a persisting discrepancy con-
sensus was soughed and reached between the researchers. The analysis was coordinated 
by the principal investigator, who did put the remaining questions each time to both 
the other researchers. an interpretative analysis of the data with the help of this 
framework enabled the identification of several related but separate topics of experi-
ence and reasoning regarding prophylactic treatment for migraine and a tentative 
model for understanding patients’ decision making regarding such treatment. 
results
Five main categories of themes emerged from the focus group meetings.
1) Previous steps taken to prevent migraine
 With regard to preventive measures, many participants were concerned that migraine 
was not well understood, and some found it hard to rely on prophylactic therapy be-
cause the mechanism was still unclear to them.
almost all patients had experimented with behavioural, lifestyle or dietary actions, 
mostly without success and later therefore abandoned. However, some patients con-
Total Female 1 Male Female 2
n = 20 n = 7 n = 6 n = 7
Pain score*  (1-10) 8.4 8.2 8.4 8.6
attack freq./month 2 - 5 16 6 5 5
age ≥ 5 4 1 1 2
< 25 4 2 - 2
25 – 50 11 3 4 4
> 50 5 2 2 1
mean 43 yrs 42 yrs 47 yrs 39 yrs
education level low 3 - 1 2
medium 14 5 5 4
high 3 2 - 1
Paid work (hrs/wk) none 5 2 1 2
< 36 8 4 1 3
≥ 36 7 1 4 2
mean (hours/
week)
22 15 29 21
* Pain level during maximum of attack on a 1-10 numeric scale (10 being unbearable pain)
The application form contained two questions on migraine (severity and frequency), 
one on the level of education and one about the number of hours in paid work. Based 
on this application form, the researcher made  a comparison with national data on 
migraine patients in general practice12. regarding the severity and frequency of the 
migraine, the composition of the three groups corresponded well with the average 
characteristics of migraine patients in Dutch general practice. The subject mentioned 
on the invitation was migraine headache in general, without a specific indication of 
our interest in preventive treatment.
Data generation
The focus group meetings were chaired by an independent moderator experienced in 
focus group research. The principal investigator (FD) observed all meetings from an 
adjacent room via a monitor with sound, but had no influence on the discussions. The 
moderator used a specially prepared interview guide (compiled by akn and FD) 
which started with an introduction and familiarization, followed by discussion on 
the characteristics of the patients’ migraine experience (e.g. age at onset, changes in 
Table 1.  Patient characteristics, 2 female and 1 male groups.
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“I already take so many medications, so don’t do that preventive thing to me. When I feel 
a headache coming, I just take a tablet and that’s prevention to me.” (Group 2, PT 3)
Most patients agreed that effective migraine treatment consists of effective attack 
management in addition to effective prophylaxis. More than half of the patients 
wanted to reduce the use of attack treatment, because they felt they were using too 
many triptans or painkillers. However, patients still focused on the importance of at-
tack treatment; prophylaxis took second place. This focus on attack treatment ham-
pered their thinking about other strategies to reduce the burden of migraine. 
“I’m afraid of the side-effects of triptans; that’s making me more open to prophylaxis.” 
(Group 1, PT 5)
The feeling of being in control of the migraine and not being controlled by it was 
considered a very important factor. Participants accepted a high frequency of migraine 
and/or long-lasting attacks as arguments for prophylaxis. However, the vast majority 
believed that if the attack treatment was extremely effective, there would be no need 
for prophylaxis. This was irrespective of the number of attacks and was in relation to 
what patients found ‘normal’ for them.
“I’m not stuffing my body with medication when I have an attack 3 times a month, even 
if it is terribly intense, but when it’s good treatable.” (Group 2, PT 7)
3) Taking the initiative for prophylaxis 
although not every patient had personal experience with migraine prophylaxis, al-
most everyone knew about its existence. Most patients received information from 
family members, physicians, the Internet, the media or pharmacists. Many partici-
pants had searched the Internet for specific information on prophylaxis and encoun-
tered both positive and negative information such as stories of patients who have had 
a lot to benefit from prophylaxis and others who had no good effect and suffered from 
significant side effects.
“I’m using preventive therapy now. I didn’t hear anything about it from the doctor … I 
found out myself that something like that was available. It was in a women’s magazine, 
not via the GP. I’m unhappy about that…“(Group 3, PT 7)
Testimonies of other patients or information of a patient headache association was 
not clear enough or too ambiguous to make a first step. It did not have a direct influ-
ence on their own health-seeking behaviour.
“Anti-epileptics, that sounds dreadful. The sort of thing you associate with lying on the 
ground with foam around your mouth.” (Group 2, PT 3)
tinued with these behaviours, even when they believed that they probably provided 
no benefit. Many participants avoided certain foods and other types of products. 
some used specific products in order to promote their health.
‘stabilizing the biological clock’, i.e., developing a stable day-night rhythm, was a 
widely used precaution by more than half of participants. Interventions were often 
supported by their physicians. For some patients, prophylaxis was the last resort.
“I ‘did’ the whole alternative circuit. I tried everything. Only after all that was I ready for 
prophylaxis.” (Group 1, PT 1)
Many types of complementary medicines had been or were being used. Most patients 
believed that although prophylactic treatment is only moderately effective, it is still 
more effective than complementary therapies. Using a complementary therapy often 
hampered patients from considering prophylaxis; they were waiting for the effects of 
the complementary interventions. Once complementary therapies had failed, they 
were more willing to try regular therapies. 
“In the beginning, when my migraines were first diagnosed, we tried everything and every 
therapy to treat the attacks. Later on, I stopped making appointments for my migraines, I 
was so disappointed … and I tried everything myself, avoided all kinds of food, gulped 
down vitamins and other supplements, relaxation therapies, etc., etc.” (Group 3, PT 5)
2) Satisfaction with current migraine treatment
Migraine patients differed in how they determined whether or not they were satisfied 
with their treatment. some patients were satisfied when they were able to keep on 
functioning at work or at home, others were only satisfied when the headache 
disappeared. 
a few participants kept a highly structured diary to ascertain whether there were any 
factors that influenced their migraine. keeping a diary made patients more accessible 
to prophylactic medication.
“My GP gave a kind of brochure; later on I continued keeping record of my headaches. I 
think that’s very important; noting parallel things, food and so, looking back whether 
medication works.” (Group 1, PT 1)
according to the patients, preventing the overuse of attack treatment was only occa-
sionally considered by the GP. according to the patients, almost no GP used that argu-
ment in the discussion about whether or not to start preventive treatment. remarkably, 
some patients who used excessive attack treatment mistakenly called it ‘prevention’. 
In their incorrect but exemplary way of thinking, they considered it to be prophylaxis 
because they used the attack treatment before a migraine attack occurred. some pa-
tients showed very limited awareness about the risks of overuse of attack treatment. 
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“Accepting prophylaxis is difficult, because my attacks sometimes stay away for a long 
time. It’s sometimes months before I have another attack, but once they start they’re very 
frequent.” (Group 3, PT 3)
“I’m now using so many triptans … this can’t be a good thing.” (Group 3, PT 2)
“I just don’t want to do it. I’m very anti-drugs.” (Group 3, PT 1)
When considering prophylaxis, all patients experienced negative or obstructive ele-
ments, as well as positive factors. Participants had differing views on this subject, 
some mainly emphasised the positive aspects and others mainly the negative 
aspects. 
The most important negative factors were the fear of side-effects, the assumption that 
prophylaxis will have little impact, and the feeling of becoming a chronic patient. The 
issue of ‘becoming a chronic patient’ was expressed in all sessions, and about 50% of 
the patients associated the use of prophylactic drugs with ‘old age’ and ‘chronic dis-
ease’. Participants emphasised that they did not feel like a ‘patient’ in between the 
migraine attacks, so it did not feel appropriate to use medication on a daily basis. 
Despite a high impact of migraine and although many (daily) preventive measures 
and behavioural adaptations has been adopted, the use of prophylactic drugs was not 
easily accepted. 
More than half of the patients stated that daily use of tablets for migraine would make 
them feel emotionally unhealthier. Other negative factors included the fear of drug 
dependency, a low assessment of their own capacity for compliance, and the negative 
reactions of persons in their direct surroundings.
“If I were to take tablets every day, I’d feel like I’m a patient. Now I just have a headache 
sometimes … actually it’s many times.” (Group 3, PT 3)
“I think I’d forget it (medication) so often that it wouldn’t be effective.” (Group 3, PT 7)
“I’m afraid of becoming dependent on those drugs.” (Group 3, PT 2)
“It’s something in the head about not wanting to take tablets every day.” (Group 2, PT 4)
“When you receive preventive therapy for something, people think you’re a pitiful case.” 
(Group 2, PT 6)
“The question is: how does migraine affect your life. I don’t want migraine to affect my 
life, and taking drugs every day would have a major effect on my life.” (Group 1, PT 6)
The factors that contribute to positive decision appear to rest on a more calculated 
way of thinking or approach; weighing the advantages against the disadvantages and 
assessment of the degree of effectiveness. 
Half of the participants had benefited from prophylaxis. The main positive benefits 
were a reduction in the burden of migraine with an increase in the range of abilities; 
this was particularly important when the impact was high. Other positive features 
were the ease of administration, an overall general gain in health, a reduction in acute 
There was no consensus as to who should take the initiative for prophylaxis. about 
half of the patients expected an active approach from their GP. Others (more urban 
and/or more highly educated) preferred to take the initiative themselves. all patients 
expected that their GP should be able to discuss the advantages and disadvantages of 
prophylaxis. 
Patients found it important that discussion about prophylaxis should take place at the 
appropriate moment. This was not necessarily at the initial diagnosis, but when the 
patient knew more about the impact of migraine and the effectiveness of attack treat-
ment. The need for prophylaxis could then be considered within a more realistic 
context.
“I never wanted it; I’m not a pill swallower. But I find it terrible to have to call my col-
leagues that I have another attack again. Then they stare at me with negatively loaden, 
piercing eyes. And I have started to think differently about daily treatment.” (Group 2, PT 
6)
Prophylaxis was often discussed when patients indicated they were no longer able to 
cope with the headache attacks. 
“My migraines were so severe that I went to the doctor … I couldn’t do anything but cry. He 
tried to comfort me and offered prophylaxis.” (Group 3, PT 4)
For a few participants, the initiative for prophylaxis was taken by the GP based on the 
amount of prescribed attack medication; these GPs actively monitored the use of 
triptans and painkillers. When confronted with such an active approach, the patients 
were initially cautious but subsequently regarded the GP’s intervention as positive. 
Ultimately, almost all patients desired to have their own control over the final 
decision. 
 “Sometimes I’m afraid he’ll phone again ... because I take too much medication. I once 
phoned for a repeat prescription, but the doctor called back and said: You’ve used too much 
this month. Then he mentioned preventive therapy. It feels OK, that he’s concerned about 
me.” (Group 1, PT 5)
4) Assessing the advantages and disadvantages of prophylaxis
From the patient’s perspective, the decision to start prophylaxis is complex. There is a 
wide range of perceived advantages and disadvantages, migraine patterns often vary, 
and the underlying concerns also differ.  
“The pattern of attacks of my migraine is too weird to be able to figure out whether prophy-
laxis will help me or not.” (Group 3, PT 2)
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“He (GP) was really concerned about me, about the enormous number of attacks I had. 
That was good and very considerate of him.” (Group 1, PT 4)
“I think that he (GP) thinks: what on earth can I do for you anyway…” (Group 2, PT 2)
“I found that now something really has to be done … so I went to the doctor. He said: It 
sounds like classic migraine; we’ll see what we can do. I should have done this much earlier 
… at last I felt that someone understood.” (Group 1, PT 2)
“There’s always that fear of the next attack, and my family doctor seemed to understand 
that fear. First and foremost, you have to be taken seriously by your doctor.” (Group 1, PT 
1)
an important influence was the way their GPs treated them. Positive factors in pro-
moting prevention were having a positive interaction and the feeling being taken seri-
ously. On the other hand, being dissatisfied about the approach of the physician 
hampered the willingness to consider prophylaxis.
“Primarily I want to be taken seriously, but I can not complain. He’s handled it well, with 
the start of preventive treatment.” (Goup1 PT 5)
“If you have more than two attacks a month, they just give you a prescription for anti-ep-
ileptics and - before you know it - you’re outside again.” (Group 3, PT 6)
disCussion
Summary of main findings
The present study describes patients’ subjective opinions about prophylaxis as a 
treatment option for migraine. 
a number of conditions that must be met before preventive therapy is accepted and 
that these often are related to each other (figure 1). These conditions can be patient 
related, clinician related or be related to the disease or the disease process.  knowledge 
on the importance of these issues for the decision making of patients is crucial for 
physicians dealing with migraine patients in daily practice.
Patients indicate a number of important factors in favour of the use of prophylaxis 
related to the perceived burden of migraine; a high frequency of attacks, severe at-
tacks, and lack of effectiveness of attack treatment. These are characteristics of the 
migraine itself, on which physicians do not have much influence (however they have 
certainly on proper attack treatment). The patient makes a balance of pros and cons. 
expectations of the beneficial effects, fear of side effects and drug dependency and 
negative health feeling in case of daily use of medication, play a considerable role in 
making this balance. 
 The willingness to try prophylaxis increased after other interventions had been tried 
(e.g. dietary changes, changes in lifestyle or previous complementary treatments). 
Patients prefer strongly to take the decision themselves and want to have responsibil-
medication, less confrontations with the GP in case acute medication was used exces-
sively, and less pressure from others close to them.  When the benefits were clearer, 
patients were able to accept prophylaxis or were at least willing to try it. Most of the 
patients stated they would accept daily drug intake if their migraine frequency would 
be halved. 
“I don’t care what I have to do; I’d do anything to get rid of my headaches.” (Gr 2, PT 4)
“If it worked for 100%, I would certainly join the users!” (Group 3, PT 3)
“With prophylactic drugs you’re able to participate much more in sport activities - which 
I enjoy very much.” (Group 1, PT 4)
“If somebody said to me: “The migraines will disappear if I cut off your hand”, then I’d 
say: Cut off my whole arm!” (Group 3, PT 3)
Many patients anticipated reimbursement problems with the healthcare insurance 
companies when receiving prophylactic therapy (in fact, in the netherlands, all costs 
of prophylactic therapies are fully covered by healthcare insurance for all patients). 
Patients who had experience with prophylaxis reported that they had no problems 
with health insurance or the financial side of treatment costs.
apart from the duration of the attack another important factor was the situation in-
volved, e.g. being at school, at work, or with friends or family. For similar attack rates 
the perceived need for prophylaxis differed between patients.  
not being able to take care of others was a strong positive factor for prophylaxis. apart 
from the impact of migraine on themselves also the impact on other persons for 
whom they are responsible (e.g. children, family members, colleagues, etc.) was an 
important argument for preventive treatment. 
“I can’t even make it to the meetings of my sports club. I might manage it once, but the 
second, third and fourth time they wouldn’t understand. When you feel that negative 
impact from migraine, then you really want to start thinking about preventive treatment.” 
(Group 3, PT 4)
5) The relationship with the physician and the feeling to be heard
at the time of diagnosis, being taken seriously about the burden of the migraine and 
acknowledgement of their suffering was considered most important. But this was not 
the appropriate time when patients were interested in prevention. Many migraine 
patients felt there was a limit to the extent to which their physician is able to compre-
hend the burden they bear. They considered that their GP unable to imagine how 
difficult it is to experience a migraine attack, whereas others mentioned a sympathetic 
response from their GP.  Patients indicated that at a later stage a good empathetic rela-
tionship with the doctor was important for the acceptance of prevention.
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Study strengths and limitations
This focus group research aimed to explore opinions through a purposeful sample 
covering a range of subjects and doesn’t provide numbers and clear conclusions such 
as quantitative research. 
We decided to have separate male and female groups based on the assumption that 
their approaches to migraine differ, and that a mixed group may inhibit the explora-
tion of some key elements of migraine for woman, such as a relation with 
menstruation.
saturation of themes occurred within the three groups, when no new themes arose 
that had not been included in our topic guide. Within the groups, a diversity of ap-
proaches was found. For example, the urban group was more highly educated and 
displayed more resistance to prophylaxis, and needed a more rational and evidence-
based requirement for its introduction. The rural group had a more passive attitude 
and indicated more acceptance to the propositions from their physician. 
a weakness of the present study is that it was conducted in the Dutch language and is 
reported in english. Qualitative studies aim to capture meaning from the narratives of 
respondents and some loss and/or distortion may have occurred in the translation 
process. However, we had the Dutch texts translated by two experienced translators 
and from the perspective of migraine a native english speaking expert physician on 
migraine looked into the patient remarks.
Comparison with other studies
Parallel to this study another qualitative study from the same research group, also on 
prophylaxis for migraine, explored the attitude of GPs20. That study confirmed the 
complexity of the decision-making process, which from the perspective of the GP was 
also not based on the impact of migraine alone. Patients and GPs showed a similar 
degree of hesitance, not because of lack of knowledge or lack of interest, but because 
of doubts about effectiveness, side-effects, and the risk of developing drug 
dependence.
Of the qualitative studies on migraine, only one has addressed preventive therapy21. 
In that study by rozen, the method (questionnaire) and setting (third-line centre) 
were different to ours and all patients had prior exposure to migraine prophylaxis. 
The decision whether or not to start preventive therapy had already been made, and 
the questionnaire mainly addressed side-effects and the choice of drugs. That study 
provided no information on its aims or how the decision concerning prophylaxis was 
made.
Two qualitative studies show agreement with our study in relation to prevention. One 
study shows remarkable similarities on the patient communication with the GP and 
on the search for complementary therapies by patients. Because this study is not 
about prevention, is does cover the influence of these two issues on prevention22. The 
other study reports that self-efficacy scores were positively associated with the use of 
positive psychological coping strategies to prevent headaches23. 
ity themselves. The individual history of earlier interventions is pivotal. several fac-
tors increase the resistance to accepting prophylaxis, such as changing the scope from 
seeing migraine as an intermittent to seeing it as a chronic disease.
Figure 1. Interactions of elements playing a role in accepting of and compliance with preven-
tive treatment
When weighing the facts and reaching a decision on prophylaxis, the physician has a 
major influence, especially by providing relevant information. In the process of get-
ting more insight on their migraine, patients feel that the physician can be helpful. 
Patients attach great importance to a good and trusted relationship with the physician 
and often prefer an active approach.
It is important to acknowledge that a patient is going through a process, and in time 
tend more and more towards a decision. It takes time to realize that one has a severe 
problem with migraine and that the migraine has a large impact. keeping a diary can 
provide such an insight in an earlier stage 19. From the management perspective, pa-
tients need to be receptive to the idea of prophylaxis at the right moment in their mi-
graine history.
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Other studies which address patient factors in migraine do not address prophylaxis 
and focus on the needs of migraine patients24,25, decision-making in migraine26-28, the 
burden of migraine and quality of life29,30, perimenopausal headache31, migraine in 
midlife women 32, and pressure on patients related to referral33, and therefore have 
almost no overlap to our study. The questionnaire study by kowacs et al. on the pa-
tients’ view on side effects of preventive treatment revealed that side effects are better 
accepted by patients with high use or actual overuse of attack treatment, which is 
consistent with our findings34. The questionnaire study of kol et al. found that 55 % of 
patients with two or more attacks per month wanted to use prophylaxis, while only 
8% actually used this treatment. This paradox is one of the underlying themes in our 
study12.
similar studies have also been conducted with other chronic diseases. For example, 
the study of adams et al. on acceptance of the preventive treatment for asthma35. 
specific for prophylactic asthma treatment is that it is given even in asymptomatic 
periods, the inhalation therapy is visible to others and there is fear for side effects on 
the longer term (‘steroid fear’). In contrast, in migraine only patients with frequent 
and severe attacks are treated, mainly the side effects on the short term are feared, and 
in general patients have no trouble with the acceptance of the migraine as such. This 
comparison shows that migraine has similarities, but also differences with other 
chronic diseases. Most likely the opinions of patients differ per indication.
ConClusions
The benefits of prophylactic medication for migraine are under-exploited. Future re-
search should focus on the various aspects involved in decisions about preventive 
treatment, as reflected in the present study. an understanding by physicians of the 
patient’s feelings and concerns towards prevention are important for more effective 
use of these agents. When advising migraine patients on prophylaxis it is important 
to explicitly address their underlying thoughts and emotions, and to consider the in-
tervention at an appropriate moment in the course of the patient’s migraine 
experience.
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introduCtion 
Migraine is a common episodic headache disorder affecting about 6% of men and 
15–18% of women in the general population,1,2 and is often associated with significant 
disability and reduced quality of life.3
Guidelines on migraine prophylaxis differ internationally, with prophylactic treat-
ment recommended for patients with two attacks per month up to twice a week. 
according to guidance from the Dutch College of General Practitioners, patients with 
migraine attack frequency of more than two times per month should be offered 
prophylaxis.4 In the Us, 50% of patients with migraine meet the criteria for use of 
prophylactic treatment, but only 5–12% actually use it.3 In the netherlands, 12% of 
all patients with migraine use prophylactic treatment.5
The first study aim was to investigate how many and which patients use prophylaxis, 
and how many patients would like to use this form of treatment. The second aim was 
to investigate how frequency, duration, severity, and impact of migraine attacks relate 
to the wish to use prophylactic treatment. 
Method 
Study design and setting 
This was a cross sectional survey conducted in three general practices with five GPs 
(approximately 10 000 registered patients). 
Patient recruitment 
Patients aged 18 to 65 years diagnosed with migraine who were treated by their GP 
and recorded in the electronic patient register, were selected using the International 
Classification of Primary Care (ICPC).6 To identify patients with migraine who were 
not given a diagnosis according to the ICPC code, the database was searched for pa-
tients who had been prescribed migraine medication. Diagnostic codes were applied 
by the GP at any time from patient registration and after establishing the diagnosis. 
Data collection 
Data on patients’ age, sex, number of visits, and the medication prescribed were col-
lected from the electronic patient register. Data regarding frequency and duration of 
migraine attacks, migraine medication, and additional symptoms were self reported 
using a mailed questionnaire. 
The disease specific quality of life of patients was measured with the Headache Impact 
Test (HIT 6), which is used to determine personal disease burden.7 The scores are cate-
gorised into four grades: representing ‘minimal’ (score of 49 or less), ‘mild’ (50–55 
points), ‘moderate’ (56–59 points), or ‘severe’ (60 points or more).8 
aBstraCt 
Most patients with two or more migraine attacks per month do not use prophylactic 
medication. The aim of this study is to investigate how many patients use prophylaxis 
or would like to use them, and which aspects of migraine contribute to the choice to 
use prophylactic treatment. In a cross sectional survey in three general practices, pa-
tients were selected who were diagnosed with migraine or had prescriptions for mi-
graine medication. a questionnaire was sent to 283 patients and completed by 166 
patients, of whom 15 were excluded. a total of 129 females and 22 males were included 
(median age 41 years). Most patients had two or more attacks per month (66.2%). 
Fifty-five per cent of patients with two or more attacks per month wanted to use 
prophylaxis; only 8% actually used this treatment. To get more insight into the ideas 
for or against prophylactic use, qualitative research is indicated. 
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22.0% of patients with migraine with a low attack frequency also reported that they 
would be interested in trying prophylaxis. In the group of patients with two or more 
attacks each month, 55.4% reported that they would like to consider prophylactic 
treatment, whereas 80.0% of the patients with more than five attacks each month 
were interested. 
apart from the duration of migraine attack, the HIT 6 score, GP consultation during 
the year prior to this study, and use of migraine medication were associated with the 
willingness to consider using prophylaxis (Table 1, page 108). Most patients (60.9%) 
felt sufficiently confident to ask their GPs about prophylaxis, rather than expecting 
the physician to initiate discussions. However, a substantial group of patients with 
migraine with an indication for prophylaxis expressed a wish to be informed by their 
GP about preventive treatment for migraine (39.1%). 
a logistic regression model showed that only frequency of migraine attacks was a 
strong independent determinant of desire for prophylaxis. 
Patients who were against use of prophylaxis (n = 84) gave the following reasons 
(more than one answer was possible): fear of side effects (38.1%), experiencing mini-
mal attacks (44.0%), feeling as if by using daily medication they had a chronic disease 
(23.8%), and ‘other’ (31.0%). 
disCussion 
Summary of main findings 
In this study, most patients with migraine attacks of five or more per month, and 
about half of patients with two or more attacks per month, would like to consider 
prophylaxis. even in the group of patients with fewer than two attacks per month, 
one in five w ould like to consider prophylactic treatment. Most patients felt suffi-
ciently confident to approach their GP themselves for prophylaxis. However, a sub-
stantial subgroup preferred an active approach by their physician. This finding is 
confirmed in a British study which reports that patients often do not consult their GP 
for their headache symptoms but still would like more help.11 
Strengths and limitations of the study 
a weakness of this study is that the question used to inquire about the wish for prophy-
laxis is rather theoretical and does not adequately address individual patient motiva-
tions and situations influencing their needs. However, the findings indicate that 
further qualitative research into the different motivations of patients and doctors is 
required. 
Patients in this study visited their GPs slightly more often and were prescribed triptans 
more than those who did not fill in the questionnaire. It is likely that those completed 
the questionnaire had a higher disease burden than those who did not fill it in. This 
might have caused a slight overestimation of the percentage of patients with migraine 
in general practice who wish to use prophylaxis.
The questionnaire explored reasons for and against using prophylaxis, and whether 
patients preferred to ask their GP for information about prophylaxis, or preferred the 
GP to raise the issue. explanations were presented in a simplified manner to make the 
information understandable to patients. The questionnaire asked the following: 
‘Consider a medicine which reduces your migraine symptoms by 50%. This medicine 
would need to be taken every day. Ten per cent of patients have mild side effects, such 
as dizziness, feeling cold, and fatigue. Would you be prepared to take this medicine?’ 
a reduction of more than 50% in disease burden is estimated to occur in over 50% of 
patients taking prophylactic therapy.9 For the remaining 50% of patients, the efficacy 
of prophylactic therapy is slightly less: for ß blockers an average reduction of 44% in 
migraine activity was shown.10 
Statistical analysis 
associations between accepting prophylaxis and frequency, duration, and severity of 
migraine attacks, HIT 6 score, and consulting the GP were calculated using odds ratios 
with 95% confidence intervals. a logistic regression model was used to analyse associa-
tions between these variables and the willingness to consider prophylaxis independ-
ently from each other. 
results
Population description 
The questionnaire was sent to 283 patients, and completed by 166 patients (response 
rate 58.7%). Thirteen patients stated in the questionnaire that they did not have mi-
graine or had not experienced an attack for more than a year, and two patients did not 
answer the questions on prophylactic treatment. The study population consisted of 
129 females (85.4%) and 22 males (14.6%). Median age was 41 years (interquartile 
range = 32–48 years). Median HIT 6 score was 64 points (interquartile range = 60–68 
points). Ten patients were already using prophylactic treatment. 
Response analysis 
Patients who completed the questionnaire visited their GP slightly more often in the 
previous year (56.6% versus 46.2%, P = 0.082), and received medication for migraine 
more often than those who did not complete the questionnaire (69.3% versus 55.6%, 
P = 0.003). 
 
Preference for prophylaxis 
Of the patients with two or more attacks per month, 7.9% already used prophylaxis. 
Most patients with migraine (78.0%) with a low attack frequency (less than two times 
per month) did not want to consider using prophylaxis. However, the remaining 
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Comparison with existing literature 
In a recent study in the Uk it was found that patients who were referred to neurologists 
more often consulted their GP and had more concerns about their headache symp-
toms.12 The current study’s finding that patients who had seen their GP in the previous 
year were more likely to report an interest in prophylactic therapy, could also be ex-
plained by an increased concern about their symptoms.
Implications for clinical practice 
The present findings suggest that physicians can play a more active role in optimising 
migraine therapy for their patients. Many patients with migraine experience disability 
and absence from work.13
 
Better management by GPs could reduce individual suffer-







Odds ratio  
(95% CI)  
Migraine frequency
<2x per month 50 (33,1) 11 (22,0) 35 (31,5)
 ≥2x per month 101 (66,2) 56 (55,4) 35 (31,5) 4,4 (2,0 to 9,6)
<5x per month 111 (73,5) 35 (31,5) 35 (31,5)
 ≥5x per month  40 (26,5) 32 (80,0) 35 (31,5) 8,7 (3,6 to 20,8) 
Migraine durationa 
<2x per month 58 (38,9) 23 (39,7) 35 (60,3) 
<2x per month 91 (61,1) 43 (47,3) 48 (52,7) 1,4 (0,7 to 2,7)
<2x per month 111 (74,5) 45 (40,5) 66 (59,5) 
<2x per month 38 (25,5) 21 (55,3) 17 (44,7) 1,8 (0,9 to 3,8) 
Additional symptoms
Not sensitive 
to  light/sound 
32 (21,2) 11 (34,4) 21 (65,6) 
Sensitive to light/sound 119 (78,8) 56 (47,1)  63 (52,9) 1,7 (0,8 to 3,8)
Nausea/vomiting absent 41 (27,2) 16 (39,0) 25 (61,0) 
Nausea/vomiting 110 (72,8)  51 (46,4) 59 (53,6) 1,4 (0,7 to 2,8) 
Other 49 (32,5) 28 (57,1) 21 (42,9)
HIT-6 scoreb
<60 31 (20,7) 9 (29,0) 22 (71,0) 
≥60  119 (79,3) 58 (48,7) 61 (51,3) 2,3 (1,0 to 5,5) 
Electronic patient register  
Medication 
No triptan use 72 (47,7) 21 (29,2) 51 (70,8)  
Triptan use 79 (52,3) 46 (58,2) 33 (41,8) 3,4 (1,7 to 6,7) 
No medication 41 (27,2) 11 (26,8) 30 (73,2)  
Analgesic use
(excluding triptan use)
31 (20,5) 10 (32,3) 21 (67,7) 1,3 (0,5 to 3,6) 
Consultation frequency 
Never 86 (57,0) 29 (33,7) 57 (66,3)  
≥1 in the previous year 165 (43,0)  38 (58,5) 27 (41,5) 2,8 (1,4 to 5,4) 
aTwo participants did not fill in this question. bOne participant did not fill in this question.   
Table 1. Participant characteristics and preference for prophylactic treatment.
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introduCtion (suBMitted)
Migraine is characterized by disabling attacks of headache and associated symptoms 
which may be treated with simple analgesics, nsaIDs, or triptans (1;2). For cost con-
straints, triptans are usually only prescribed if first line treatments have failed (1;3). 
Many patients are undertreated as little is known of who might benefit most from 
switching to triptans (1;3).
Traditionally, antimigraine efficacy is established by assessing “2hr pain-free rates af-
ter treating a single, moderate/severe attack in parallel-group studies” (4). While use-
ful against placebo, the validity of this design to detecting clinically relevant differences 
between established agents seems limited (5). although responder rates versus pla-
cebo usually are higher for triptans than for analgesics/nsaIDs (6) and triptans gener-
ally are considered more effective than painkillers (1), only small differences were 
found in traditional comparator trials (5;7;8). a possible explanation for this discrep-
ancy may be that migraineurs asses drug performance on a range of attributes in 
multiple attacks rather than on just a single attribute in only one attack (6;9-12). 
Moreover, patients cannot truly compare treatments in a parallel-group design.
Post-treatment patient-preference (PTPP) trials, in which patients express preference 
after exposure to both treatments, are a promising, relatively new and potentially 
more valid approach to detecting clinically meaningful differences between estab-
lished treatments (9;13-25). such trials perfectly fit recent strong recommendations 
for a greater involvement of patients in treatment decisions: “… it [therefore] is in-
creasingly the clinician’s responsibility to find out what patients want” (26;27). PTPP 
studies must not to be confused with designs in which, to avoid bias, the allocation to 
a treatment group is based on the patients’ pre-study preference (24;25).
Here, we present the results of the first randomized, double-blind, PTPP migraine trial. 
Migraineurs expressed a quantified preference after treating three attacks with riza-
triptan and three with ibuprofen. This novel trial design allows for a better real-life, 
yet controlled evaluation of treatments and may also be used to compare other 
medications. 
Methods
Triptan and ergot-naive migraineurs(28) of 18 years or older with an average frequency 
of 1 to 7 migraine days per month during the last 6 months were invited to participate 
and screened for eligibility. exclusion criteria were aimed at avoiding contraindica-
tions for study medication and included: history of atherosclerotic cardio- and cere-
brovascular disease, blood pressure above 160/95, impaired hepatic or renal function, 
aBstraCt (suBMitted)
Background
The 2hr pain-free rate after treating a single migraine attack in a parallel-group study 
design is the recommended primary endpoint to establish acute antimigraine efficacy 
versus placebo. However, when comparing established treatments, the clinical valid-
ity of this approach seems limited. Cross-over trials, in which patients express a pref-
erence after exposure to both treatments, may better detect differences that are 
clinically meaningful for individual patients.
Methods
In a randomized, double-blind, cross-over, clinical trial, 29 triptan-naive patients ex-
pressed a quantified preference (0-5) after treating three attacks with rizatriptan 10 mg 
(r) and three with ibuprofen 400 mg (I).
Results
Ten (35%) patients expressed strong preference for r and six (21%) for I (p = 0.15). 
Thirteen (45%) had no or only a moderate preference. Mean (+ sD) overall preference 
(on a 10 point scale) was 0.62 + 2.61 in favour of r (p = 0.219). Patients with high 
MIDas baseline disability had stronger preference for r (73% vs. 9% for I; p = 0.039). 
Conclusions
Most patients had a clear preference for one of both treatments, which was correlated 
only moderately to 2hr pain-free responses. Multi-attack, cross-over, patient-prefer-
ence trials, may better detect clinically meaningful differences between established 
treatments.
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There were three pre-planned study visits: (i) at baseline, when patients were fully 
explained about the study design and purpose, gave oral and written informed con-
sent, underwent a baseline assessment including the validated Migraine Disability 
assessment scale (MIDas) (32), and received the study treatment for the first three 
attacks; (ii) after the first treatment period, when the diary results and remaining 
study medication were checked and the study medication for the second treatment 
period was distributed; and (iii) after the second treatment period when the diary re-
sults and remaining study medication were checked, and the treatment preference 
and reasons therefore, were recorded. 
Preference was recorded on a Visual analogue scale ranging from -5 (extremely strong 
preference for first treatment) to +5 (extremely strong preference for second treat-
ment), and where 0 indicated no preference (Figure 1). reasons for preference were 
noted firstly in the patient’s own words and then by ticking off a list of predefined 
drug-attributes. The proportion of attacks with 2hr pain-free was the secondary end-
point. To minimize the burden to the patients and to mimic a real life situation as 
closely as possible, the study diary was kept as simple as possible and thus no other 
assessments were done.
Data analysis and sample size
We tested whether the overall mean preference score significantly differed from 0 (no 
preference), using the single t-test. We compared the study medications for the 
number of (i) participants with a clinically relevant preference score (strong to ex-
tremely strong: 2.6-5); and (ii) first and total attacks resolved within 2 hours post dose, 
using Chi-square analysis. We used the Gee-model (generalized estimating equations, 
repeated measures) to correct for different numbers of attacks per patient treated in 
the two study arms. Correlations were tested by calculating the correlation coefficient 
(r). Post hoc analyses were done for differences in outcome for attacks treated at mild 
and moderate or severe headache, and for MIDas disability grades I – IV. success of 
blinding was tested by guessing which medication was received in the second period 
and analysis for period effects by comparing the results for each sequence.
It was estimated that a total of 22 randomized subjects was needed to demonstrate a 
clinically relevant and statistically significant difference of 1.5 cm between the “mean 
preference score” and “no preference”, with 80% power at p<0.05. To allow for drop-
outs we included 30 subjects.
results
Flow diagram and study population
We assessed 283 subjects for eligibility and excluded 253, mainly because they had 
ever used at least one dose of triptans or ergots (Figure 2). Thirty patients, who never 
gastrointestinal disorders, asthma, use of propranolol or MaO-inhibitors, and abuse 
of alcohol or recreational or analgesic drugs. Females had to use a medically accepted 
form of contraception and were not pregnant or breastfeeding. The study was ap-
proved by the Medical ethics Committee of LUMC and all patients gave written con-
sent. Trial registry id: nTr33 (www.trialregister.nl).
In a single-centre, randomized, double-blind, cross-over study, participants treated 
three migraine attacks with rizatriptan 10 mg and three attacks with ibuprofen 400 
mg. each treatment period could maximally last three months. Participants who were 
extremely dissatisfied after treating at least one attack with study medication, or who 
had suffered intolerable adverse events, could make an early (though still blinded) 
cross-over to the other treatment. They were instructed to treat as soon as possible after 
onset of a migraine headache and recorded time of onset of the attack, timing of dos-
ing, and headache severity (none, mild, moderate, severe)(4) immediately prior to 
and two hours post dose. Participants could take a second blinded dose of study medi-
cation at two hours after the initial dose and rescue medication at three hours (but not 
rizatriptan or ibuprofen).
Ibuprofen 400 mg was chosen as it is globally the most widely recommended nsaID 
and dose for migraine (29-31). some physicians might argue that a higher dose could 
have a better analgesic effect. However, as preference not only assesses efficacy but 
also tolerability and higher doses may increase the risk of adverse events and thus 
potentially could bias against ibuprofen, we decided to use an initial dose of 400 mg, 
but allowed for a second dose at 2hrs in case of inefficacy. rizatriptan was chosen be-
cause it is one of the triptans with the highest responder rates in traditional trials (1;6) 
and the manufacturer could provide both the active medication and fully matching 
placebos. all triptans are fully reimbursed in the netherlands, so readiness to pay 
could not be assessed.
For this study, triptan naivety was required because the easily recognizable qualities of 
triptans would disrupt the blinding. Triptan naivety in the netherlands is rare; it was 
difficult to find suitable candidates for this study. Most patients used ibuprofen before 
the study. However, this does not imply that patients had a preference for ibuprofen, 
resulting in bias pro ibuprofen. When they had been satisfied with ibuprofen, there 
was little scope to engage in this study. Most participants used only OTCs, never con-
sulted a physician for the attack treatment of migraine and all per definition never 
used a triptan as alternative.
randomization was done by computer in blocks of four to ensure equal numbers in 
both groups. For blinding purposes, a double-dummy technique was used with fully 
matching placebos without encapsulation. randomization and medication prepara-
tion were independently done by the hospital pharmacist who also kept the code 
until the study was completed.
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5/18 (28%) ibuprofen, and 10/18 (55%) had no, or only some preference. as severity 
of the study attacks intra-individually varied, this could not be analyzed as a predic-
tive factor.
Pain-free responses and relation with preference
an analysis of all 153 treated attacks on the endpoint 2 hr pain-free showed a differ-
ence between rizatriptan and ibuprofen in favour of rizatriptan. 28.8% off all patients 
were pain free at 2 hours. Patient using rizatriptan were 2 hr pain-free in 35.4% and 
patients using ibuprofen in 21.6%. The odds ratio (Or), calculated with correction for 
headache severity at the time of treatment, was 2.611 (1.145 – 5.956, p = 0.084). 
When performing a subgroup analysis on severity on the 130 severe and moderate 
attacks, we found 24.6% 2 hr pain-free for the total, 32.4% for rizatriptan and 15.3% 
for ibuprofen. The Or was 2.755 (1.103 - 6.883, p = 0.030). For the remaining attacks, 
obvious all mild, we found 2 hr pain-free for all 23 patients 52.2%, for rizatriptan 62.% 
and for ibuprofen 46.7%. The Or was 2.038 (0.242 – 17.195, p = 0.513). 
Thus the 2hr pain-free rates were numerically higher for rizatriptan, reaching statisti-
cal significance for attacks treated while moderate or severe. similar results were 
found for the 17 patients, who had treated, per protocol, three attacks in each treat-
ment arm (data not shown). There was no clear benefit of attacks that were treated 
early, within an hour from onset, compared to attacks treated later (data not shown).
Figure 4 shows, for each study participant, the individual correlation between direc-
tion and strength of their preference (y-axis) and number of attacks with 2hr pain-free 
with rizatriptan or ibuprofen (x-axis). Data are presented as number of 2hr pain-free 
attacks with the preferred treatment minus those with the non-preferred treatment. 
The overall correlation was modest (r = 0.56; p = 0.001; slope = 0.346). For instance, six 
participants without any attack with 2hr pain-free with either study drug still ex-
pressed very strong preference for one, three participants (n=3) with equal numbers of 
attacks with 2hr pain-free with both study drugs still expressed a very strong prefer-
ence for one, and seven participants who experienced 2hr pain-free more frequently 
with the one study drug, either expressed preference for the other, or could not decide 
between the two.
However, when studied at the group level, of the 16 subjects with a very strong prefer-
ence, the 2hr pain-free attack rate with the preferred drug was 22/48 (46%) and 7/39 
(18%) with the not-preferred drug. This difference was particularly large for partici-
pants very strongly preferring rizatriptan: 15/30 (50%) versus 3/24 (12.5%).
Un-blinding and period effects
We asked participants to guess their treatment in the second period: 15/29 (52%) 
guessed correctly (of these 6 strongly preferred rizatriptan and 4 ibuprofen), 8/29 
(27%) made a wrong guess and 6/29 (21%) could not decide (r = 0.31; p = 0.146). The 
had used triptans or ergots, were randomized. Twenty-nine completed the study and 
treated in total 153 attacks: 79 with rizatriptan and 74 with ibuprofen. Twelve partici-
pants experienced and treated less than three attacks in one or both treatment periods. 
One participant was withdrawn in the second treatment period because of starting 
daily doses of ibuprofen for fibromyalgia.
Baseline characteristics of the 30 study participants are summarized in Table 1. The 
majority (67%) had mild or moderate (grade I - II) MIDas disability and 33% had high 
(grade III-IV) MIDas disability. Twenty-one (70%) were using ibuprofen for their at-
tacks, either alone (n=17), or in combination with acetaminophen (n=4). Prior to the 
study, none spontaneously expressed major dissatisfaction with their current 
medication.
The majority of study attacks (130/153; 85%) were treated while the headache was 
moderate or severe, 70 with rizatriptan and 60 with ibuprofen. Only 23/153 (15%) 
attacks were treated while the headache was mild, 9 with rizatriptan and 14 with ibu-
profen. Treatment delay ranged from 0-11 hrs (median = 1hr). 
Preference
The individual and summed preference scores are depicted in Figure 3. Ten partici-
pants (34.5%) had a strong to very strong preference (scores: 2.6 – 4) for rizatriptan 
and six (20.7%) for ibuprofen, while 13 (44.8%) had either no preference (n = 4) or 
only a slight to moderate preference (scores 1 - 2.5) for rizatriptan (n = 5) or ibuprofen 
(n = 4) (p = 0.15). The overall mean preference score was 0.62 + 2.61 (sD) in favour of 
rizatriptan (p = 0.219). The results were very similar for the subgroups of 17 partici-
pants who had treated, per protocol, three attacks in each treatment arm, and for 21 
participants who treated their pre-study attacks with ibuprofen (data not shown).
The spontaneously reported reasons for preference are given in Table 2. no main rea-
son stood particularly out. several aspects of “a rapid and complete reduction of pain 
severity” were listed as a reason by 9/16 (56%) of the patients who expressed (very) 
strong preference and by 19/25 (76%) of those with at least some preference. When 
asked to tick off from a list of predefined reasons for preference, 5/16 (31%) of the 
participants with (very) strong preference indicated “restoration of the ability to 
function normally” as their main reason, 6/16 (37%) “rapid onset of relief”, and 2/16 
(12%) “complete freedom of pain” (Table 3 and 4). 
Predictive factors for preference
Of the 11 subjects with high (grades III-IV) baseline MIDas disability, 8/11 (73%) ex-
pressed very strong preference for rizatriptan and 1/11 (9%) for ibuprofen (p = 0.039); 
the remaining two had no, or only some preference. In contrast, of the 18 subjects 
with low (grade I-II) MIDas disability, 3/18 (17%) very strongly preferred rizatriptan, 
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prevention approach” was that many subjects had to be excluded from participation, 
limiting the generalizability of the results to “triptan-naïve migraineurs not overtly 
dissatisfied with their current treatment”.
Bias in comparing 2hr pain-free rates may also be introduced if the average number of 
attacks per patient significantly differs between the treatment arms (34;35). However, 
only slightly more attacks were treated with rizatriptan and there was no difference in 
outcome when only including, for each patient, the first attack treated with each 
study drug. 
In summary, traditional trials estimate the average response in a group of patients and 
attempt to identifying “the overall winning drug” for all patients on the basis of the 
success rate for a single attribute. In contrast, in PTPP trials the individual patient will 
be the winner as the PTPP design seeks to identify the best match between individual 
needs and specific drug profiles. PTPP trials may therefore prove superior in assessing 
clinically meaningful differences between established agents and identifying patient-
profiles predictive of success. Patients with high migraine-related MIDas disability 
and moderate to severe attacks are likely to benefit most from switching from first-line 
acute antimigraine medication to triptan therapy. This study provides evidence for 
the assertion that different drugs work for different patients.
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observers guessed correctly in 15/29 (52%) of the cases (r = 0.19; p = 0.341). The mutual 
agreement r was 0.66 (p = 0.001). There were no period effects for any of the endpoints 
(data not shown; p = 0.996).
disCussion
We used a novel, real life, yet controlled, multi-attack study design to assess which 
patients on pain killers might benefit most from switching to triptans. after double-
blind multi-attack exposure to a triptan for the first time in their life, one third of the 
participants expressed very strong preference for the triptan and could thus be consid-
ered undertreated (33). The clinical challenge now is to identifying such patients.
Our study suggests that high baseline disability and attack severity may be useful indi-
cators for a successful switch to triptans. among the 11 subjects with a grade III or IV 
MIDas baseline disability, two-thirds very strongly preferred rizatriptan and only one 
ibuprofen. In contrast, among patients with low baseline disability, preference was 
equally distributed between both treatments. similarly, rizatriptan showed higher 
2hr pain-free rates than ibuprofen in moderate or severe, but not in mild attacks. Both 
findings are in accordance with a previous report that high MIDas disability predicts 
higher pain-free response to triptans than to non-triptans (3). although the results 
were already statistically significant, despite the small number of participants, they 
need to be confirmed in larger trials using a similar design.
a major advantage of the present PTPP design is that patients can truly compare the 
effects of both treatments over a number of attacks and for a wide range of treatment 
attributes. It allows for a real personal judgment of what is clinically meaningful. This 
sharply contrasts to traditional comparator trials where, for methodological reasons, 
patients only treat a single attack with only one of the study drugs. Moreover, superi-
ority is claimed for a single treatment-attribute that is defined by investigators, but 
may not necessarily be relevant to all patients (34;35). For example, “restoration of 
the ability to function normally” (and not “fast headache relief”) was the most fre-
quently reported reason for preference in our trial. The only modest correlation of 2hr 
pain-free with preference underscores that patients evaluate treatments on the basis 
of overall performance rather than on speed of headache relief alone. 
Potential limitations of cross-over studies are increased risk of un-blinding, pre-study 
bias, and patients dropping out prematurely. In our study, blinding appeared to have 
been well preserved and only one participant was withdrawn because of reasons unre-
lated to the study. To minimize the risk of pre-study bias in favour or against either 
study medication, we only included patients who were not overtly dissatisfied with 
their current treatment and who never had used a triptan. The downside of this “bias 
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Age, mean (SD), y 44 (9.6) 43 (12.0) 46 (6.8)
Sex, n (%)
Female 25 (83) 11 (79) 14 (88)(*)
Male 5 (17) 3 (21) 2 (13)
Diagnosis, n (%)
Migraine without aura 19 (63) 8 (57) 11 (69)(*)
Migraine without aura 11 (37) 6 (43) 5 (31)
Age at onset, y (SD) 22 (11) 19 (10) 25 (12)
Attack frequency / month (SD) 2.1 (1.5) 2.3 (1.9) 2.0 (1.2)
Disability grade, n (%)
Grade I (0-5) 11 (37) 8 (57) 3 (19)
Grade II (6-10) 8 (27) 1 (7) 7 (44)(*)
Grade III (11-20) 10 (33) 4 (29) 6 (38)
Grade IV (≥ 21) 1 (3) 1 (7) -
Average MIDAS-score (SD) 8.3 (7.0) 7.4(8.3) 9.2(5.5)
Usual acute migraine treatment, n (%)
Only Ibuprofen 17 (57) 8 (57) 9 (56)
Both ibuprofen and acetaminophen 4 (13) 2 (14) 2 (13)(*)
Only acetaminophen 2 (7) 1 (7) 1 (6)
Combination tablets 2 (7) 1 (7) 1 (6)
Other (acetylsalicylic acid, naproxen) 4 (13) 1 (7) 3 (19)
No medication for attacks 1 (3) 1 (7) -
Prophylaxis, n (%) 1 (3) 1 (6) -
Numbers are patients (%), unless otherwise mentioned. (*)Including one drop out.
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Table 1. Baseline characteristics of study population
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Total All preference
any (Very) strong
(n = 25) (n = 25) (n = 16)
Decrease severity of attack 10 (34.5) 8 (32.0) 4 (25.0)
Rapid onset of relief 5 (17.2) 5 (20.0) 2 (12.5)
Complete pain free 3 (10.3) 3 (12.0) 3 (18.8)
Return to normal function 3 (10.3) 3 (12.0) 3 (18.8)
No adverse events 4 (13.8) 4 (16.0) 3 (18.8)
One dose sufficient 1 (3.4) 1 (4.0) 1 (6.3)
None 3 (10.3) 1 (4.0) -
        
Total All preference
any (Very) strong
(N = 29) (n = 25) (n = 16)
Return to normal function 6 (20.7) 6 (24.0) 5 (31.3)
Rapid onset of relief 11 (37.9) 10 (40.0) 6 (37.5)
Complete pain free 2 (6.9) 2 (8.0) 2 (12.5)
No adverse events 2 (6.9) 2 (8.0) 1 (6.3)
Prevent worsening of pain 1 (3.4) 1 (4.0) 1 (6.3)
Decrease of photo- and phonophobia 2 (6.9) 1 (8.0) -
Decrease of nausea 2 (6.9) 1 (4.0) 1 (6.3)
Reliable effect, consistency 1 (3.4) 1 (4.0) -
One dose sufficient 1 (3.4) - -
No reason 1 (3.4) 1 (4.0) -
        
Preference for rizatriptan Preference for ibuprofen No preference
any (Very) strong any (Very) strong -
(n = 15) (n = 10) (n = 10) (n = 6) (n = 4)
5 (33.3) 2 (20.0) 3 (30.0) 2 (33.3) 2 (50.0)
3 (20.0) 1 (30.0) 2 (20.0) 1 (16.7) -
3 (20.0) 3 (30.0) - - -
3 (20.0) 3 (30.0) - - -
1 (6.7) 1 (10.0) 3 (30.0) 2 (33.3) -
- - 1 (10.0) 1 (16.7) -
- - 1 (10.0) - 2 (50.0)
       
            
Preference for rizatriptan Preference for ibuprofen No preference
any (Very) strong any (Very) strong -
(n = 15) (n = 10) (n = 10) (n = 6) (n = 4)
5 (33.3) 4 (40.0) 1 (10.0) 1 (16.7) -
5 (33.3) 3 (30.0) 5 (50.0) 3 (50.0) 1 (25.0)
2 (13.3) 2 (20.0) - - -
- - 2 (20.0) 1 (16.7) -
- - 1 (10.0) 1 (16.7) -
1 (6.7) - - - 1 (25.0)
1 (6.7) 1 (10.0) - - 1 (25.0)
1 (6,7) - - - -
- - - - 1 (25.0)
- - 1 (10.0) - -
       
Table 2. Main spontaneously reported reasons for preference (determined by open question)
Table 3. Main reasons for preference from a predefined list
Values are numbers of patients (%). 
Values are numbers of patients (%). Patients could tick off only one main reason.
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Total All preference
any (Very) strong
(N = 29) (n = 25) (n = 16)
Return to normal function 18 (62.1) 17 (68.0) 11 (68.8)
Rapid onset of relief 22 (75.9) 18 (72.0) 10 (62.5)
Complete pain free 14 (48.3) 12 (48.0) 10 (62.5)
No adverse events 12 (41.4) 12 (48.0) 7 (43.8)
Prevent worsening of pain 12 (41.4) 10 (40.0) 8 (37.5)
Decrease of photo- and phonophobia 11 (37.9) 8 (32.0) 6 (25.0)
No recurrence after initial relief 7 (24.1) 7 (28.0) 4 (25.0)
Reliable effect, consistency 9 (31.0) 7 (28.0) 5 (31.3)
Decrease severity of attack 7 (24.1) 5 (20.0) 4 (25.0)
Decrease of nausea 4 (13.8) 4 (16.0) 4 (25.0)
One dose sufficient 5 (17.2) 4 (16.0) 4 (25.0)
Taste 2 (6.9) 2 (8.0) 1 (6.3)
        
Preference for rizatriptan Preference for ibuprofen No preference
any (Very) strong any (Very) strong -
(n = 15) (n = 10) (n = 10) (n = 6) (n = 4)
10 (66.7) 7 (70.0) 7 (70.0) 4 (66.7) 1 (25.0)
9 (60.0) 6 (60.0) 9 (90.0) 4 (66.7) 4 (100)
9 (60.0) 8 (80.0) 3 (30.0) 2 (33.3) 2 (50.0)
9 (60.0) 6 (60.0) 3 (30.0) 1 (16.7) -
5 (33.3) 4 (40.0) 5 (50.0) 4 (66.7) 2 (50.0)
6 40.0) 5 (50.0) 2 (20.0) 1 (16.7) 3 (75.0)
4 (26.7) 2 (20.0) 3 (30.0) 2 (33.3) -
6 (40.0) 4 (40.0) 1 (10.0) 1 (16.7) 2 (50.0)
3 (20.0) 3 (30.0) 2 (20.0) 1 (16.7) 2 (50.0)
4 (26.7) 4 (40.0) - - -
3 (20.0) 3 (30.0) 1 (10.0) 1 (16.7) 1 (25.0)
2 (13.3) 1 (10.0) - - -
       
Table 4. All reasons for preference from a predefined list
Figure 1. Preference scale
Values are numbers of patients (%). Patients could tick off several reasons
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Figure 2. Flow diagram of the study participants Figure 3. Distribution of preference scores
Figure 4. Correlation between direction and strength of preference and 2hr pain-free
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Figure 4. Correlation between direction and strength of preference and 2hr pain-free 
 
Each triangle represents one patient. Per patient the number of attacks with 2h pain free and the 
preference for rizatriptan (right) or ibuprofen (left) is shown. Patients with a preference for rizatriptan are 
shown in the upper half; patients with a preference for ibuprofen are shown in the bottom half. The 
patients of the black triangles all have three attacks treated. Six patients had an attack with 2h pain free in 
the opposite arm, which is indicated by * (for rizatriptan) or # (for ibuprofen). The overall correlation was 
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Assessed for eligibility 
(n = 283) 
Each triangle represents one patient. Per patient the number of attacks with 2h pain free and the preference for rizatriptan 
(right) or ibuprofen (left) is shown. Patients with a preference for rizatriptan are shown in the upper half; patients with a 
preference for ibuprofen are shown in the bottom half. The patients of the black triangles all have three attacks treated. Six 
patients had an attack with 2h pain fr e in the opposite arm, which is indicated by * (for rizatriptan) or # (for ibuprofen). The 
overall c rrelation w s modest (r = 0.56; p = 0.001; slop  = 0.346).
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introduCtion
Migraine is a common, often highly disabling brain disorder, characterised by recur-
rent attacks of severe headaches, autonomic dysfunction and, in one-third of patients, 
neurological aura symptoms.1,2 There is a remarkable inter- and intraindividual vari-
ability in attack frequency, duration, symptomatology, severity, and response to 
treatment.3 Treatment guidelines often recommend a stepped care approach, starting 
with paracetamol or others ‘simple analgesics’. If these prove ineffective, non-
steroidal anti-inflammatory Drugs (nsaIDs) are recommended. The third step usually 
consists of triptans (selective 5-HT1B/1D receptor agonists).
4,5 In most countries only 
10-40% of migraine patients receive prescription medications, mostly due to unjusti-
fied safety concerns, cost restraints, and limited awareness that potentially better 
treatments are available.1,2,6,7
acute antimigraine efficacy is traditionally assessed using “the 2hr pain-free rate” in 
randomised, parallel-group trials, in which patients treat a single attack.8 There is evi-
dence that this is a justified approach to establish efficacy versus placebo, but the clini-
cal validity for comparing established treatments seems limited. In trials versus 
placebo, triptans generally show higher “2hr responder rates and therapeutic gains” 
than analgesics or nsaIDs.4 In clinical experience, in particular for severe attacks, 
many physicians and patients consider triptans to be more effective than analgesics or 
nsaIDs.5,7,9 However, in traditional, single-attack, parallel-group, comparator trials, 
evaluating the 2hr responder rates of a triptan versus an analgesic or nsaID, no or only 
a few statistically significant differences were found.7,9-13 The remarkable discrepancy 
between clinical trials and experience in clinical practice complicates rational treat-
ment recommendations and suggests that the traditional trial design and choice of 
endpoints may miss clinically relevant differences between established treatments.
Migraine patients treat multiple attacks, not just one, and assess treatments on the 
basis of the overall performance on a range of both positive and negative treatment-
attributes. some patients prioritize rapid onset of relief, while others may prioritize 
absence of adverse events, longer duration of action, consistent effect over multiple 
attacks, or good tolerability.14-20 Moreover, in parallel-group trials patients cannot 
truly compare the treatments.
Post-treatment patient-preference (PTPP) cross-over trials, in which patients express a 
preference after exposure to both treatments, are a promising, relatively new and po-
tentially more valid approach to detecting clinically meaningful differences between 
established treatments.21-37
There is an increased emphasis on the experience of the patient and the patient plays 
an increased role in decision making, which makes it appropriate to give serious con-
sideration to the preferences of the patient35 and the matching design to ensure pa-
aBstraCt 
Background
In clinical trials comparing triptans with analgesics, no clear difference for on the 2hr 
pain free rate endpoint has been observed. The validity of testing efficacy using single 
attack treatment, with the endpoint pain free rates, seems limited. We evaluated 
whether patients preference after exposure to both treatments is better suited to detect 
clinical meaningful and relevant differences. 
Design
randomised, double blind, double dummy, crossover clinical trial. 
Method
31 triptan-naive participants were randomised to naratriptan 2.5 mg or paracetamol 
1000 mg with a crossover after three attacks. 28 participants were able to make a pref-
erence assessment.  Primary outcome measure was direction and strength of patient 
preference (10 point scale).
Results 
Preference score was 0.17 in favour of naratriptan. nine (32%) participants strongly 
preferred naratriptan, and also nine (32%) paracetamol. When looking at all the 
preferences 16 (57%) participants preferred naratriptan and 11 (42.1%) preferred pa-
racetamol. The 2hr pain-free attack rates were 15/76 (20%; naratriptan) and 9/74 
(12%; paracetamol) for all attacks (p = 0.25). When treating the first attack naratriptan 
has a higher pain-free rate (p = 0.05). Correlation of 2hr pain-free response with prefer-
ence was poor (r = 0.27).
Conclusion
The preference from patients as a group for either naratriptan or paracetamol in the 
acute attack treatment of migraine is similar, but individual patients have a strong 
preference for one or the other, with no relation to attack severity or migraine impact. 
Multi-attack, cross-over, patient-preference trials may better detect clinically mean-
ingful differences between established treatments.
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blood pressure above 160/95, impaired hepatic or renal function, current abuse of al-
cohol or any other drug, including analgesics, a history of basilar, hemiplegic or 
ophtalmoplegic migraine, any other severe concurrent medical condition, which 
might effect the interpretation in a clinical trial, or known or suspected hypersensitiv-
ity to, intolerance of, or contraindications to any component of the study medication. 
Females had to use a medically accepted form of contraception and were not pregnant 
or breastfeeding. 
This study was approved by the medical ethics committee of LUMC and all patients 
gave written consent.
In a randomised single centre, double blind, double dummy, crossover study, partici-
pants were randomised to either naratriptan 2.5 mg or paracetamol 1000 mg with a 
crossover after three attacks or three months with at least one treated attack. 
Participants who were extremely dissatisfied with treatment or suffer from intolerable 
adverse events were allowed to make an early (still blinded) crossover to the other 
treatment. They were instructed to treat as soon as possible after onset of a migraine 
headache and recorded time and onset of the attack, timing and dosing and headache 
severity during start of treatment and two hour post-dose. Participants could take a 
second dose of study medication after four hours and if that did not work, they could 
take their own rescue medication, as long as it was not paracetamol or naratriptan. 
randomization was done by computer in blocks of four to ensure equal numbers in 
both groups. For blinding, a double-dummy technique was used. Both were inde-
pendently done by the hospital pharmacist who also kept the code until the study was 
completed.
There were three pre-planned study visits: (i) at baseline, when patients were fully 
explained about the study design and purpose, gave oral and written informed con-
sent, underwent a baseline assessment including the validated “Migraine Disability 
assessment scale” (MIDas)56 and Migraine specific Quality of Life Questionnaire’ 
(MsQ) version 2.156-60 and received the study treatment for the first three attacks; (ii) 
after the first treatment period, when the diary results and remaining study medica-
tion were checked and the study medication for the second treatment period was dis-
tributed; and (iii) after the second treatment period when the diary results and 
remaining study medication were checked, and the treatment preference and reasons 
therefore, were recorded. The MsQ was also completed during each next visit. 
Participants were also asked to give a treatment appreciation on a scale of 1-10 (pre-
treatment, first and second treatment period).
The patient’s preference was recorded on a visual analogue scale ranging from +5 (very 
strong preference for first treatment) to -5 (very strong preference for second treat-
ment), where 0 indicates no preference (Figure 1). ‘appreciation’ is listed here in the 
meaning of a separate appreciation for both treatments, and ‘preference’ is the prefer-
ence for one of these treatments. 
tients’ influence (PTPP studies).24,34 PTPP studies should not to be confused with 
pre-treatment patient-preference trials in which, to avoid pre-study bias, the allocation 
to a certain treatment group in a standard parallel-group randomised trial is based on 
the patients’ pre-study preference (or lack of preference) for a certain treatment.36,37 
Here, we present the results of a single-centre, double-blind, double-dummy, cross-
over PTPP trial, in which triptan-naïve participants were randomised to treat three 
attacks with naratriptan 2.5 mg and three attacks with paracetamol 500 mg. The pri-
mary outcome measure was the direction and strength of patient preference after 
having completed both treatment options. This allows a real life, controlled evalua-
tion of acute treatments in a number of attacks. Many patients consider consistency 
of effectiveness over multiple attacks an important attribute of acute antimigraine 
treatments,4,14-18,20 yet this is not assessed in traditional single attack studies. 
naratriptan 2.5 mg was selected for the following reasons: (i) efficacy is well estab-
lished and (ii) tolerability has proven to be good: the overall incidence of adverse 
events during treatment with naratriptan 2.5 mg was similar to that observed for pla-
cebo and (iii) is in some countries available as over-the-counter medication.4,38-40
We selected paracetamol because paracetamol is an effective drug for the attack treat-
ment and it is the most frequently used as over-the-counter analgesic for migraine.13,41-46 
It is often recommended to combine paracetamol with anti-emetics such as domperi-
done or metoclopramide to increase absorption.47,48 However, it has never been 
shown that such regime is also associated with an increase in clinical efficacy.49 
Therefore, we decided not to combine paracetamol treatment with an anti-emetic.
There are no randomised direct head-to-head comparisons of naratriptan with para-
cetamol.13,31,50 Yet there are rCTs comparing paracetamol with other triptans, showing 
equal efficacy13,46,51,52 or even more efficacious when used in combination with aspirin 
and caffeine.53 recently the results of a non-published trial looking at preference for 
naratriptan or naproxen became available from manufacturers data.54,55
The aim of this study is (i) to determine the preference of patients for either naratriptan 
or paracetamol in the attack treatment of migraine, and (ii) to evaluate whether a pa-
tients preference design is more sensitive to detect clinical relevant differences be-
tween a triptan and an analgesic compared to the traditional study design, using only 
the effect on pain as the primary outcome measure. 
Methods
Triptan and ergot-naïve migraine patients of 18 years or older, with an average fre-
quency of 1 to 7 migraine days per month during the last 6 months were invited to 
participate and screened for eligibility. exclusion criteria related to avoiding contrain-
dications for study medication and included: history of atherosclerotic disease, 
ischemic heart disease, transient ischemic attack or cerebrovascular accident, current 
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Preference
Preference scores are presented in Figure 3. nine participants (32%) had a strong to 
very strong preference (scores: 2.6 – 4) for naratriptan and also nine (32%) had strong 
to very strong preference for paracetamol. Two third of the patients (n = 18) expressed 
a very strong or strong preference for either one of the treatments. seven (25%) had a 
slight to moderate preference (scores 1 - 2.5) for naratriptan and three for paracetamol. 
Of all patients 16/28 (57%) preferred naratriptan and 12/28 (43%) preferred paraceta-
mol (p = 0.42). The mean preference score for naratriptan was 2.8 cm (sD=1.2) and for 
paracetamol 3.4 cm (sD=1.6). The overall mean preference score, was 0.17 ± 3.4 cm 
(sD) in favour of naratriptan (p= 0.17). 
The main reasons for preference are given in Table 2. rapid onset of relief was the most 
given reason for preference (n=13/28, 46%) and was also the most frequently indicated 
reason when patients could indicate multiple reasons (n=20/28, 17%) (Table not 
shown). return to normal function and complete pain free came in second and third 
place as a reason for preference. When only the main reason for preference could be 
given, then just three reasons played a decisive role; rapid onset of relief, return to 
normal function and complete pain free. Participants with high preference scores did 
not differ significant in their choice of reason for preference from participants with a 
low preference score.
Predictive factors for preference
The height of the MIDas-disability did not match with the patient preference for one 
of both treatments. In this there was also no difference in preference by MIDas grade. 
The ten participants with the highest MIDas disability grade (Class III-IV) had an 
equal preference for naratriptan as for paracetamol.
The MsQ score did not show a significant correlation with the reported preference. 
There was no influence of the MsQ on the preference of patients in this study.
Participants rated their appreciation for the study medication before and after each 
treatment (each cross-over phase) on a visual analogue scale ranging from 1-10. The 
satisfaction with used medications in advance and during the study ranged from 5.0 
- 5.9 on a scale of 10. The appreciation (mean score) was 5.9 for naratriptan and 5.1 for 
paracetamol (Mean difference 0.842 [95% CI (-2.12203) – (-0.43631)], P= 0.1880. 
There were no significant differences in appreciation between the by the participants 
in advance used medication compared with the both studied treatments. 
Overall there was no correlation between the results of the medication appreciation 
scale and the measured value of the preference. In many patients there was agreement, 
but in some patients there was no matching. These patients proved to be mainly pa-
tients with side effects and had a major negative influence on the correlation. 
reasons for preference were noted firstly in own words and then by ticking off items 
on a list of pre-defined drug attributes. secondary outcome measure was percentage of 
attacks that was pain free (no headache) at 2hr post-dose. 
We tested whether the overall mean preference score significantly differed from 0 cm 
(no preference) by using the single t-test.  We compared the study medications for the 
number of (i) participants with a a priori determined clinically relevant preference 
score (strong to very strong: 2.6-5); and (ii) first and total attacks resolved within 2 
hours post dose, using Chi-square analysis. Correlations were tested by calculating 
the correlation coefficient (r). Posthoc analyses were done for differences in outcome 
for attacks treated at mild and moderate or severe headache, for MIDas disability 
grades I – IV at baseline and for MsQ Quality of Life score. success of blinding was 
tested by guessing which medication was received in the in the second period and by 
analysis of period effects.
Sample size
It was estimated that a total of 22 randomised participants were needed to demonstrate 
a clinically relevant and statistically significant difference of 1.5 cm between the 
‘mean preference score’ and ‘no preference’, with 80% power at p<0.05.61 To accom-
modate for possible dropouts we included 31 participants.
results
Flow diagram and study population
We assessed 287 subjects for eligibility and excluded 256 (Figure 2). Thirty-one pa-
tients, who never used triptans or ergots, were randomised. Twenty-eight completed 
the study and treated in total 154 attacks; 79 with naratriptan and 75 with paraceta-
mol. Two participants had no attacks during the second period and therefore we could 
not record their preference. One participant was withdrawn due to the development 
of angina (second period, participant used paracetamol, which was found after 
unblinding).
Baseline characteristics of 31 participants are presented in table 1. The majority had 
disability grade I (23%) or II (45%), indicating little to mild disability. Participants 
were triptan naive by definition, 7 (23%) participants used paracetamol as first choice, 
15 (48%) used an nsaID, 5 (16%) used combination tablets and one used acetylsali-
cylic acid. One subject used prophylactic therapy (propranolol) and one subject used 
metoprolol for moderate hypertension, without being aware of its preventive effect 
on migraine.
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asked for the appreciation of the treatment effect in the last three attacks, they mainly 
look at the effect on the headache itself. When they determined their preference for 
one of the two treatments, also the side effects matter and in some patients this counts 
heavily.
The 2hr pain free rate in attacks treated while moderate or severe is the usual recom-
mended endpoint to determine and compare efficacy in traditional acute antimigraine 
trials8. Our study was not powered to detect a difference between naratriptan and pa-
racetamol in moderate or severe attacks, and naratriptan proved to have equal efficacy 
as paracetamol. 
This study does not support the often-heard opinion that a high migraine-related 
MIDas disability is an indicator for benefit from a triptan. 
Because both in mild and severe attacks the 2hr pain free rate between naratriptan and 
paracetamol was nearly equal, the attack severity is not a good indicator for choice of 
therapy.
The PTPP design offers some major advantages, but also a few potential limitations. 
The most important advantage is that patients can truly compare the effects of both 
treatments over a number of attacks and for a wide range of both positive and negative 
treatment attributes. The preference endpoint allows for a truly personal judgment of 
what is clinically meaningful. This contrasts sharply to traditional head-to-head 
comparator trials where generally patients treat only a single attack with only one of 
the study drugs. Moreover, superiority in these trials is claimed on the basis of success 
for a single treatment-attribute that is selected by the investigators but may not neces-
sarily be important to the majority of patients.62-64 as an example, “restoration of the 
ability to function normally” (and not “fast headache relief”) was the most frequently 
reported reason for preference in this trial.
In our study, blinding appeared to have been well preserved throughout the study as 
is shown by the guessing of the treatment in the second period and the MsQ-score and 
satisfaction per attack.
In summary, whilst traditional trials estimate the average response in a group of pa-
tients and attempt to identify “the overall winning drug” for all patients on the basis 
of the success rate for a single attribute, in PTPP trials the individual patient will be the 
winner. The PTPP design seeks to identify the best match between individual needs of 
a patient and specific drug profile. PTPP trials may therefore prove useful to assessing 
clinically meaningful differences between established agents and identifying patient-
profiles predictive of success. at present it is still a major challenge for the clinician to 
identify patients who most benefit from therapy change. Trying out as well paraceta-
mol as triptans (or nsaIDs) in the individual patient, for at least three successive at-
tacks, will eventually create the greatest patient satisfaction. 
Pain-free response at 2 hours post dose
Fourteen participants had at least one attack with 2hr pain free with naratriptan (of 
which four with strong preference for naratriptan and three with a strong preference 
for paracetamol) and eight had at least one attack pain free at 2 hr with paracetamol 
(of which four with strong preference for naratriptan and two with a strong preference 
for paracetamol). Fourteen patients had no attacks with 2h pain free. Yet, three of 
these preferred naratriptan and five of these preferred paracetamol. The remaining six 
had only moderate preference, four for naratriptan and two for paracetamol. There 
was no overall correlation between the individual pain free rates and the strength and 
direction of the preference(r = 0.27; p = 0.187; slope = 0.066). 
When studied at the group level, of the 18 subjects who expressed a strong to very 
strong preference for either naratriptan or paracetamol, the overall 2hr pain free rate 
was 4/51 (8%) with the preferred drug, compared to 7/51 (14%) with the not-preferred 
drug. Unexpectedly, participants who strongly to very strongly preferred naratriptan 
showed a smaller 2hr pain free rate for attacks treated with naratriptan (3/26 = 12%) 
compared to 6/26 (23%) for attacks treated with paracetamol. For patients strongly to 
very strongly preferring paracetamol, the 2hr pain free rates were 1/25 (4%) for para-
cetamol-treated attacks versus 1/25 (4%) for naratriptan-treated attacks. 
Unblinding and period effects
We asked patients to guess their treatment in the second period. 15/28 (54%) guessed 
the sequence correctly, 11 (39%) guessed wrongly, and 2 (7%) were not able to make a 
choice (r = 0.31; p = 0.146).  The researchers, who provided the medication, took back 
the completed diaries and heard the experiences of the patients, also made a (blinded) 
guess and guessed correctly in 19/28 (68%) of the cases. as the researchers’ guesses 
differed in 3 cases from the patient’s guesses, the mutual agreement was good (k= 
0.746, r = 0.749; p < 0.001). There was no period effect for the preference scores or 2hr 
pain free rates (data not shown).
disCussion
We used a relatively new real life, randomized, controlled, cross-over, and multi-attack 
study design to asses whether patients using painkillers or nsaIDs would prefer nar-
atriptan or paracetamol. after double-blind multi-attack exposure to a triptan for the 
first time in their life, one third of the study participants expressed a strong to very 
strong preference for naratriptan rather than paracetamol. However, also one-third 
preferred strong to very strong preferring paracetamol. 
remarkably, the endpoint ‘preference’ and the endpoint ‘2hr pain-free’ showed al-
most no correlation. They probably measure different aspects.
The individual appreciation for each treatment of three attacks in each arm did not 
correlate with the patient preference; a hypothesis for this is that when patients were 
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Age, mean (SD), y 44 (10.3) 46 (12.7) 41 (8.8)
Sex, n (%)
Female 28 (90) 12 (39) 16 (51)
Male 3 (10) 1 (3) 2 (6)
Diagnosis, n (%)
Migraine without aura 24 (77) 10 (32) 14 (45)
Migraine with aura 7 (23) 3 (10) 4 (13)
Age at onset, y (SD) 20 (9.6) 26 (9.4) 16 (8.0)
Attack frequency per month (SD) 1.4 (0.7) 1.3 (0.4) 1.6 (0.9)
Disability grade, n (%)
Grade I 7 (23) 5 (16) 2 (6)
Grade II 14 (45) 5 (16) 9 (29)
Grade III 5 (16) 2 (6) 3 (10)
Grade IV 5 (6) 1 (3) 4 (13)
Average MIDAS-score (SD) 12.1 (13) 9.7 (15) 13.9(11)
Quality of Life score
Average MSQ 2.1 score (SD) 39.5 (13) 37.2 (12) 41.1 (14)
First choice of acute treatment before intervention, n (%)
Ibuprofen 10 (32) 4 (13) 6 (19)
Paracetamol 10 (32) 5 (16) 5 (16)
Combination tablets 5 (16) 2 (6) 3 (10)
Other (acetylsalicylic acid,  
other NSAIDs)
6 (19) 2 (6) 4 (13)
Prophylaxis, n (%) 2 (6) 0 2 (6)†










(n = 28) (n = 28) (n = 28) (n = 28) (n = 28) (n = 28)
Rapid onset of relief 13 (46.7) 9 (50.0) 8 (50.0) 5 (55.6) 5 (41.7) 4 (44.4)
Return to normal function 6 (21.4) 3 (16.7) 3 (18.8) 1 (11.1) 3 (25.0) 2 (22.2)
Complete pain free 5 (17.9) 3 (16.7) 3 (18.8) 2 (22.2) 2 (16.7) 1 (11.1)
Decrease of photo- and 
phonophobia
1 (3.6) 1 (5.6) 1 (6.3) 1 (11.1) - -
Decrease of nausea - - - - -
No adverse events 1 (3.6) 1 (6.3) - -
Reliable effect, consistency - - - - - -
One dose sufficient - - - - -
Long lasting effect 2 (7.1) 2 (11.1) - - 2 (16.7) 2 (22.2)
Taste - - - - - -
No reason - - - - - -
Table 1. Baseline characteristics
Table 2. Main reasons for preference 
†One patient used metoprolol for moderate hypertension. Values are numbers of patients (%). Participants selected one reason from predefined list.
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All Treated Naratriptan
All Pain free (%) All Pain free (%)
All treated attacks (all severities) 150 24 (16.0) 76 15 (19.7)
First treated attack (all severities) 56 13 (23.2) 28 9 (32.1)
For each drug first treated moderate 
or severe attack
37 7 (18.9) 17 4 (23.5)
All treated moderate or severe attacks 109 13 (11.9) 53 7 (13.2)
All treated mild attacks 44 11 (25.0) 25 8 (32.0)
  
Paracetamol Paracetamol
All Pain free (%) OR (95%CI) P value
74 9 (12.2) 1.777 (0.660 - 4.478) 0.255
29 4 (14.3) 2.842 (0.986 - 8.191) 0.053
20 3 (15.0) 1.621 (0.373 - 7.055) 0.520
56 6 (10.7) 1.057 (0.366 – 3.051) 0.919
19 3 (15.8) 2.560 (0.788 - 8.318) 0.118
Table 3. Pain free rates at 2hrs post-dose
Figure 1. Preference scale
Estimates obtained by generalized estimated equations.
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Figure 2. Flow diagram of study participants Figure 3. Preference for naratriptan or for paracetamol
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Allocated	  to	  paracetamol	  treatment	  
(n=	  18)	  
Allocated	  to	  naratriptan	  treatment	  
(n=	  13)	  
Lost	  to	  follow-­‐up	  (n=2)	  
Reasons:	  no	  attacks	  second	  period	  
Lost	  to	  follow-­‐up	  (n=1)	  
Reason:	  developing	  contraindication	  
Allocated	  to	  paracetamol	  treatment	  
(n=	  13)	  
 
Excluded	  (n=	  256)	  
Not	  meeting	  inclusion	  criteria	  (n=	  205)	  
Too	  low	  a	  frequency	  (n=	  105)	  
Not	  triptan	  naïve	  (n=42)	  
No	  migraine	  or	  no	  migraine	  attacks	  anymore	  (n=37)	  
Pregnancy	  or	  wish	  to	  (n=6)	  
Relocation	  or	  emigration	  (n=3)	  
Cardiovascular	  disease	  (n=3)	  
Psychotropic	  overuse	  (n=2)	  
Asthma	  (n=2)	  
Old	  age	  (>80yrs)	  (n=2)	  
Migraine	  sans	  migraine	  (n=2)	  	  
Non	  Dutch	  speaking	  (n=1)	  
Refused	  to	  participate	  (n=	  51)	  
 
16	  completed	  protocol	  
11	  patients	  who	  treated	  3+3	  attacks	  
3	  patients	  who	  treated	  3+2	  attacks	  
1	  patient	  who	  treated	  2+3	  attacks	  
1	  patient	  who	  treated	  1+2	  attacks	  
12	  completed	  protocol	  
7	  patients	  who	  treated	  3+3	  attacks	  
1	  patient	  who	  treated	  3+1	  attacks	  
3	  patients	  who	  treated	  2+2	  attacks	  






Assessed	  for	  eligibility	  
(n=	  287)	  





Strong of very strong preference >2.5 is shown in outer columns. Preference for naratriptan is presented on the left side and 
for paracetamol on the right side, in a scale from +5 to -5 (5 represents strong preference and 0 is no preference).
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introduCtion
Migraine is a common 1,2, highly disabling 3,4, and costly 5 episodic brain disorder 6. 
attacks typically last 1-2 days and strike with a median frequency of 1.5 per month; 
ten percent of patients have two or more attacks per week6.  a high attack frequency is 
associated with a substantial increase of disability 4,7,8, costs 5,9, and risk of ischemic 
brain lesions 10,11. Overuse of acute headache agents is increasingly recognised as a 
paradoxical but major reason for sometimes dramatic increases of the attack frequency 
(medication-overuse headache; MOH) 7,12-15. MOH is increasingly recognized as a 
problem worldwide, with an estimated prevalence in the general population of 1-4% 
12,14. 
Triptans, selective 5-HT1B/1D (serotonin) receptor agonists, are specific, effective, and 
well tolerated agents to treat migraine attacks 16-18. regular use of a triptan on ten or 
more days a month for more than three consecutive months, may cause triptan-
overuse headache (TOH) 13. studies in headache clinics and open populations suggest 
an average critical dosage of 18 single doses per month 19,20 With the increasing avail-
ability of triptans over-the-counter and the currently often advocated 21, but still un-
proven instruction to treat attacks as early as possible while the headache is still mild, 
the prevalence of TOH is likely to increase. This might have a major impact on the 
quality of life of migraine patients 22,23 and will cause a considerable increase in costs 
9. 
Overuse of triptans does not suddenly emerge; it starts with increasing use, develops 
in to more use, even more use and than sometimes results in overuse. To describe this 
phenomenon these different levels of triptan use are relevant, starting from a lower 
threshold of triptan overuse (overuse or serious at risk, which may give an overestima-
tion) up to a strict threshold (which may result in underestimation). To this end, we 
had access to an unique database of the national Dutch Health Care Insurance Board, 
which monitors, at the individual level, the dispense of prescribed drugs at pharma-
cies for all inhabitants of the netherlands.
In the present study, we sought to assess: (i) the prevalence and associated costs of 
triptan-overuse in the Dutch general population; (ii) the demographic characteristics 
of triptan-overusers to identify possible risk factors; and (iii) whether the level of 
overuse differs among the seven available triptans. 
Methods
Study Setting
Data were obtained from the Drug Information Project (GIP database) of the Health 
Care Insurance Board (CVZ). The CVZ is a public authority in the domain of drugs. as 
an independent non-profit governing body, it monitors conditions of the health in-
surance scheme in the netherlands. In 2005, more than 10 million persons (65% of all 
inhabitants of the netherlands) were mandatory insured on the grounds of the 
aBstraCt
Introduction
Population-based observational study to assess the prevalence, demographics, risk 
factors, and costs of triptan-overuse, defined as more than 30 (IHs Criteria) or 54 
(stringent Criteria) “defined daily doses” (DDD) per 3 months. 
Methods
analysis of the Dutch Health Care Insurance Board Database for 2005, which included 
prescriptions for 6.7 million people (46% of the total Dutch population). 
Results
Triptans were used by 85,172 (1.3%) people; 8,844 (10.4%; 95% CI 10.2 - 10.6) were 
IHs-overusers and 2,787 (3.3%; 95% CI 3.2 - 3.4) were stringent-overusers. The 
triptan-specific odds ratios for the rate of IHs-overuse, compared to sumatriptan were: 
0.26 (95% CI 0.19-0.36) for frovatriptan; 0.34 (95% CI 0.32-0.37) for rizatriptan; (0.76; 
95% CI 0.68-0.85) for naratriptan; 0.86 (95% CI 0.72-1.02) for eletriptan; 0.97 (95% CI 
0.88-1.06) for zolmitriptan; and 1.49 (95% CI 1.31-1.72) for almotriptan. Costs for 
overuse were 29.7 million euros; for the IHs criteria it was 46% and for stringent 
23%.  
Discussion
In the Dutch general population, 1.3% used a triptan in 2005, of which 10.3% were 
overusers and accounted for half of the total costs of triptans. Users of frovatriptan, 
rizatriptan and naratriptan had a lower level of overuse. 
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Use of migraine prophylactic medication was defined as the dispense of minimally 
one prescription in 2005 of any medication that is registered in the netherlands for 
migraine prophylaxis. Most migraine prophylactic agents have, however, multiple 
disease indications. as the indication for a prescription is not recorded in the database, 
we could not establish whether the medication was prescribed for migraine or another 
disorder. 
Statistical analysis
Data are summarised as means with 95% confidence intervals (95% CIs) for continu-
ous variables and as numbers and percentages of subjects for categorical variables. 
Differences between groups are presented with 95% CIs. For differences among the 
triptans for the rate of overuse, we calculated the odds ratios (Or) with 95% CIs using 
sumatriptan as the reference. as sumatriptan is the longest available and most widely 
prescribed triptan, we adjusted the Or for duration of availability, by the method of 
indirect standardisation. For this duration we took the number of years the drug was 
on the market without any surcharge (corresponding to the start of substantial use in 
the netherlands). For statistical analyses we used sas enterprise Guide version 4.1.
sickness Fund act. People were eligible for sickness fund insurance if they had a yearly 
income of less than € 33.000. The GIP registered prescribed drugs dispensed at phar-
macies for patients that are insured by sickness funds. all prescription drugs are coded 
according to the anatomical, Therapeutic and Chemical (aTC) classification 24. each 
registered patient has an anonymous unique identification number, which allows 
complete observation of medication use over time per patient. each prescription also 
includes information on what insurance companies pay to the pharmacist, allowing 
an exact calculation of the costs. For migraine patients in the netherlands, there were 
no financial restrictions in using acute or prophylactic headache therapy in the study 
year 2005 as long as a physician prescribed the medication. In the netherlands over-
the-counter sales of triptans is prohibited. 
Definitions
a triptan-user was defined as a patient for whom minimally one prescribed triptan was 
dispensed in 2005. We used two definitions for triptan-overuse. One based on the 
criteria of The International Headache society (IHs), i.e. use of a triptan on more than 
10 days a month for ≥ 3 months 13, and a second more stringent definition, based on 
studies in headache clinics, i.e. use of 18 single doses or more per month for ≥ 3 con-
secutive months 19. When patients use 18 DDDs or more over a long period, chronic 
daily headache based on medication overuse is evident 19.   
We converted these criteria into Defined Daily Dose (DDD) per year, which is, accord-
ing to the World Health Organization (WHO), the standardised dosage per day of a 
drug when prescribed for the registered indication (Table 1) 24. The DDD system has 
been used in previous triptan database studies and is the system of choice when com-
paring drugs (http://www.whocc.no/)25. accordingly, “IHs triptan-overuse” was de-
fined as use of 120 DDDs or more per year and “stringent triptan-overuse” as use of 216 
DDDs or more per year. as use and overuse of triptans may fluctuate considerably 12 
(and see the result section of the present study), and because our aim was to identify 
consistent rather than incidental overuse, we calculated the 3 month use using the 
average triptan consumption over a 12 month period rather than over a 3 month pe-
riod only. For calculating the DDDs we had the real number of tablets (and other for-
mulations) at our disposal.
Triptan Year of 
introduction
Formulation Defined daily 
dose (DDD)
Sumatriptan 1991(1996*) 50 mg tablet 1 tablet
100 mg tablet ½ tablet
25 mg suppository 1 supp
20 mg nasal spray 1 spray
6 mg subcutaneous 
injection
1 injection
Naratriptan 1997 2.5 mg tablet 1 tablet
Zolmitriptan 1997 2.5 mg tablet 1 tablet
Rizatriptan 1998 5 mg tablet 2 tablets
10 mg tablet 1 tablet
Eletriptan 2000 20 mg tablet 2 tablets
40 mg tablet 1 tablet
Almotriptan 2000 12.5 mg tablet 1 tablet
Frovatriptan 2001 2.5 mg tablet 1 tablet
  
Table 1 Defined daily dose per triptan according to the World Health Organisation. 24 
* First year of full availability of tablets without any surcharge..
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results
We did find that 10% of all triptan-users, which is 0.1 % of the total Dutch general 
population, were overusing triptans. They were responsible for nearly half of the total 
costs for triptans. 
We could assess the medication use of 6.7 million persons, covering approximately 
46% of the total Dutch population and 67% of all persons that were insured with the 
sickness fund. The remaining part of the population could not be included in this 
study because of reasons unlikely to have introduced bias, such as non-connectable 
databases and other ways of health insurance. 
In 2005, 85.172 persons (1.3% of the total sample) had received at least one prescrip-
tion for a triptan. Of these 31,841 (37.4%) had received only one prescription and 
5,536 (6.5%) had received prescriptions for more than one triptan. The vast majority 
of prescriptions (95%) was from general practitioners; only 5% were from neurologists 
or other specialists. Table 2 compares the characteristics of triptan-users to those of 
the total population. The majority of triptan-users were female and over thirty years 
of age. nineteen percent of triptan-users also took medication indicated for migraine 
prophylaxis. 
numbers and characteristics of overusers versus non-overusers are presented in table 
3. among the 85,172 triptan-users, 8,844 persons were overusers according to the IHs 
criteria (10.4%; 95%CI: 10.2-10.6), and 2,787 persons according to the stringent crite-
ria (3.3%; 3.2-3.4). IHs triptan-overusers accounted for 47.3% (47.2-47.3) and strin-
gent overusers for 23.0% (20.0-24.1) of the total use of triptans. Overusers were 
equally distributed among females and males and across the whole life span, although 
on average they were older than non-overusers: 60% of overusers were in the fifth and 
sixth decade of life. Prophylactic medication was more frequently dispensed in over-
users, 30.4% of IHs and 32.1 % of stringent overusers, than in non-overusers 
(17.9%).
sumatriptan is available in four different formulations and two oral doses. The vast 
majority used just one formulation, although overusers (IHs: 17.2%; stringent: 24%) 
more often used multiple formulations than did non-overusers (5.8%). The majority 
exclusively used tablets: 64.2% of the total sample; 62.4% of the non-overusers; 
75.4% of the IHs-overusers; and 74.1% of the stringent-overusers. subcutaneous in-
jections were used by 10.3% of the non-overusers, 6.6% of the IHs-overusers and 4.6% 
of the stringent-overusers.
Total population Triptan users
N = 6,704,627 N = 85,172 
n (%) n (%)
Females 3,665,773 (55) 71,047 (83)
          Age
 
< 20 685,352 (19) 1,916 (3)
20 – 29 459,630 (13) 9,616 (14)
30 – 39 586,641 (16) 16,620 (23)
40 – 49 588,504 (16) 21,628 (30)
50 – 59 503,518 (14) 14,615 (21)
60 – 69 365,634 (10) 4,926 (7)
> 70 476,494 (13) 1,726 (2)
Males 3,038,854 (45) 14,125 (6)
          Age < 20 719,131 (24) 871 (13)
20 – 29 447,465 (15) 1,782 (25)
30 – 39 486,320 (16) 3,499 (26)
40 – 49 433,975 (14) 3,644 (19)
50 – 59 371,537 (12) 2,725 (9)
60 – 69 297,714 (10) 1,194 (3)
> 70 282,712 (9) 410 (3)
Prophylactic medication* 437.354 (6.5) 16.327 19.2
         Propranolol 54,254 (0.8) 6,267 (7.4)
        Metoprolol 339,244 (5.1) 6,985 (8.2)
        Pizotiphen 4,028 (0.1) 1,400 (1.6)
        Flunarizine 2,803 (0.0) 218 (0.3)
        Valproic acid 30,228 (0.5) 1,713 (2.0)
        Clonidine 13,363 (0.2) 747 (0.9)
        Topiramate 3,325 (0.0) 1,084 (1.3)
 
      
Table 2. Clinical characteristics and demographics of triptan users compared to the total 
population.
Source: GIP database/Health Care Insurance Board. *Medication which can be prescribed as prophylactic therapy for migraine. 
Amitriptyline is not registered and not prescribed as migraine prophylaxis in the Netherlands. Methysergide can only be pre-
scribed for a short period to prevent adverse events and was therefore excluded.
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Total Non-overusers
< 30 DDDs/qtr 
N = 85,172 N = 76,328
Female, n (%) 71,047 (83) 63,622 (83)
Mean age, y (SD) 43 (13) 42 (13)
Age, n (%) < 20 2,787 (3) 2,765 (4)
20 – 29 11,398 (13) 10,913 (14)
30 – 39 20,119 (24) 18,439 (24)
40 – 49 25,272 (30) 22,275 (29)
50 – 59 17,340 (20) 14,861 (20)
60 – 69 6,120 (7) 5,210 (7)
> 70 2,136 (2) 1,865 (2)
Prophylaxis, n (%) 
        Propranolol 6,267 (7.4) 5,287 (6.9)
        Metoprolol 6,985 (8.2) 5,868 (7.7)
        Pizotiphen 1,400 (1.6) 1,133 (1.5)
        Flunarizine 218 (0.3) 165 (0.2)
       Valproic acid 1,713 (2.0) 1,352 (1.8)
       Clonidine 747 (0.9) 628 (0.8)
       Topiramate 1,084 (1.3) 757 (1.0)
        Any of the above 16,327 (19.2) 13,635 (17.9)
 














N = 8,844 (95% CI) N = 2,787 (95% CI)
7,425 (84) 1% (-0.2 to 1.4) 2,294 (82) -1% (-2.5 to 0.4)
47 (11) 5 yrs (4.7 to 5.3) 48 (11) 6 yrs (5.2 to 6.2)
22 (0) -3% (-3.5 to -3.2) 6 (0) -3% (-3.6 to -3.1)
485 (6) -9% (-9.3 to -8.3) 113 (4) -10% (-11.0 to -9.4)
1,680 (19) -5% (-6.0 to -4.3) 515 (19) -6% (-7.1 to 4.2)
2,997 (34) 5% (3.7 to 5.7) 964 (35) 5% (3.6 to 7.2)
2,479 (28) 9% (7.6 to 9.5) 789 (28) 9% (7.2 to 10.6)
910 (10) 4% (2.8 to 4.1) 298 (11) 4% (2.8 to 5.1)
271 (3) 1% (0.3 to 1.0) 102 (4) 1% (0.6 to 2.0)
980 (11.1) 4% (3.5 to 4.8) 326 (11.7) 5% (3.6 to 6.0)
1,117 (12.6) 5% (4.2 to 5.7) 352 (12.6) 5% (3.7 to 6.2)
267 (3.0) 2% (1.2 to 1.9) 106 (3.8) 2% (1.7 to 3.1)
53 (0.6) 0% (0.2 to 0.6) 17 (0.6) 0% (0.2 to 0.8)
361 (4.1) 2% (1.9 to 2.8) 123 (4.4) 3% (1.9 to 3.5)
119 (1.3) 1% (0.3 to 0.8) 38 (1.4) 1% (0.2 to 1.0)
327 (3.7) 3% (2.3 to 3.1) 130 (4.7) 4% (2.9 to 4.5)
2,692 (30.4) 13% (11.6 to 13.6) 895 (32.1) 14% (12.5 to 16.0)
 
       
Table 3. Clinical characteristics and demographics of triptan overusers compared to non-
overusers
Source: GIP database/Health Care Insurance Board. *Medication which can be prescribed as prophylactic therapy for mi-
graine. Amitriptyline is not registered and not prescribed as migraine prophylaxis in the Netherlands. Methysergide can only 
be prescribed for a short period to prevent adverse events and was therefore excluded.
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group of patients using more than one triptan is twice as high, compared to the use of 
just one triptan. The crude odds on overuse compared to sumatriptan (1.00) is 2.01 
(95% CI 1.87-2.16) for the IHs criteria and for the stringent category it is 2.12 (95% CI 
1.98-2.37). In the group of patients using more than one triptan, it is not possible to 
calculate the adjusted odds because of the differences between duration on the market 
of the different triptans.
Total Non-overusers Overusers






N = 85,172 N = 76,328 N = 8,844 N = 2,787
n (%) n (%) n (%) n (%)
Single triptan use 79,636 (94) 71,837 (94) 7,799 (88) 2,416 (87)
        Sumatriptan 41,352 (52) 35,798 (50) 5,554 (71) 1,952 (81)
        Naratriptan 3,798 (5) 3,437 (5) 361 (5) 86 (4)
        Zolmitriptan 4,983 (6) 4,397 (6) 586 (8) 134 (6)
        Rizatriptan 25,796 (32) 24,770 (35) 1,026 (13) 182 (8)
        Eletriptan 1,455 (2) 1,289 (2) 166 (2) 37 (2)
        Almotriptan 1,295 (2) 1,206 (2) 89 (1) 23 (1)
        Frovatriptan 957 (1) 940 (1) 17 (0.2) 2 (0.1)
Multiple triptans 5,536 (6) 4,491 (6) 1,045 (12) 371 (13)
 
Table 4. Use of the various triptans in non-overusers versus overusers
Figure 1. The part of patients with and without triptan overuse according to “IHS criteria”, 
with the associated cost and drug use. 
 Table 4 shows the numbers and proportions of patients in each of the three categories: 
all users of a triptan, triptan non-overusers and triptan-overusers. The majority of 
patients used only one triptan. sumatriptan was by far the most frequently prescribed 
triptan in all three categories. Overuse was observed for all triptans, but the level of 
overuse differed significantly per triptan as presented in table 5. Compared to su-
matriptan, the odds ratio (Or) for the rate of IHs-overuse was 0.11 (95% CI 0.08-017) 
for frovatriptan, 0.27 (95% CI 0.25-0.28) for rizatriptan, 0.48 (95% CI 0.40-0.57) for 
almotriptan, 0.68 (95% CI 0.62-0.74) for naratriptan, 0.83 (95% CI 0.72-0.95) for 
eletriptan and 0.86 (95% CI 0.80-0.93) for zolmitriptan. When adjusted for the differ-
ent durations of availability, the level of overuse remained significantly reduced for 
frovatriptan (0.26; 95% CI 0.19-0.36), rizatriptan (0.34; 95% CI 0.32-0.37) and nar-
atriptan (0.76; 95% CI 0.68-0.85), but not for eletriptan (0.86; 95% CI 0.72-1.02), zol-
mitriptan (0.97; 95% CI 0.88-1.06) and almotriptan (1.49; (95% CI 1.31-1.72). similar 
profiles were seen for stringent-overuse. It should be noted that the absolute numbers 
of users and overusers for naratriptan and especially frovatriptan are very small, and 
that the duration of availability of especially frovatriptan was very short. These factors 
might have biased the results for these triptans (see discussion). The overuse in the 
Values are numbers (%) of subjects. * ‘Stringent overusers’ are a subgroup of ‘IHS overusers’. Source: GIP Database/ Health 
Care Insurance Board.
Percentage of patients with “IHS overuse”, generated cost and DDDs (daily defined dose). On top the “IHS overuse” of ≥ 30 
DDDs/qtr and below the non overusers. Source: GIP Database/ Health Care Insurance Board.
The costs of triptan-use and -overuse are shown in Figure 1 and 2. Total costs of 
triptan-use in 2005 were 29.7 million euros, i.e. 349 euros per triptan-user and 4.43 
euros per inhabitant. Patients overusing triptans accounted for 46% (IHs criteria) and 
23% (stringent criteria) of the total costs, i.e. 1543 euros per IHs-overuser and 2468 
euros per stringent-overuser.
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disCussion
We analysed the use and overuse for all seven available triptans in the Dutch general 
population in the year 2005. We could make use of an unique national Health Care 
Insurance Board Database, which covered the medication use of 6.7 million people. 
Of these, 1.3% had used a triptan at least once in 2005 and 0.13% (10.4% of all triptan-
users) was overusing triptans. Overusers accounted for almost half of the total costs 
for triptans. remarkably, the level of overuse differed significantly per triptan. Users 
of rizatriptan, and possibly of frovatriptan and naratriptan, showed substantially 
lower levels of overuse. When patients use more than one triptan, the level of overuse 
is additional high: a doubling of levels of overuse compared to when the patient is 
only using one kind of triptan.
Figure 2. The part of patients with and without triptan overuse according to “Stringent crite-
ria”, with the associated cost and drug use.
Table 5. Level of overuse for each triptan relative to sumatriptan. 
Percentage of patients with “Stringent overuse”, generated cost and DDDs (daily defined dose). On top the “Stringent 
overuse” of ≥ 54 DDDs/qtr and below the non overusers. Source: GIP Database/ Health Care Insurance Board.
Values are numbers (%).*’Stringent overusers’ are a subgroup of ‘IHS overusers’. † Adjusted odds for duration of availability 
of the drug, by method of indirect standardisation. §When using more than one triptan, the adjusted odds can not be cal-
culated (#) because of the variation in the duration of the availability of the triptan. Source: GIP Database/ Health Care 
Insurance Board.
Total Non-overuse Overuse













n (%) n (%) Adjusted 
odds†
n (%) Adjusted 
odds†
Sumatriptan 41,352 35,798 (87) 5,554 (13) 1.00 (ref) 1,952 (5) 1.00 (ref)
Naratriptan 3,798 3,437 (91) 361 (10) 0.76 (0.68-
0.85)
86 (2) 0.52 0.42-
0.64
Zolmitriptan 4,983 4,397 (88) 586 (12) 0.97 (0.88-
1.06)
134 (3) 0.63 0.53-
0.75
Rizatriptan 25,796 24,770 (96) 1,026 (4) 0.34 (0.32-
0.37)
182 (1) 0.17 0.15-
0.20
Eletriptan 1,295 1,206 (93) 89 (7) 0.86 (0.72-
1.02)
23 (2) 0.63 0.45-
0.86
Almotriptan 1,455 1,289 (89) 166 (11) 1.49 (1.31-
1.72)
37 (3) 0.95 0.73-
1.22
Frovatriptan 957 940 (98) 17 (2) 0.26 (0.19-
0.36)
2 (0) 0.08 0.03-
0.22
>1  triptan§ 5,536 4,491 (81) 1045 (19) -# -# 371 (7) -# -#
 
The results of the present study appear robust and representative because of the large 
number of patients included. We used an independent and unbiased nation-wide da-
tabase with an accurate count of actual dispense of triptans at pharmacies, covering 
nearly half of the total population of The netherlands. a potential limitation is that 
we couldn’t measure the actual use of triptans by patients. It seems, however, very 
unlikely that with an average use of 210 DDDs in IHs overusers and of 420 DDDs in 
stringent overusers, many patients would not have used the dispensed medication. 
With regard to these thresholds we can argue that overuse lies somewhere in between 
the two presented thresholds. The lower limit, the IHs criteria may give an overesti-
mation, and the upper threshold, the stringent criteria, is probably an underestima-
tion. With these stringent criteria, the existence of medication overuse headache is 
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the risk of incorrectly assigning someone (this applies to each type of triptan) to 
overusers group is negligible when applying the stringent criteria (> 216 DDDs/yr). 
The relative degree of overuse in this group was very similar to that when using the less 
stringent IHs criteria, with the understanding that the differences with sumatriptan 
are magnified to some extent. Use of almotriptan, sumatriptan and zolmitriptan was 
in both groups clearly associated with the highest level of overuse and use of rizatrip-
tan, frovatriptan and naratriptan was associated with the lowest level of overuse. 
Furthermore, from clinical experience we know that, for a variety of reasons, many 
patients divide 100 mg tablets into two of 50 mg, thereby doubling the actual number 
of doses used. also for another reason the extent of any possible bias by an erroneous 
classification of the WHO-DDD is small; only 27.6% of all sumatriptan is delivered by 
pharmacies as 100mg tablets. Consequently, any possible bias by an erroneous classi-
fication of the WHO-DDD is small in relation to the difference we found.  We, there-
fore, are confident that the applied approach provides a reliable estimate of the 
relative levels of overuse for the various triptans.
a second potential confounding factor is that patients with cluster headache may 
sometimes use very high quantities of subcutaneous sumatriptan to treat their attacks, 
without necessarily being an overuser 33,34. This could have biased the results towards 
overuse of sumatriptan. However, use of the subcutaneous formulation of sumatriptan 
made up for only 8.8% of the total use of sumatriptan in the IHs-overuse group and for 
only 5.7% in the stringent-overuse group. This is less than in the non-overuse group 
(10.5%), making a major impact of overuse of subcutaneous sumatriptan unlikely. In 
other countries than the netherlands Cluster headache patients are sometimes 
treated with high dosages of oral sumatriptan because of cost considerations. all 
triptans are carefully reimbursed in the netherlands, so this is unlikely in present 
study.
a third potential bias we need to discuss is the difference in duration of availability of 
the various triptans (Table 1). This might have led to preferential use of the earlier 
available agents by the most disabled patients who are likely to have a higher level of 
overuse. sumatriptan was the first available triptan (1991), but because of complicated 
reimbursement issues in the netherlands, the oral formulation became fully reim-
bursed only in 1996. sales for sumatriptan really started only then. Overuse before 
that time was very rare in the netherlands35  The other triptans were always fully reim-
bursed from  , frovatriptan and naratriptan were marketed as “gentle” triptans, with 
fewer adverse events and a slower onset of action, best suited for milder migraine at-
tacks 16. Combined with their significantly lower 2- and 24-hour efficacy rates16, this 
might well have led to a preferential use of frovatriptan and naratriptan by patients 
with milder migraines, which are known to be associated with a lower level of overuse. 
These considerations do not seem to apply to rizatriptan, whose user numbers were 
very high ((n=25,796 users and n=1,026 overusers) and whose 2- and 24-hour efficacy 
rates are among the highest of all triptans 16. 
One can ask whether the package size of the triptans can explain the differences. 
evident. With the IHs criteria there is either overuse or eminent high risk on overuse. 
The results are in agreement with a smaller population-based study in Denmark. Here, 
5% of sumatriptan-users used > 30 DDDs per month and were responsible for 38% of 
the total sumatriptan consumption and costs 26. In two French studies, 25-30% of 
triptan users were overusers 27 and 12% became overusers (defined as ≥180 DDDs/yr) 
within one year from starting using triptans 28. In an Italian study a much lower rate of 
overuse was found (3.2%), but this is probably due to a low overall use of triptans in 
this country 29. 
One might argue that the prevalence of triptan overuse was overestimated given the 
nature of sickness fund-based databases. Patients included in such databases generally 
tend to come from relatively lower socio-economic classes, compared to patients with 
private health insurance. Low educational level is known to be associated with a 
higher risk of medication overuse 12,30. 
Given the nature of our sickfund-based database, our population had a relatively 
lower socio-economic status. However, our population represents 65% of the Dutch 
population in 2005 and other studies in this database revealed that data from these 
patients are similar to those in the general population. 31,32. We also compared our data 
with those of a smaller database of dispensed drugs in pharmacies, including all in-
come classes. Those data were very similar to the one in the present study. In particular, 
there was no evidence for socio-economic class major difference in use of triptans.
In our analysis we calculated the average triptan consumption, namely in a timeframe 
of 12 months, using the criteria that are based on a 3-month period. In this way we 
were able to provide more stable and reliable estimates than for shorter periods, since 
use and overuse of acute antimigraine medication are known to fluctuate substantially 
12. Indeed, we found 9,120 IHs-overusers (30 DDDs or more) in the first 3-month pe-
riod, 10,287 in the second trimester, 10,128 in the third and 11,088 in the final trimes-
ter; the average was 10,156 overusers. Of all overusers in the first quarter, only 63-65% 
was also overuser in at least one of the subsequent three trimesters.
The most striking finding of our study was that level of overuse differed among the 
triptans. In particular, use of frovatriptan, rizatriptan, and to a lesser degree nar-
atriptan, was associated with remarkably lower proportions of overusers compared to 
the reference agent sumatriptan and the other triptans. several confounding factors 
could potentially explain this finding and need to be discussed.
First, for practical reasons, we used the number of DDDs to define overuse. However, 
triptan overuse is in fact defined by the number of days on which at least one dose of a 
triptan is taken, irrespective of the total number of dosages per day or the amount of 
mg per dose. In 2001, the DDD for sumatriptan was changed from 100 mg to 50 mg 
(http://www.whocc.no/atcddd/) 24. Thus, one tablet of 100 mg sumatriptan suddenly 
was equal to 2DDD. as a result, patients using 61-107 tablets of 100 mg per year were 
assigned as “IHs overusers” (122-214 DDDs/yr), without necessarily fulfilling the IHs 
criteria for triptan overuse (use of at least one dose on > 120 days per year). This could 
have potentially biased the results against sumatriptan in these patients. However, 
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However, triptans are used in such large quantities that each prescription usually in-
volves multiple packages.The package size of the various triptans varies. nevertheless, 
we found no correlation between the size of the package and the association with 
overuse for the various triptans (data not shown).”
Whether the observed differences also reflect a true clinical benefit, can only be tested 
in prospective randomized clinical trials.
Overusers accounted for almost half of the total costs of triptans. These costs could be 
significantly reduced if physicians would better monitor prescriptions and would 
consider prophylactic treatment earlier in case of increasing headache frequency to 
prevent overuse.  Once overuse is established, withdrawal of overused medication is 
the most appropriate therapy36.
To our knowledge, this is the first extensive study reporting the prevalence of overuse 
of all currently available triptans in the general population. although the overall 
prevalence of overuse was low, overuse accounted for a large health burden and a 
substantial proportion of total costs of migraine therapy. The level of overuse differs 




- aTC: anatomical Therapeutic Chemical classification, designed for drug utiliza-
tion studies, developed and maintained by the WHO Collaborating Centre for 
Drug statistics Methodology
- CVZ: Health Care Insurance Board; independent non-profit governing body in 
the netherlands
- DDD: Defined Daily Dose, standardized dosage per day according to the WHO
- GIP database: Drug Information Project, database monitoring conditions in 
health insurance, owned by the CVZ
- IHs: International Headache society, responsible for the International 
Classification of Headache Disorders (ICHD-2)
- MOH: Medication Overuse Headache
- TOH: Triptan Overuse Headache
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Our recommendation is to discuss preventive treatment with the patient starting 
from two attacks per month. Then, together with the patient, can be decided to agree 
or disagree on initiation, and at what moment it should be done. The Dutch general 
practitioners Headache guideline recommends discussing preventive treatment from 
two or more attacks per month and, subsequently, to make a decision about the therapy 
in dialogue with the patient1. Therefore, the Dutch guideline is appropriate in this 
context. also, in this guideline the patient’s involvement is considered to be high. 
In conclusion, there is no evidence for a rigorous threshold, because there is a large 
variation among patients on what conditions they are willing to start preventive 
therapy. Furthermore, factors which are important for the patient need to be consid-
ered explicitly in a conversation between physician and patient (Chapter 4, 5 and 6). 
b. Effectiveness of preventive treatment
The review on preventive treatment (Chapter 2) demonstrates that preventive treat-
ment of migraine is a worthwhile intervention, for which beta-blockers and anti-epi-
leptic drugs can be used. It can be argued that preventive treatment will contribute to 
a much greater reduction in disease burden than can be established with attack treat-
ment only. Preventive treatment does not ensure that headaches disappear com-
pletely, but great benefits can be gained. especially for patients with a high disease 
burden preventive treatment can be of major importance (Chapter 2). Preventive 
treatment appears to be cost-effective in the primary care setting compared with at-
tack treatment only2. 
not many preventive studies have been performed in general practice. Consequently, 
the study population used in these reviews does not correspond with the population 
in general practice. There is also doubt whether the results of this review can be ap-
plied to general practice. This should be a reason for further investigation using the 
appropriate (primary care) population, like the recent study of smelt et al.3. Our study 
(Chapter 3) in daily general practice also shows that preventive treatment can be well 
performed in general practice.
In conclusion, preventive therapy is presumably a suitable intervention in primary 
care and can generally be carried out properly. Consequently, GPs can offer this treat-
ment to patients without hesitance.
c. Hesitation about preventive treatment in patients and physicians
However, many GPs are sceptical about the effectiveness of preventive treatment 
(Chapter 4). Moreover, the conclusions from the review and the observational study 
are contradicting (Chapter 2 and 3), since the review shows that preventive treatment 
is an effective intervention, but many GPs are doubting that.   
Because about half the disease burden can be decreased, there is a large gain to be ex-
pected for patients with a high disease burden (Chapter 2).
Patients and GPs both have the same hesitations regarding preventive treatment of 
migraine. They largely use the same attributes in their decision to accept and/or to 
general disCussion
The studies in this thesis present existing gaps in our knowledge about migraine; gaps 
of knowledge of importance for primary care. The main conclusions are summarized 
in Chapter 11.
Headache, especially migraine, is a frequently presented complaint in general prac-
tice. This thesis covers an important issue, because patients often suffer much. 
Headaches have great impact on patients, because it’s not just the pain, but headaches 
also affect social functioning and cause failure in various social roles (like school and 
work).
The preventive treatment is described in Part 1, chapters 2-6 of this thesis. In Part 2 
two randomized controlled crossover trials (rCTs) between a triptan and a nsaID or 
analgesic are presented. These trials focus on the ongoing discussion which attack 
treatment is most effective in migraine. In Part 3 various aspects of medication overuse 
by triptans is presented. We studied how prevalent it is, which triptans are concerned, 
whether all triptans are equally involved, the extent in which it takes place and what 
the costs are. 
The main characteristics of the studies in this thesis and the implications for practice 
and research will be highlighted and discussed. some recommendations for future 
research are presented. 
1. preventive treatment for migraine
a. Moment of starting preventive treatment
no clear threshold or consensus when to start preventive treatment is found in litera-
ture (see Chapter 2). Mostly, the recommendations are based on the frequency of mi-
graine. However, in the many published guidelines no supportive evidence has been 
provided for the recommended thresholds. There are no known studies exploring this 
issue. so, we’ll have to conclude that there is little justification for the frequently 
chosen threshold of three attacks per month. 
nearly always physicians, not the patient, draw up these guidelines and they deter-
mine when to advise to start preventive treatment. We found that in fact the opinion 
of the patient, which we consider important, is poorly appreciated (Chapter 2). Given 
the importance of intrinsic motivation of the patient, making an authority-based de-
cision based on only one single factor, such as frequency, cannot be recommended 
(Chapter 4, 5 and 6). 
so, there is room for input from the patient. Our studies show that there is great diver-
sity in patient desires. not only impact, duration and/or severity of the attacks count, 
but issues as being negative about daily medication and patient’s experienced effect of 
attack treatment, are also meaningful (Chapter 6).
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5). Our study reveals that many doctors underestimate the positive intentions of pa-
tients and their participation in a favorable way (Chapter 4).
It is also noticeable that only sparsely attack treatment is combined with preventive 
treatment. Preventive treatment is prescribed to only 4.8% of triptan users (Chapter 
3). The non-users, despite of an indication, may simply use their attack treatment and, 
therefore, they are satisfied. 
When considering prophylaxis, one has to realize that not every beta-blocker shows 
similarly good results. Propranolol shows a weaker performance than metoprolol and 
atenolol. Therefore, other beta-blockers should be preferred in general practice. 
Choosing the most appropriate beta-blocker is therefore an important issue (Chapter 
3). 
In daily practice often only one preventive attempt is carried out (Chapter 3). For 
other diseases, such as hypertension, it is entirely usual to apply several different 
treatments up to the point where an effective treatment has been found. We expect 
preventive treatment of migraine may improve when multiple attempts are made if 
the first attempt in has failed.
In conclusion, an active approach by GPs has to be pursued, emphasizing offering 
preventive treatment at the appropriate time for patients. 
2. attack treatment, triptan versus other attack treatments
a. Choice attributes and preference in attack treatment
Patients’ choice for an attack treatment is based on a number of significant attributes 
of that treatment. Those choice attributes are different for everyone (Chapter 7 and 8). 
Based on these studies the most important attributes are: rapid onset of relief (31.6%), 
decrease severity of attack (17.5%), return to normal function (15.8%), complete pain 
free (14.0%) and no adverse events (8.8%). 
realizing this, it becomes apparent why patients choose differently. There is no out-
standing attribute and, therefore, an effective endpoint applicable for everyone is not 
available. Thus, the optimal therapy varies, depending on the preferences of the 
patient.
To find out for which attack treatment patients have a preference was the main aim of 
the studies in chapter 7 and 8. In these studies the personal preference on a -5 to +5 (10 
point) scale addressing various degrees, is the primary endpoint. Therefore, these 
rCTs can be characterized as post-treatment patient-preference trials, in which pa-
tients express preference after exposure to both treatments. Patient’s preference is a 
so-called ‘patient centered endpoint’.
One of the most remarkable findings in these rCTs is when patients express a prefer-
ence for either triptan or nsaID / analgesic, that preference was strong. some benefit 
more from the triptan and others benefit more from ibuprofen or paracetamol. There 
is only a small group benefiting from both, indicating they have no clear preference. 
In the naratriptan-paracetamol study actually all patients showed preference for one 
advise preventive treatment (Chapter 4 and 5). This provides a good base for shared 
decision making. However, because some cognitions are incorrect, additional post-
graduate teaching is needed.
GPs mention a complex of inhibitory and stimulating factors, sometimes based on 
views about migraine treatment, and sometimes based op process factors (Chapter 
4). 
Patients mention a comparable complex of factors, including the perceived burden of 
migraine and questions about autonomy and self-determination. Moreover, in their 
opinion the influence of the physician is the key factor (Chapter 5). 
The hesitations against preventive treatment are often subjective in nature (Chapter 
4 and 5). We expect that understanding the hesitations and the discussion of these 
hesitations with the patient can lead to more clarity and acceptance. This could be 
evaluated in further studies.
On average, there is a long delay between the diagnosis of migraine and the start of 
preventive treatment (Chapter 3). The motivation for preventive treatment arises 
only after a long period of perceived burden of disease and at an older age. For general 
practitioners, it is important to realize that the patient must be motivated to accept 
preventive treatment. However, this is often not the case at the moment making the 
diagnosis (Chapter 3). Consequently, the topic of prophylaxis, when indicated, 
should be raised in usual patient contacts.
d. Experiences with preventive treatment in daily practice
The low expectations of success of preventive treatment are in contrast with what GPs 
normally meet in daily practice. The lack of confidence in preventive treatment is not 
reflected in the prescription data from GPs. (Chapter 3). 
Once the preventive treatment is started in general practice, it usually goes well. The 
frequently applied beta-blockers show to perform well. More than half (56%) of the 
patients is using preventive therapy during nine months or more (Chapter 3). 
The actual percentage of Dutch migraine patients using preventive treatment is 13%. 
Though this percentage may seem low, it is also found as one-year prevalence  in many 
other studies on preventive treatment4-12. From our study, it appears that many more 
patients have ever used preventive treatment. During a period of 11 years 44% of mi-
graine patients have had with experience with preventive treatment (Chapter 3). 
That’s a convenient percentage because it roughly corresponds to the percentage of 
migraine patients with two or more attacks per month13.
e. Expectations and problems in the application of preventive treatment
surprisingly, patients want preventive treatment more often than GPs are expecting 
(Chapter 4 and 6). Both the qualitative studies and the questionnaire study emphasize 
that the opinion of patients is crucial (chapters 4, 5, and 6). It is particularly important 
that the patient is motivated for preventive intervention. This is not only necessary 
for the acceptance of the treatment, but also stimulates proper compliance (Chapter 
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words: patients choose their own endpoint. satisfaction with a self-preferred endpoint 
provides also the biggest chance on satisfaction with attack treatment for the 
individual. 
However, with use preference trials it is not possible to determine the general effec-
tiveness and / or efficacy between two active migraine treatments Then trials with 
classic endpoints continue to be more valuable.In conclusion, ‘preference’ (PTPP) 
trials are relatively new and should potentially be a more valid approach to detect 
clinical meaningful differences between established treatments (Chapter 7 and 8).
d. Strategy in attack treatment for migraine
Patients are well able, upon request, to present their preferences between two attack 
treatments.  They can present their preferences between analgesics, nsaIDs and 
triptans in an excellent way (Chapter 7 and 8). Furthermore, they can also present 
their preferences between different triptans20-26. 
a practical strategy should be that the patient uses a drug for three consecutive attacks, 
after which an appropriate choice can be made, namely continuation or change (ac-
cording to the selected method in the “preference trials” Chapter 7 and 8). Because 
multiple attributes contribute to that choice, at least three consecutive attacks are 
desirable to gain insight. several known effective treatments (paracetamol, nsaIDs, 
triptans, and several of the latter category) can best be tested one by one using this 
strategy. Because migraine attacks occur one after the other for years, there is plenty of 
time in each patient to find out what works best. 
3. extent of triptan overuse
a. Extent and recognition of overuse
Medication overuse and especially triptan overuse is a common problem in the 
netherlands (Chapter 9), often resulting in chronic daily headache with high disease 
burden. The costs of triptan use and overuse in this large-scale research turned out to 
be higher than in earlier (smaller) studies. Triptan overuse entails high cost, estimated 
between the 23% and 47% percent of the total cost of triptans (Chapter 9). 
When some ‘number crunching’ is performed, the question arises whether triptans in 
the netherlands do induce more headaches than they cure. 
Triptan overuse is a common problem at national level. However, in a single general 
practice it concerns only a few patients. Of all medication overuse only triptan overuse 
is well known by GPs. .Consequently, overuse of analgesics and nsaIDs resulting in 
chronic daily use is mostly unknown to the GP. We recommend to pay more attention 
to this in guidelines and (post-graduate) education.
b. Opinions and recommendations with respect to overuse
all interventions that can help to reduce the magnitude of this problem are a welcome 
contribution.
of the treatments. The studies show that, as mentioned before, when patients don’t 
benefit from nsaID or analgesic they often do respond to a triptan. Therefore, it 
makes really sense to actively monitor treatment response in all patients, because if 
there is no response to nsaIDs or analgesic patients should be motivated to consider 
the use of a triptan.
In conclusion, the main argument on which the choice of attack treatment should be 
based is the preference of the patient and not the relative effectiveness from popula-
tion-based studies.
b. The role of impact in attack treatment
The height of the MIDas-score did correspond with the expressed preference in de 
rizatriptan-ibuprofen study. However, this was only the case in a subgroup of patients 
with a strong preference for one of two treatments, not in the entire study population. 
Our two studies here differ. In the rizatriptan-ibuprofen study the patient outcome 
was largely influenced by the pre-measured impact of the MIDas-core in favor of 
rizatriptan in the specified subgroup with strong preference. It was striking in the 
naratriptan-paracetamol study this was not the case at all. Migraine patients with 
high or low impact showed an equal preference for the triptan or paracetamol. In 
conclusion, the pre-measured impact did not have a consequent influence on the 
outcome in our studies. We advise to study this aspect in other preference studies. 
c. Preference trials versus ‘regular’ trials
One of the differences between usual study designs and the preference studies in 
Chapter 7 and 8 is that these studies evaluated three successive attacks on each of the 
studied medications. Mostly only one attack is treated in comparative studies between 
two different attack treatments14,15. We think in daily practice, an evaluation more 
attacks is preferable. Only one attack doesn’t sufficiently predict the general pattern, 
since in our studies the two-hour pain-free attack rate for the first treated attack dif-
fered from the total pain-free attack rate.   
During the development of this thesis, the discussion which endpoint is best to com-
pare attack treatment in migraine is actively held within the IHs16,17. The former vision 
of the IHs the two-hour pain-free period should be the primary endpoint18,19. sustained 
pain-free is also a well-accepted endpoint. now discussions are held about combining 
the ‘two-hour pain free’ and the ‘sustained pain free’ endpoint. a disadvantage is that 
those endpoints do not take into account what patients expect from therapy. In re-
search with ‘regular’ rCT-design and with classical endpoints such as 2-hour pain-free, 
the patients preference disappears into nothingness. This can be considered as a gen-
eral disadvantage of rCTs.
Patients make their own assessments based on several attributes and their reasons for 
preferences vary widely, see the above paragraphs. Therefore, a preference study bet-
ter demonstrates the views of the patients. They are best aware which of the advantages 
or disadvantages are most important or most annoying for themselves. In other 
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Possibly, maximizing the reimbursed triptans to 15 to 20 DDDs per month would very 
likely indicate and discourage excessive overuse. It could induce prophylaxis more 
easily and, thereby, possibly reduce the amount of overuse and related headache 
burden. 
The current electronic prescribing systems can monitor drug treatment much better, 
but they still are unable to alert for triptan overuse. a modification of the electronic 
prescribing systems and feedback systems for medication overuse headache is needed 
and could result in more health benefits (e.g. nHGdoc). Monitoring for triptan use is 
a prerequisite, accompanied by an increase in awareness in GPs, practice assistants, 
but also in pharmacists.
In conclusion, based on this thesis it is worthwhile paying attention to the prevention 
of MOH during consulting hours when headache is discussed and when an attack 
treatment is prescribed.
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Interdisciplinary Processing of Clinical Information (IPCI) database, a GP research 
database. all prevalent and incident migraine patients (n = 7367) were included. 
about 13% of all migraine patients currently use preventive therapy. 44% of all mi-
graine patients started with preventive therapy in the study period. Therefore this 
large primary care database reveals, that a limited number of patients are current users 
of preventive treatment, but many patients have prior use. 
Of those starting with preventive treatment 56% still used it after 9 months, meaning 
that once preventive therapy is started the therapy adherence is mainly good. 
There was a long delay between migraine diagnosis and start of preventive treatment. 
Thus it often takes a long time before a patient is willing to embrace preventive 
treatment. 
When preventive treatment is applied, usually there is only one effort carried out with 
one type of medication. Therefore more attempts with various medications per pa-
tient can be made. 
In chapter 4 we present a focus group study in Dutch general practice on the preven-
tive treatment of migraine by exploring the opinions of GPs. Four focus groups (6 GPs 
each) were formed. GPs were purposively sampled to acquire a range of participants, 
reflecting the more general GP population. 
six themes emerged: GPs general views on migraine, reluctance to start preventive 
therapy, initiating preventive medication, taking the initiative for preventive ther-
apy, patient or physician, starting and managing preventive therapy, and the expec-
tations of the benefit of preventive therapy. GPs were aware of the functional impact 
of migraine and the benefits of preventive therapy. However, some were hesitant to 
start prescribing prophylaxis due to doubts about effectiveness, potential side effects 
and the risk of developing drug dependency. GPs’ decisions were often based on con-
siderations other than those presented in national guidelines, e.g. the patient’s need 
to control their own problem. Many GPs consider the responsibility for initiating 
preventive therapy to lie with the patient.
We conclude that various considerations hamper GPs from managing migraine with 
preventive medication, and various patient-related concerns cause GPs to deviate 
from national headache guidelines.
In chapter 5 a qualitative study is presented on the patient’s view on the preventive 
treatment of migraine. This qualitative study explores the opinions, motives and ex-
pectations of patients regarding preventive migraine therapy. Three focus group 
meetings were held with 6-7 migraine patients per group (2 female and 1 male group, 
total 20 patients) recruited from urban and rural Dutch general practices. all partici-
pants were migraine patients according to the IHs-criteria (International Headache 
society); 9 had experience with prophylactic medication. The focus group meetings 
were analysed using a general thematic analysis.
For patients several distinguished factors count when making a decision on preven-
suMMary
Chapter 1 provides the general introduction of this thesis. Headache is a problem for 
which patients occasionally attend a GP. Only a small proportion of people with 
headache visit the GP, although there is often a high disease burden. 
This thesis is mainly about migraine, a disabling headache disorder which is charac-
terized by unilateral location, pulsating quality, moderate or severe intensity, aggra-
vation by routine physical activity and association with nausea and/or photophobia 
and phonophobia.
addressed in this thesis are three elements of migraine. Firstly, the preventive treat-
ment of migraine, which is often undervalued and not frequently used. secondly, at-
tack treatment of migraine. In the third and last part follows attention for medication 
overuse headache.
part 1 preventive therapy for migraine
In chapter 2 we present a narrative ‘umbrella’ review on the preventive treatment of 
migraine, based on a search in Medline and embase, including an overview of indica-
tions for preventive treatment mentioned in guidelines. 
according to most sources, patients with an average of two or more attacks per month, 
when using attack treatment, are eligible for preventive treatment. This decision is 
also based on the (average) duration of attack, severity of attacks, and the response to 
attack treatment. In the present guidelines there is only limited involvement of pa-
tients, whereas this is an essential condition for treatment continuation and success. 
Before starting prevention, the average attack frequency should be determined, pref-
erably using a headache diary for 2-3 months, because of the highly variable frequency 
of migraine attacks. none of the currently available preventive medications (such as 
beta-blockers, sodium valproate, topiramate and candesartan) are specific for mi-
graine. To obtain a good outcome, preventive treatment should be titrated up step-by-
step to the highest possible dose without side effects. 
according to literature, for about 50% of patients with preventive treatment, a 50% 
reduction in attack frequency can be achieved and the remaining attacks tend to be-
come less severe.
In conclusion, preventive treatment of migraine is a worthwhile intervention in pri-
mary care, for which beta-blockers and anti-epileptic drugs can be used. For many 
patients preventive treatment will contribute to a greater reduction in disease burden 
than can be established with attack treatment alone.
In chapter 3 we present an insight into the actual preventive treatment of migraine 
in general practice in the netherlands. We present an observational population-based 
study, assessing current use, previous use, duration and course of preventive treat-
ment of migraine in Dutch general practice conducted between 1997 and 2007 in the 
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nor researcher could distinguish the verum from placebo and each patient still had 
active treatment. 
29 triptan-naive patients expressed a quantified preference (0-5) after treating three 
attacks with rizatriptan 10 mg and three with ibuprofen 400 mg. Ten (35%) patients 
expressed strong preference for rizatriptan and six (21%) for ibuprofen, which was not 
a significant difference. Thirteen (45%) had no or only a moderate preference. Mean 
overall preference (on a 10 point scale in cm) was 0.62 cm in favour of rizatriptan. 
Patients with high migraine-specific baseline disability on the MIDas scale had 
stronger preference for rizatriptan.
Most patients had a clear preference for one of both treatments, which was correlated 
only moderately to the usually reported “two-hour pain free responses”. 
The two-hour pain free rate after treating a single migraine attack in a parallel-group 
study design is the recommended primary endpoint to establish acute antimigraine 
efficacy versus placebo. However, when comparing established treatments, the clini-
cal validity of this approach seems limited. Multi-attack, crossover, patient-preference 
trials, may better detect clinically meaningful differences between established 
treatments.
The design of the study in chapter 8 was very similar to the study in chapter 7. We 
performed a randomized, blinded, crossover study with double-dummy medication 
between a triptan and a painkiller. Primary outcome measure was direction and 
strength of patient preference (10 point scale).
31 triptan-naive participants were randomised to naratriptan 2.5 mg or paracetamol 
1000 mg with a crossover after three attacks. 28 participants were able to make a pref-
erence assessment. Preference score was 0.17 in favour of naratriptan. nine (32%) 
participants strongly preferred naratriptan, and also nine (32%) paracetamol. When 
looking at all the preferences 16 (57%) participants preferred naratriptan and 11 
(42.1%) preferred paracetamol. The two-hour pain-free attack rates were 15/76 (20%; 
naratriptan) and 9/74 (12%; paracetamol) for all attacks (p = 0.25). When treating the 
first attack use of naratriptan has a higher pain-free rate. Correlation of two-hour 
pain-free response with preference was poor (r = 0.27).
The preference from patients as a group for either naratriptan or paracetamol in the 
acute attack treatment of migraine is similar, but individual patients have a strong 
preference for one or the other, with no relation to attack severity or migraine impact. 
Multi-attack, crossover, patient-preference trials better detect clinically meaningful 
differences between established treatments.
part 3 Medication overuse headache
In chapter 9 a large observational analysis of the Dutch Health Care Insurance Board 
Database for the year 2005 is presented, which included prescriptions for 6.7 million 
people (46% of the total Dutch population). We assessed the prevalence, demograph-
tive treatment. The decision of a patient on preventive medication depends on experi-
ence and perspectives, grouped into five categories, namely the context of being 
active or passive in taking the initiative to start prophylaxis; assessing the advantages 
and disadvantages of prophylaxis; satisfaction with current attack migraine treat-
ment; the relationship with the physician and the feeling to be heard; and previous 
steps taken to prevent migraine.
In addition to the functional impact of migraine, the decision to start prophylaxis is 
based on a complex of considerations from the patient’s perspective (e.g. perceived 
burden of migraine, expected benefits or disadvantages, interaction with relatives, 
colleagues and physician). Therefore, when advising migraine patients about prophy-
laxis, their opinions should be taken into account. Patients need to be open to advice 
and information and prophylaxis has to be offered at an appropriate moment in the 
course of migraine. 
In chapter 6 a cross-sectional questionnaire study on migraine patients’ acceptance 
or rejection of preventive treatment is presented. Most patients with two or more mi-
graine attacks per month (indication for preventive treatment) do not use preventive 
medication. We investigated how many patients use preventive treatment or would 
like to use it, and which aspects of migraine contribute to the choice whether to use 
preventive treatment treatment. 
In three general practices, patients were selected who were diagnosed with migraine 
or had prescriptions for migraine medication. a questionnaire was sent to 283 patients 
and completed by 166 patients (58.7%), of whom 15 were excluded. a total of 129 fe-
males and 22 males were included (median age 41 years). Most patients had two or 
more attacks per month (66.2%). Fifty-five per cent of patients with two or more at-
tacks per month wanted to use prophylaxis; only 8% actually used this treatment. The 
migraine frequency contributed most to the acceptation of preventive therapy. To a 
lesser extend the measured impact of migraine contributed to the acceptation of pre-
ventive therapy (measured with the HIT-6-score, a validated impact score). Patients 
who had seen their GP in the previous year were more likely to report an interest in 
preventive therapy.  
In conclusion: interest in preventive therapy can be explained by an increased con-
cern about migraine symptoms and the findings suggest that physicians can play a 
more active role in optimising migraine therapy.
part 2 attack treatment of migraine
In chapter 7 we present a patient preference study. In this randomized, crossover, 
blinded rizatriptan-ibuprofen multi-migraine attack trial we used a novel patient 
centred endpoint, the ‘patient preference’. after the first three attacks treated with 
either a triptan or nsaID, the patients were asked to treat another three attacks with 
the opposite medication. The double-dummy technique ensured that neither patient 
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ics, risk factors, and costs of triptan-overuse, defined as more than 30 (IHs Criteria) or 
54 (stringent Criteria) “defined daily doses” (DDD) per 3 months.
Triptans were used by 85,172 (1.3%) people; 8,844 (10.4%) were IHs-overusers and 
2,787 (3.3%) were ‘stringent’-overusers. 
The triptan-specific odds ratios adjusted for durations of availability for the rate of 
IHs-overuse, compared to sumatriptan, were: 0.26 (95% CI 0.19–0.36) for frovatrip-
tan, 0.34 (95% CI 0.32–0.37) for rizatriptan, 0.76 (95% CI 0.68–0.85) for naratriptan, 
0.86 995% CI 0.72–1.02) for eletriptan, 0.97 (95% CI 0.88–1.06) for zolmitriptan and 
1.49 (95% CI 1.31–1.72) for almotriptan (an Or < 1 means a higher lower probability 
on overuse and an Or > 1 indicates a smaller higher probability of overuse). Costs for 
overuse were 29.7 million euros per year for the netherlands. The IHs criteria overus-
ers used 46% of the total expenditure on triptans, and for stringent overusers this was 
23% of the total expenditure. Users of frovatriptan, rizatriptan and naratriptan had a 
lower level of overuse. 
We conclude that overuse of triptans, resulting in chronic headache, occur frequent 
and creates unnecessary high cost. 
In the general discussion in chapter 10 findings and conclusions from the various 
chapters of this thesis are discussed.
The common thread through all parts of this thesis is what patients want in migraine 






In hoofdstuk 3 presenteren we een inzage in de feitelijk toegepaste preventieve be-
handeling van migraine in de huisartsenpraktijk in nederland. We presenteren in een 
observationele studie het huidige gebruik, eerder gebruik, duur en het verloop van de 
preventieve behandeling van migraine in de nederlandse huisartsenpraktijk, zoals 
het heeft plaats gevonden tussen 1997 en 2007. We gebruikten de Interdisciplinary 
Processing of Clinical Information (IPCI)-database, een huisarts research database. 
alle prevalente en incidente migrainepatiënten (n = 7367) werden opgenomen.
Ongeveer 13% van alle migrainepatiënten maakt op enig moment gebruik van pre-
ventieve therapie. 44% van alle migrainepatiënten zijn in de onderzoeksperiode ge-
start met preventieve therapie. Uit deze grote eerstelijns database blijkt dat er op enig 
moment maar een beperkt aantal patiënten actieve gebruikers zijn, maar veel patiënten 
er wel ervaring mee hebben.
Diegene die starten met preventieve behandeling gebruikt 56% het nog steeds na 9 
maanden, wat betekent dat wanneer preventieve therapie wordt gestart de therapie-
trouw is meestal goed is.
er was een lang tijdsverloop tussen de migrainediagnose en de start van de preventieve 
behandeling. Het blijkt dus vaak lang te duren voordat een patiënt bereid is om tot 
preventieve behandeling.
als preventieve behandeling wordt toegepast, wordt er meestal slechts één poging 
met één soort medicatie uitgevoerd. Het verdient aanbeveling om vaker profylaxe te 
proberen met verschillende medicijnen.
In hoofdstuk 4 presenteren we een focusgroepstudie in de nederlandse huisart-
spraktijk over de preventieve behandeling van migraine door onderzoek naar de me-
ningen van huisartsen. Vier focusgroepen (elk 6 huisartsen) werden gevormd. Bij de 
huisartsen werd een brede steekproef genomen met een  diversiteit aan deelnemers, 
met als doel een goede weergave van meningen onder huisartsen in het algemeen.
Zes thema’s kwamen naar voren: algemene opvattingen van huisartsen over migraine, 
terughoudendheid om preventieve therapie te starten, het nemen van het  initiatief 
voor preventieve therapie door patiënt of huisarts, het starten en uitvoeren van pre-
ventieve therapie, en de verwachtingen over van het nut van preventieve therapie. 
Huisartsen waren goed op de hoogte van de functionele impact van migraine en de 
voordelen van preventieve therapie. echter, sommige waren terughoudend om te 
beginnen met het voorschrijven van preventie vanwege twijfels over de effectiviteit, 
de mogelijke bijwerkingen en het risico op het ontwikkelen afhankelijkheid. 
Beslissingen van huisartsen werden vaak op basis van andere overwegingen genomen, 
dan die welke in de nationale richtlijnen staan. Bijvoorbeeld zoals in welke mate 
patiënten voor zich op kunnen komen. soms vinden huisartsen dat de verant-
woordelijkheid voor het initiëren van preventieve therapie bij de patiënt ligt. 
We concluderen dat verschillende overwegingen de huisartsen belemmeren om mi-
graine middels preventieve medicatie aan te pakken, en diverse patiënt-gerelateerde 
aspecten zorgen er voor dat de huisarts afwijkt van de landelijke richtlijnen.
saMenvatting
Hoofdstuk 1 bevat de algemene introductie van dit proefschrift. Hoofdpijn is een 
probleem waarvoor patiënten af en toe een huisarts raadplegen. slechts een klein deel 
van de mensen met hoofdpijn bezoekt de huisarts, maar vaak is er een hoge 
ziektelast.
Dit proefschrift gaat vooral over migraine, een invaliderende hoofdpijnsoort, geken-
merkt door eenzijdige locatie, bonzend, matige of ernstige intensiteit, verergering 
door fysieke activiteit en waarbij misselijkheid en / of fotofobie en fonofobie 
voorkomt.
In dit proefschrift komen drie elementen van migraine aan bod. als eerste de preven-
tieve behandeling van migraine, die vaak wordt ondergewaardeerd en weinig gebruikt. 
als tweede aanvalsbehandeling van migraine. In het derde en laatste deel volgt aan-
dacht voor medicatieovergebruikshoofdpijn.
deel 1 preventieve therapie voor migraine
In hoofdstuk 2 presenteren we een narratieve ‘paraplu’ review over de preventieve 
behandeling van migraine, op basis van een zoekacties in Medline en embase. er 
wordt ook een overzicht gegeven van de aanbevelingen in richtlijnen ten aanzien van 
preventieve behandeling.
Volgens de meeste  richtlijnen komen patiënten met een gemiddelde van twee of meer 
aanvallen per maand in aanmerking voor preventieve behandeling. De beslissing om 
te starten met preventieve behandeling wordt af en toe ook gebaseerd op de (gemid-
delde) duur van de aanval, de ernst van de aanvallen, en de respons op de behandeling. 
In deze richtlijnen is er slechts beperkte betrokkenheid van de patiënten, terwijl dit 
een essentiële voorwaarde voor de continuïteit en van de behandeling en daarmee het 
succes er van. 
Voordat preventie medicatie wordt gestart, dient de gemiddelde aanval frequentie te 
worden bepaald, bij voorkeur met een hoofdpijndagboek gedurende 2-3 maanden, 
vanwege de zeer variabele frequentie van migraineaanvallen. Geen van de momenteel 
beschikbare preventieve medicijnen (zoals bètablokkers, natriumvalproaat, 
topiramaat en candesartan) zijn specifiek voor migraine. Om een  goed resultaat te kri-
jgen, moet preventieve behandeling stap voor stap worden getitreerd tot aan de 
hoogst mogelijke dosis zonder bijwerkingen. 
Volgens de literatuur wordt bij ongeveer 50% van de patiënten door preventieve be-
handeling een vermindering van 50% in de aanval frequentie bereikt en worden de 
resterende aanvallen meestal minder ernstig. 
Concluderend is de preventieve behandeling van migraine een waardevolle interven-
tie in de eerste lijn, waarbij bètablokkers en anti-epileptica worden gebruikt. Voor veel 
patiënten kan preventieve behandeling bijdragen aan een grotere vermindering van 
ziektelast dan kunnen alleen met aanval behandeling bereikt kan worden.
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migrainefrequentie draagt het meest bij aan de acceptatie van preventieve therapie. 
In mindere mate speelt de gemeten impact van migraine een rol in de acceptatie van 
preventieve therapie (gemeten met de HIT-6-score, een gevalideerde impactscore). 
Patiënten die de huisarts in het voorgaande jaar hadden bezocht, rapporteerden vaker 
belangstelling voor preventieve behandeling.
Concluderend: interesse in preventieve therapie kan worden verklaard door een 
toegenomen bezorgdheid over migraine symptomen en de bevindingen suggereren 
dat artsen een meer actieve rol in het optimaliseren van migraine therapie kunnen 
spelen. 
deel 2 aanvalsbehandeling van migraine
In hoofdstuk 7 presenteren we een ‘patient preferentie’ studie. In deze gerandomis-
eerde, cross-over, geblindeerde rizatriptan-ibuprofen multi-migraineaanval studie 
gebruikten we een nieuwe patiëntgerichte eindmaat, de ‘voorkeur van de patiënt’. na 
eerst drie aanvallen met of een triptaan of nsaID te hebben behandeld werden de 
patiënten gevraagd nog eens drie aanvallen met het andere medicament te behande-
len. De dubbel-dummy techniek zorgde ervoor dat noch de patiënt noch onderzoeker 
de verum kon onderscheiden van de placebo en elke patiënt nog steeds (gedeeltelijk) 
actieve behandeling kreeg. 
29 triptaan-naïeve patiënten uitten een kwantitatieve voorkeur (0-5) na de behande-
ling van drie aanvallen met rizatriptan 10 mg en drie aanvallen met ibuprofen 400 
mg. Tien (35%) van de patiënten hadden een sterke voorkeur voor rizatriptan en zes 
(21%) voor ibuprofen, hetgeen geen significant verschil was. Dertien (45%) hadden 
geen of slechts een matige voorkeur. De gemiddelde algemene voorkeur (op een 
10-puntsschaal in cm) was 0,62 cm in het voordeel van rizatriptan. Patiënten met 
hoge MIDas-score (grotere impact van migraine) hadden een sterkere voorkeur voor 
rizatriptan. 
De meeste patiënten hadden een duidelijke voorkeur voor een van beide behandelin-
gen. De voorkeur correleerde slechts matig met de meestal gebruikte “2-uur pijnvrij 
score”. 
Multi-aanval, cross-over, ‘patient-preferentie’ studies zijn zeer goed in staat om kli-
nisch relevante verschillen tussen bestaande behandelingen te detecteren.
Het design van de studie in hoofdstuk 8 was vergelijkbaar met de studie in hoofdstuk 
7. We voerden een gerandomiseerde, geblindeerde, cross-over studie met dubbel-
dummy medicatie uit tussen een triptaan en een pijnstiller. Primaire uitkomstmaat 
was de richting en de sterkte van voorkeur van de patiënt (10 puntenschaal).
31 triptaan-naïeve deelnemers werden gerandomiseerd in een groep die drie aanval-
len behandelde met 2,5 mg naratriptan en een groep die drie aanvallen behandelde 
met paracetamol 1000 mg, met daarna een cross-over. 28 deelnemers waren in staat 
om een voorkeur uit te spreken. De voorkeur score was 0.17 in het voordeel van nar-
atriptan. negen (32%) deelnemers hadden een sterke voorkeur naratriptan en ook 
In hoofdstuk 5 wordt een kwalitatieve studie gepresenteerd over de meningen van 
patiënten over de preventieve behandeling van migraine. Deze studie verkent de me-
ningen, motieven en verwachtingen van patiënten ten aanzien van preventieve be-
handeling van migraine. Drie focusgroepbijeenkomsten vonden plaats met 6-7 
migrainepatiënten per groep (twee vrouwen- en een mannengroep, totaal 20 
patiënten) gerekruteerd uit stedelijke en landelijke nederlandse huisartspraktijken. 
alle deelnemers waren migrainepatiënten volgens de IHs-criteria (International 
Headache society); negen hadden ervaring met preventieve medicatie. De focus-
groepen werden geanalyseerd met behulp van thematische analyse.
Voor patiënten tellen verschillende factoren mee bij het maken van een beslissing 
over preventieve behandeling. De beslissing van een patiënt over preventieve medi-
catie is afhankelijk van eerdere ervaringen en vooruitzichten, gegroepeerd in vijf cat-
egorieën: het actief of passief zijn in het nemen van het initiatief om preventie te 
beginnen, het beoordelen van de voor-en nadelen van preventie, de tevredenheid 
met de huidige aanvalsbehandeling van migraine, de relatie met de arts en het gevoel 
te worden gehoord, en voorafgaande stappen om migraine te voorkomen.
naast de functionele gevolgen van migraine is de beslissing om profylaxe te beginnen 
op basis van een complex van overwegingen vanuit de patiënt (bijv. ervaren last van 
migraine, verwachte voordelen en nadelen, interactie met familieleden, collega’s en 
arts). 
naast de functionele impact van migraine wordt de beslissing om met preventie te 
beginnen genomen op basis van een complex aan overwegingen vanuit de patiënt 
(bijv. ervaren last van migraine, verwachte voor- en nadelen en interactie met fami-
lieleden, collega’s en huisarts). 
Daarom moet bij het adviseren van migrainepatiënten over preventie rekening 
worden gehouden met hun mening. Patiënten moeten openstaan  voor advies en in-
formatie en preventie moet worden aangeboden op het juiste moment in het beloop 
van migraine.
In hoofdstuk 6 wordt een vragenlijststudie over aanvaarding of verwerping van 
preventieve behandeling van migraine onder een dwarsdoorsnede van patiënten in 
de huisartspraktijk gepresenteerd. De meeste patiënten met twee of meer migraine-
aanvallen per maand (indicatie voor profylaxe) gebruiken geen preventieve medicatie. 
We hebben onderzocht hoeveel patiënten preventieve medicatie gebruiken of deze 
willen gaan gebruiken, en welke aspecten van migraine bijdragen aan de keuze voor 
preventieve behandeling.
In drie huisartspraktijken werden patiënten geselecteerd, met de diagnose migraine of 
die recepten voor migrainemedicatie hadden gekregen. er werd een vragenlijst gestu-
urd naar 283 patiënten en ingevuld door 166 patiënten (58,7%), van wie er 15 werden 
uitgesloten. In totaal 129 vrouwen en 22 mannen antwoordden (gemiddelde leeftijd 
41 jaar). De meeste patiënten hadden twee of meer aanvallen per maand (66,2%). 
Vijfenvijftig procent van de patiënten met twee of meer aanvallen per maand wilde 
preventieve behandeling, slechts 8% gebruikte daadwerkelijk deze behandeling. De 
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na een aantal jaren werk ligt er nu dan een proefschrift, dat slechts een paar summiere 
vragen over hoofdpijn beantwoordt. Gelukkig wel op een voor huisartsen belangrijk 
terrein. nu is het dan zover om alle mensen te bedanken, die aan dit onderzoek en 
proefschrift hebben bijgedragen en het mij hebben mogelijk gemaakt er aan te 
werken.
Velen hebben geholpen met dit proefschrift. In de eerste tijd op de gezellige kamer in 
het oude gebouw met Joyce, Willie, Wouter en later ook Wendy, Jeannette en Jiska. 
Later in de nieuwbouw met Yvonne, Margot, en Gerda. Weer later ‘verbannen’ naar 
het hoofdgebouw met sjoerd, anne, Jamilla, Margereth, Iris, annemarie, Marjolein 
en anderen, in wisselende samenstelling. Zo’n eerste periode met de eerste stappen in 
het onderzoek. Met zulke prettige mensen als steun in de buurt, kun je niet beter tref-
fen. Deze mensen betekenen veel voor mij.
Dank aan alle medeauteurs: een proefschrift schrijven doe je niet alleen. nathalie 
Wiendels, eerder gepromoveerd in 2007, was erg belangrijk bij een aantal studies uit 
dit proefschrift. Zeer goed op hoogte, goed wetend waar ze het over heeft en het was 
ook gezellig. Boukje andriesse, je hebt veel gedaan voor de kwalitatieve studies in dit 
proefschrift zonder dat je daar zelf veel belang bij had. Dank voor je onbaatzuchtige 
hulp. Celeste van Vliet en Vincent de Valk van het CVZ zijn noodzakelijk geweest voor 
de studie over overgebruik. De nuchtere aanpak van Celeste en de grapjes van Vincent 
zullen me altijd bijblijven. Jeanne Dieleman, vanuit de IPCI van de erasmusMC, bleef 
vriendelijk en behulpzaam en vooral deskundig, ook bij alle specifieke en gekke vragen 
over migraine en IPCI. en voor allebei was de eerste beste acceptatie in een tijdschrift, 
zonder enige revisie, een verassing. 
De ‘vrienden’ van PCn-Hoofdpijn, een clubje huisartsen met specifieke belangstelling 
voor hoofdpijn, ben ik veel verschuldigd. Zij hebben mijn interesse in hoofdpijn 
zeker gestimuleerd. nico van Duijn, arie knuistingh neven, Paula van der Velden, 
Bart Veling en Paul van de Weert, dank!
De deelnemende huisartsen aan onderzoek zijn er vele geweest en ze hebben soms zelf 
bijgedragen door middel van participatie of door leveren van patiënten. allemaal erg 
bedankt voor jullie hulp naast de dagelijkse andere drukke activiteiten: V.H. van 
andel, s.M. Bakker, J.C.H. Biemans, M. van den Biggelaar, M. Bijlmer, a. Boels, C.M. de 
Boer, a.P. Bolhuis, I.B. Booij, W.F. van Brussel, M.J. Buitendijk, T. Buiter - van der kooi, 
J.P. Cleveringa, r. Daan, r.H. Dijkstra, a.J. Dolmans, C.r. Drijver, J.B.e. eysink smeets, 
L.M. Fabriek, C.H. Franse, r.s. Gebel, a.G. Glansdorp, B. Groeneveld, H.J.M. Guijt, 
G.C.H.a. Hageman, P. Hendrikx, P. Hilderink, G.J. Hoogenkamp, a.a. den Hollander, 
r.G. Iflé, e. de Jager, J.W. de Jonge, a. van de kamp, J.s. de kanter, P.J.a. kerstens, e.P. 
klaassen, L.D. kling, G.n. konijn, a. kortmann, B. kortmann, a. Lacroix, M.H. 
Landheer, r. van Leeuwen, a.a.e.M. te Meerman, M.T. Moorrees, P. Muilwijk, J.M. 
Muis, J.C.a. newsum, J.M.T. Oltheten, I. Osinga, C.G. van der Plas, H.T. Pleij, C. 
rietsema, M.L.T. rodewijk, e.J. scheltens, P.F.H.M.J. schleijpen, a.B.J. scholtes, B. 
negen (32%) voor paracetamol. Wanneer we kijken naar alle voorkeuren toonden 16 
(57%) deelnemers de voorkeur voor naratriptan en 11 (42,1%) de voorkeur voor para-
cetamol. De 2-uur pijnvrij aanval ratio’s waren 15/76 (20%; naratriptan) en 9/74 
(12%; paracetamol) voor alle aanvallen (p = 0.25). Bij de behandeling van de eerste 
aanval resulteerde gebruik van naratriptan in een hogere mate van pijnvrij na 2 uur. 
Correlatie van 2-uur pijnvrij respons met ‘patient-preference’ was slecht (r = 0,27).
De voorkeur van patiënten als groep voor naratriptan of paracetamol bij de behande-
ling van de acute migraineaanval is even groot, maar de individuele patiënt heeft een 
sterke voorkeur voor het ene of het andere. Deze voorkeur wordt niet bepaald door de 
ernst van de migraineaanval of de impact van migraine. Ook hier is de multi-aanval, 
cross-over, ‘patient-preferentie’ trial beter in staat om klinisch relevante verschillen 
tussen bestaande behandelingen te detecteren.
deel 3 Medicatieovergebruikshoofdpijn
In hoofdstuk 9 is een grote observationele analyse uitgevoerd met gebruik van de 
GIPdatabank van het College voor Zorgverzekeringen, met gegevens uit het jaar 2005. 
De databank bevat voorschriften van 6,7 miljoen mensen (46% van de totale 
nederlandse bevolking). Wij hebben de prevalentie, demografie, risicofactoren, en de 
kosten van triptaan overgebruik, gedefinieerd als meer dan 30 (‘IHs’-criteria) of 54 
(‘strikte’-criteria) “defined daily doses” (DDD) per 3 maanden.
Triptanen werden gebruikt door 85.172 (1,3%) mensen, 8.844 (10,4%) waren ‘IHs’-
overgebruikers en 2787 (3,3%) waren ‘strikte’-overgebruikers.
De triptaan-specifieke odds ratio’s gecorrigeerd voor duur van beschikbaarheid, voor 
de mate van ‘IHs’-overgebruik, vergeleken met sumatriptan, waren: 0.26 (95% BI 
0,19-0,36) voor frovatriptan, 0.34 (95% BI 0,32-0,37) voor rizatriptan, 0.76 (95% BI 
0,68-0,85) voor naratriptan, 0,86 (95% CI 0,72-1,02) voor eletriptan, 0.97 (95% BI 
0,88-1,06) voor zolmitriptan en 1.49 (95% BI 1,31-1,72) voor almotriptan (een Or <1 
betekent een lagere kans op overgebruik en een Or> 1 geeft een hogere waarschijnli-
jkheid van overgebruik). kosten voor overmatig gebruik waren 29,7 miljoen euro per 
jaar voor nederland. De ‘IHs’-criteria overgebruikers gebruikten 46% van de totale 
uitgaven voor triptanen en voor ‘strikte ‘`overgebruikers was dit 23% van de totale 
uitgaven. Gebruikers van frovatriptan, rizatriptan en naratriptan hadden een lager 
overgebruik.
We concluderen dat overgebruik van triptanen, wat resulteert in chronische hoofdp-
ijn, vaak voorkomt en onnodig hoge kosten veroorzaakt.
In de algemene discussie in hoofdstuk 10 worden de bevindingen en conclusies uit 
de verschillende hoofdstukken van dit proefschrift besproken.
De rode draad door alle onderdelen van dit proefschrift is wat patiënten willen bij 
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